var title_f8_59_9136="Vancomycin allergy skin lesions";
var content_f8_59_9136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Skin lesions due to vancomycin hypersensitivity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 164px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photographs of erythematous macules, vesicles, tense bullae, and erosions on the left hand (A) and tense bullae and erosions on the dorsal surfaces of the feet (B) in a 63- year old man with skin eruptions after vancomycin administration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clin Infect Dis 2004; 38:398. Copyright &copy; 2004 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9136=[""].join("\n");
var outline_f8_59_9136=null;
var title_f8_59_9137="Bullous subconjunctival hemorrhage";
var content_f8_59_9137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous subconjunctival hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 271px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEPAagDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5dgt9/LHjvV6KIRoGVcqTgms+Lc0w25PPaujttNZWTJ2hsMB1FYVHYzs29xIbCXGYixUgE8dKlkvYNPjaMsXm4IqPUtaW2D29oCG+6zZrniWkYsxJJ6mphBvWR0042LU873Upkk6mpIV5GaghSrka4wacmenQg92X4Y1kHyfeIyPrUtxAYgGY8ntVeFgoBA561JJI0pGfTFc7PYgkkMB9KcDgdKVUOcVKFGKls1hBsTOEPrUfepdvtTNvvSLaYqdc9qdzimouO9TrHnHNDZUItiRjJGOTVtIl8ndznpils7UyOBjAPQ571d+ylAVOcbhkgZx/nNJHbSp9zPlUNtI9MU6FeM4PFXpYIkXPmk9tuKr+ZsUjpjgA0WszVQSdx3mup4yD14p5nZtoKg4O3kdfeopGbcSAP8KdCNzKD1GT+OavZaA9WXYtkrSq+3ac4+tRwWcCRMzsS3pQsIkYBcJ8x4PGKeWjVQpyTk7WFTzaisSLZRgnLMiEY6VBPaTw4fcCrHHpilhuFYHzpXxgkZpbyZXjASRd3Q81an5icbmW6/eDcsx69qijtozkudvHFTl1A4Ocdc0zzUO7cAOMYFVz33MJ00JPCqxFtpGDwaqEMcHPAq5LcKylVUYOKiEqhcCMe9RzIzlBX3IkbGRjJNStJvAULyOx+lKJxuBKLjGMYqR5Imk3CPbxjA70KTegKPmRJGZAAxAOOOKSO3UnDNg1Kr7W4x9aimOSCePpTTSQnDqNmtAi5Lqfaq+xVC5JBPWpycD1qvImenWhTMakLaoZsdcFeh9qhnG4fMvzetTGR14BPFRNJz8wzzWikcc4xejK4izn0qFk2nI6VoxBJWwRhRyeaq3ETRtz07VaaOSdO2xWPv0pF6Y6U4sB2oRlxzTOd7i8AcdaglJLEnmpWI52nio+D+NNET10IV60jJkc1I6hPxqPPNUc7SWjIyCDVizm2SjeTsqMnrTM+1VuZWsaMzho2Hy4HAINVJJQmQpz71Ew+Xg4qEihImUnEsLcspbngjHFAnPy7uSO5qtSVXKjPnZfmnDRrnr6e1UjzSbjjFKODQlYTdxKKD1opknXaZYW6R5bbjGdxrP1XVmGIbcj5f4hVS+1V5jtg+SPGPc1mgkmsY09byCI8ZZizck81YiXJpkY6VcjXApyZ30KdxY0qwgoQcCpRHnGetYNnrU6dloCjtViEAVGq7KsRjJA7mspM7aMNR+OmBQvBxUo4H4UpHSs7ndyEbDHSk2Z59akdevp2pQhxSuPkuyMJg81ahUYBPSmouWFTB9rcUG9KCWrLVrJ5OSQNoORmpGvcxgEFSvzHHeqYBZs0xkL5GR+NJXWpvstCdphMcKMZNSQ2zzMSy/xfiarwKIT82Dg/XIrXtrkYVZCFLAbSe1a3XUmKcitdWTRRhm9ASCazROwfcMBvYV2X9jXGqQ741ZkU4DY601PBN20m0q3JIHHelKD3RE6sYPVnHidwfvc5pXkZgPbiuhk8KTW6yfbJFjZGxjOf0pp0NFjVo3VgcjJqFTZH1iC3ZzMkhXrnpinQ5c/KpY+1dVpvh6GeR/PdSFGQCeua6CLSNOtOWjHTrnAFbKjc5KmNjB73PPBp13IvyRMRnHFDaXcIH3ofl9q9ZtraxFvCwYKc5bAyeK0Liz06UARFAZhvX2qvY67mH1+N9UeKm1OzOzHuaiaADB7nsK9fXR9NmlkiuyEdQMDA6VmX/hGwkkDQTK3U/Ke1U6JqsfTe6PMxau5O0cD1NQsmMYNekp4SRrSQiVeDwecnNZmq+C5bXO3JAAPFZulJI1jWpz2OLwAOvam43Dg5rUudKmgkMZXc/TAqzDo9wkbB0wdw7ZxWSi27M6OVMwXjKgZ6EZqLAwa3Z7VkjYSrgAYBxWTcQ7Dgcjrmm1YzlT0uijLiqrqQauuhqvInJrSLPNrwb1KxYqc5604Sg/eOc0kiHtUDAg1qjz5NxHyAE8DFRMuBT1OCKDzVGUknqQnim4561MVB6VEetUYyjYjkBwM1HVioXGKpMwnHqMPem5p9MIxVGLHE8U080bsU0nNMltMaRTakpKZk0MopaSmSFFFFACgZqVE70qLUyJUNnRTp3CMc1biGeDUaKKsqMcisZM9KhTsPTA71Kh5zUaoTUiqRismd8E0SZ3HFWLfgg5qqMg1PGeQKhnXSeupbXBAxU0EZYFscDrUdttypxzkc1oLLGNu0YTvx1rF6bHp0lfVlZkBIpjEDgDpUsjLvPljj3qJkJJNSmbSXYap5qQDkCoTkHpU0YJ7ZoZEHfQ0olhGUBDSkdTVGcYkYLzzTFcxklevr6U1ZB5vOST6VcXfQ1lNWsxOQwJrZ06wNzOqyL8vUHofpVA+cNwVPm64K9q3tDs3ll3ylvu5GD0Fa+zbZyVsQqMWzq9J1O4s1jVFykf8Na5166knZpP3cIw2AORXOXKywszRfNwMgdTVhTIYmUggsQFPbBreC5VY8CvivaajtWmS7vfOLcNng9Mdqp+QnnW9soBDFjwenHetC60wECONscjLDqMU+3sHa4DFclsrkD9aNzjdcw44phPMqJh0YbU9R7VovGZkjdTuOeVPcVtJpMjXCMwwy85PuanTTTwXKpg4GKfK2ZSxDOcnRyAylY5g3AHQjHNMJke5UsSpjyfl5HYV0kmnwtGW3DIyaiGnwkytuwR/9ai1iPrDOf8ANn8zzp8FnIXPYLjiq8bSR2xSIsZCGB56DrW5PpIfrKNoO7H4VnyWsqQMVjO4k4J9KpJh9ZG2N9Ilsys4LbsBTWnJq7pAPtA8wLxwO2axPKeJnLDL9Tx0NVJZWSJ03Hpxmm79TWGK1Og0a3stRa4mmfY+/Chh09K6k6Laz6e8iYY7Rkg8E15ta3GBKIwRkhh/Wuh0vVjCm2R2CY5XPBqUo7HcsXLTUyvElisdtKChDAYyOlcBcMhXB3BgSMGvTddKaraulo5LYJCg15ffQT2sxjuUZHH94Vy1IuJ7WGrKcCFlAGc1A8QOSDz6YqbdmoicNUJsuoosrPFj3qvLHgcCtL73GKikQGrjOxx1cOpLQzGXjgVGVyPSr0yBenWqzgHNbpnm1aXK7EIFMK89ae/AGKSquczS2I24qFuanPJppWqTMZRuNjAOQ4zgHGKilRlALKQD0qYDBzRM+9QCSSKpMylDTUpsvfNNXg1IetGyruczjroIBSEe1TKlIRSuXyaEBFJT2HNMIqkYSVhKKKKZJbRasxigR+9Sotc7kevSpWHKtSqORSKOPpUkYzWbZ3QgTIMtVhIQ2cD3qKJcnOavW+1XBIrCTPUoU1LcrmH04NKIsDmtCWONnzGeoz0qWO1BQHsR3FZ+0OuOFu9CrbRE847VYKOE2OD0HWnQHyZBuXOD3qxczI8WEHJOc/0pcx206SUTP6N71NHg9agcc05WKgCkRF2eo90AY81EzY+tSlsj3qvNx3pIVR2V0MI6knio9wXJyc9qRpVAwT7Vd0C2a6utrR7o/fvW0IOWh51avGmrnS6JJJNLp9xcpGYoVKHI+/n1rrkt7ZUBRwBISdncAVk6dZqESAKSobgAdK6KDTt+xnQ/KpG7HQc12xg0tD57EY32knZkZiWQg2+QFTCg+5xV+00xmRA4+ToCasPNaWSLggsBtrKutdCRlQw2qeDVKHc8+dW5veVbQW2ZDvdTg+/NVZ9VtrdiUCqOo75ri9T8Rkwkg4GeQD6Vy1/r7MQoY4GR161tyJGLk2ejXHiYfM27k9+n4Vn/APCQEKpaRvfBrzwag9yjAsTtGetOt7hm43ED3+tLRBG7Oyn8RMM4c7QQc96rL4jLOQxwDx97rXIL5024bsLnGcVUJZZNgboeaejVhSuju010l3G7qOtTR+IyPkLnGNp4rz77Q3nIFBzxmr94HhiQn+Kp07GZ20WtQvK/m7SnoetWZprG6RgpCZOdw5rzI3jodqn5jwTWja3zbG28kDIFUldF3kjqntArgxk7VGOO9Pjw1xiflei5rJsNQmaQEsD6itm0lW4UCUYYnAJ+tRypbGkKsk9SOMSWiCVchWyR7nn/AAqr4sMWpaFHdgf6VCAWI9O+a2bu2ljt8IyvGMKvtXOygwrLA4Do42tnvWVSOlkephcZyyV9jjoyT9KUqa6O/wDDcy6BpesWkTrY3fnxh3YcvETu/DAP5GudVgSAOa4pJxep9DSqRqxTixVGDzRL2p0iHGO/Wo8E4BqUayVtCrJzmqsg7VemTHI96pTHI9DXRA8vEK25WkBBqPo3tUjjFRt1rVHmTEJGBgdKM80lJVGVxxqOQ4FOLYBqORs9qaJm7IY9MXrT+tN24Y1ZzNdSZfu01hk0q9KdxUG9roiaPIqF0xVtjx0qFxkVSZjUguhXxRTyKKu5zOJqqOamReaVY+mKnjXjFcbkfSU6QwJwafGuKn2ArS+UQKzcjsjRaegQjJwOtacVsU2lhlWX8qoxqQOnQ1uW0fm20bADgYNYzZ6OHp6EkECLyQu7gDNOH+jyBtwOM8HoKkMBZdjZDKc7hUUwKuR2GRmsX3PWp0tLlZ1389DUBBBOTVg5A461C4oTJqRRXbk0venPwKiOc4qzkegjvjkVVuJDUsvAJFX9H0xJI2nvMgdUXHWt6VNyeh5+LxHs46sr6TpUlz+/nUrAPXvXbaVarFlYsBeo4/Wq1lEHKxouI0wQPatxPIihXIAbOeBXfGmobnyeJxcqsrdDTs/Lt1DoeTjJPatO71AnTVZEPQDK+9cvdXSwxYQgkZB/GqMmrmKKNScgY3D2FXE4nKxZ1O9d2nVH4jfn8a5m+vm+fBySDj3qzrEwu1kayfazDLY4rJ/su5+wrOytncRz6daqVh2uUtUlbyGIY8HpWI8vnBtowR710lrF5imN0yHzg1hmze21KSKQd+w7VHP0NIwuQafJIZ1VuSeOPSuisLGSS5EZOAfWqel6aq6pEGUkHIxXQXJFnIjp3PHtTbRfLYtxaUYM4UkE5Fc7qdoYbmRk6GunfxDI8CqygFO+Kq3SR39p50IKt0bB9utSrrUTVzlVDBw+0blPIzW7qsDtZW5C8OPlPvWbJEPPCLk4+8fSuzuLMPpVuo5ZVB61Dl1JcNThvshVN+3jpii1hbYCWG4HrXax6YBDtPTBJyKzYtMJjkAQAA5HPeqc7Fcmhm2a+WF2lg2Meta1pcyRoAdpAGcHrUWm2Mk10IVU+ZjGau3totuGjBDbcDOKOchxL9lf+aCG7A8HpUlxaW13a7oiPOGKxZDEoILAfLkc4q3aXHkqjRvxsycHqciraIi2izoWvt4auba0v0+16CZytzbzqXEccpAlZP7px6e9Y3xA8OronifWxYiJ9MjvXEDQtuVUYBkXPsGx9Qa27z/TYGI++3JyOK5jWYJlQRxMyqT+8QH5SPX61y1ldWPWy3E8lVcz0MWN+OeRTZMdaaRtkdST8pIp3AFcdrM+pUuaJC65+bGTnpmqF7G0eHwQCe9aEpKYdTgjnNU55t8TJIN2TXRTloebi4q1jMd+abnPWhlw9J0roPDbd9Rrn0pAxpGOTTBz0qkjKUtSbqtRuOalTkfhSSL60kVJXREvWlfmjbikY0zO1lYQHFLmmjrTj0piTHfw0wihjwKKEDdxjCin0U7mbidBsZTkjOakhHPzA4IqaSNgxBXK9jVpLYBVznkda89y0PrqdP3iLyw5UgqOP6VNBbmRSSe9Tx2wLZQcdATT1EkbjZwSc+vFZOR6EaaWpJBpspj4TcxY8VesbGbKoGKk/wAPYVowsIrVXjOH5JB6nitazt0mVZo2BP8AF7Vm3c6aaMaeFkHlvuEgJzjjNZRDM5z3zXU3Kb5fm4yxCk+3/wCus25sJITnaCoBYkdqybPSpRutTEZcHpUTr3q/Ku/ayjORVaSM4AxyacRVKZQkqGRgB71auY2jIyDg1Xjga4uI4l6scVvFXPLrXjcu6HpjajIWY4jRhnPANbWoSRrLsjGFXjHtWleqmm6LHGiKrY2sR3Nc5b/PKDk4NerSh7ONz43NMS5y5VsjdsGCxMQTg8cdqWa6VSCzcA/nVQ74A+1seoHrVC7uG8reFIIPOKu9zxVK5Nf3gKlk+b8cYrISdpJGVmCgDr681Xa5LkjOFZsEk9Kz2eWJy4Hy7uaGrofLdl1ruW1DSREkqcOPUVr6R4kE0vk3Z+UgqG7cjFZ1v5F2BuZUYrhfepW8MTNBuiGXXLYFZJ2eptGNzr49MtzEjx/w4wB3pPEOhLdQLqFvtDYwwrl7TVLm0QebkbBg89qm1HxE13EFtmKoB0z3pcrZ0Qg1ubNnZww2zXE52uEIGfWueu71ZUIY5AO0flWRqWq3KxCN5flJwB6e9Ygv2yyKSQctzWkYLuRUlZmvc6gIX8st1AODTbHXntVfJO3OMVhStLNjcM55564qFo/lkPOexzTaWxg5nStrizSOdpCtySBXc+EdSjulCSMAAVAzXjykq2FJxxnmtKz1OazlQpIdgPJFKUE1YaqH0I3kJCxYxsoUgYrIeRY7MbQoaQ46V5jB4tmUlZGYYPzHPUVtx+KY52iWJslD36Vg4SWxsppo9Rh0k22kR3NtbFryVTgism8sHtLALcANcOSzA9vQUuh+Nnhsoo5MFFz161DdeJ4b5y3lK/JBJprmYaM4HVhLudnDKBkD6VDb3uzAR2OEUDJ6UzxfqglnKIxVOm0VgW02FBDcgDoe1dEZN6GM42PQtJvlcFGOSBVy/tkmjE8bfMOueRXI6fLgIVfBArotOusq8bkEH8s5olFdTGNTl2Myewju/MkKiOWJcsoHDe9YUhAJC8j2rr75Fgl8yPOxso3PGK5q90q5tEadELWueCO31rkrUrao+my3G88fZy3KWQVKmqUqgE1Y3FuR0NQvzmsY6HdWtJGfMuDxVZzVycc1UkU11RZ4deNnoRN92kFBFIK0OJvUnU8ZHTFS8nGeh4+lQoTz9KljIDjIyOmKk3TuMkjwTg5FQkVYx1+tR4+bHansKUbkAGDShs8U5hgnFNA5pmFmhWFIOeKVqSgHuO2+9FIDzRSKTR35hVnAJPXKk960jAXtwuF4PH1qrpYS+lhXbjOK6FdHmjkQsD5QJJPtXnyskfWU2r3RjPJIsS4gxhcEj1qliUSZckZ6sBnFejxaVavEkS4fBBP5VM3hqJLaRFC5aQYyOoNYc53RrRjuefLJcW+c5ePHBI4+tddok8SWMfmKMyAfMvr1rRutFWyIt5EEkJwCwq7pXhSEQM1vMyq3Khx0PtSlK70OuFena7K1za6feWYeKXy3BJP51iXMhs2Icq0ckbDk1rX+lXENw0d5GEGRtlXoeKz76yBdoHcCWMZU/wB4HFZX7o76Nnqnc5+XyljiKHg8tx0OahlbfOPLAIHU4pb20mgKGQ8PyKpKxhlJPLCtE10NpSsR3wZdwwT3H0q94Hs3udVaRF3NENwPvUUZM7jcw3Mu3ntXaeBdLmtLKWUJgucBh9a3oyvI8PNW4U3JGL4wkaWXy0ODnnjvWJaJ5MiF1B9a3fEkbRyhnI3FixrDhlJZiAAeSM81617o/PK129S8sqgPv+bJ+nNNMkU8YUjvx+dR3yskauOdxyD2rn5rkxzZUtgHGc+9RfsYInvdMjkZzHKFZSRg1TgjktnC3EWUbnJHBpm4yNIckZORk981ZmvZI9okYZXsRxTVzRdiFrAm4SW0yNxIC+leiaLKYbJY7oAS4249a5HQ9Uge9j84BVBxntXWa9PFJaRz25VmAJOP0rOcu5100t2c34zitmTdEqo65Le9cF9rMUj4U4Ax1rW125e4d85DDk5PGK5xQXbaT1ODirgtCq07IdeXDThX+Y//AFqLaJjyowCO9aenWQkeKMqWLuI1CrliT0AA5NdHJ4ae1nuYrq3uIZbZWkkRoWUhAQC3I6ZI5odRLc8+8pnLrasEUggNjuKry2zvllRvl+9x0GK7iDQnlZ4oo3lYgbFiUuzH2A+tVNZ0a60u8u7O4hkiu4SFmhdSrLkZGQe3NNVIsHBrc5PUdOu7FbJ7q28tbyEXEJz99CSM/mDWciHByOewrVuklg8oySvIUXYqk52r6fTms98Jlg4JPP0qtCOtkRS7UkPvRHM0TKUY4BzimupK7jjJOajIxjkHIqk7DudHp2sEFUZuSPzq2dcIgKIMFc5561yKnBzT95IFRJNu5tGppqalzeeewJOCRiqscpHIGSeMGqpY9Rwe1SxFimQfueoqr2QnUudDYTkIvzHOAAfSt6yuSsoLE/ezXHWdyyhThRn3rfsZd/AAJPvRG/U52mdbPMLm1wpJbORgda0vCix3IezmP7t1KlSPWuXtZ9mAD0Ard8PP5WpoQTz2NJxvudGHqOEk0c14h0z+ytQltxkqOVOO1YkgwPxr3nxHoltfacHkhVpZEOMdQwrxG7gMUjRupVlbBBrgqLkkfY05e3pKRjzqetVZQcVrTR98VSni2itITPOxOHauZxGaDwKldeaaRkVtc8twsMSTB5qUk9arkfMRUiE4xTaJhJ7MeD8pNBwxGKQj5c5FMHDA0im7EkoAGahqdyDGMetQU0TU3CijFBFMgSilooEfVHxD+HjaX4gvNT0y0KafkM+wYAJ64HpVKwkSK3zOodFGN2K+jtV02DVoUjuWcwAktGpwJOOh9q8U8d+Hr3QLqJo0WSxn+b5R/qznofwrhxNJw95bHsZfi1VtTluZF5BaXMObVHiuOPmUcH1NGmX01xDJb3KgtaOMnpkdqoXmpX0EpzFiPsyjtT9Eu43tZ7h3CTXDgHd6VxKWp9AqDcTpbyzG19y8MQcjmi282ztgRH51qoBYd0PenW2pb4TFPGAo+UEd8VZgDsHcZ+Zcsg6GqavqmQlKKsxdV04X+mbl5B+YA9V4rgLjSWN1smk2zxnK8/eX0ru3Yx2H7osGX+E9xXPTkzXJMAV2PzYPVcdqykrO6PRwM5wur6HFawC0flsQw3YGOxHUVzDruYn866zxJi2u94yY3+bB7VytxyznsemKUGz15WcbldW8t1b0NeweFL+NtBhjVMH5iD/tV46w2umcV6b4LmLaGiu0YYOSB3+tdmH+I8LNI3os5nxc+68I9uB6YrDt0ChSzcE81teJYQLpieQx3ZzWH5MvzuisAB0zwK9O/Lofnda/Ma0qrPprA4ZVPy478Vx1/C5kbYCMDvXSW7MsBGG4HXHfNN1ewlkjS5i+ZQMMMc8Vmk09DNb2ONRbuEbQFYE5J9KmvLlpY9kkeCeN1a8ZjUgumQzc57VPeQQXMWeAcYBNWk2dMafPI5SIhGUKT3xV9NWngTYJDtJ6GnG0iWZuccgYpl1FFGoKklgcn06USsmd8aPLqynczIwZ3ViT696oRGMTJ5gz820gU+ebzHYgdOgqBDmQEg0RTRyYhJqyPZfg14j0Pwn4hj1LV7GOeBwsXnGPe9qxJxIg/njmvpjxhrOi6n8O9evbS/s7i3m0+eFZkdWyWQgL9ckcetfDen3rQNy+cdq6CDWEeJozBGNxDkjsR0NO1lZHCopbn1n8FdN0O08KQyaWiNfj5byR8NKsmBlSey+gryD9pO1J8eW97a7FtL7S/K89cFZJYpW3c+oVlFcBY+JJ7KS9NrLJE08QjkZJSpce/ODUHifUVl0/Skj1Se72RO5gkYlbdm4Kj/vkc1L0XKW0m7nnl/G/nMpkZgv8R71TaEleW+Y8c1varLBcXpa3h8uJwFVAcndj9cms1w2zcig47fSqitCHG2pRZNj43A4pkmSAcY7VYmbc2WQnOMYHSq7HAbscfnV2ERVJHgZJojX5u341ISdw3Y5IzjtTKURHKmFQOWHX6UsbhYnwOW4zTSoGcAllOT9KEXlduemc0rg0W7dQyRnIyentW/YoRGFH3xnn1FYFrhWQZYc9a6CzLKMlugGM9uKq/QzkTTT7WLsOOhH6V0WhzE3UJH8GAa5+4YMCCOCN2fX3rS0OXdNCVG3J5waTHT3PfrKFbvQicAMAH3EV5N4/8PzDUpdRt1D20xGNo745r2LwmVm097cjckkWVz64rn/Edus8UlqjFeSAvYY561zYiN1c+vyh+7yvY8Hli+U5HPpVC6i45FejanoybSPLAkwckdK4W9tmikeNxyK5F7rPUxNJSWhz06YcioDwa0riDnNUJYyDXVCSZ8xXpODehARkmgZqUrgUqrWlzk9nqIqgpRtFPUfKaaevFK5o4pJDTwtQ96sdqgbrVIyqIdSHpTd1ODUWFdMbRTi+aKZLsfpAJI7C8uJQzGCQ5fnIRqZ4l0warYZiZSVG4AjIYelZd1ONcsnhtHNu12jvBKehYDABrM8GaxqNiZIfECrFH532XduyBKq5OB2BqHJP3XszWNGcf3kX70eh4nrsWr6NewwalC6wXitJbs3ULkj/AA496htNDlv4lFvcFQpztY85619HeOPDFv4n0owttW4jBaCXGdrdvwryPX9CTw3q2jR/MYrywxKS/wAwnQ/Oce+4flXm18K6bv0PpsuzeFeKptWl/X6GfY3EqSPbshYxDawPUfSugtLtWaMW2OmDnqDXO3M8UUnmrvaVgVAH3uDxVxLdzaNcQ8XAwcg4/OueMrHrVKakrs1dSSWO3nlG18Lyo64rmFuojbsZB5Vzt+Ugc4zW3Z3qXciRyELMp+Yg5zVPUdPitrjezg8FgRSnL7SKw9oPknucp4hima1R5QsirkZA5Irk5LI+W0iAnPQV6DqTM9o4iCsRk/hXNIkMSxkhsnGR7+lSn1PXpu8dUcwlu0soBXk8c10XhyWS2uzbS8HHy5+meKsx2guVcBVVlyw9aqyu0ojmGNyIdx9CM11Up2dzgxsFKDiSeJogl2UYgqDgn0rDgkWYup9cfWt/Wm+0afFdbSu8At+FcrZRstwwYkHPPtXp/Ero/NsXTcJNG1aw4UjH3TVqIr5h38EfKAeh5qKBkikIySuB9atCFJZVz3Oc1LucqOfu7RYJ5FPQkkcdqpyS29shLMrL65q14ldoZJMNyT+lcmJU8x1lYYx3q4Lm3O+m7ahdXCCZfm4wSSKzJpw2/knPHNSXIjiZirAgg4qhKxySRzwcUW1NKlW6GOwDZ5+lOtwNpLuwwCelRMQcnAz+gpYnIwQfXgnrV6o4JO7LUnMvOQM54Gavifyo2HJOMdPes+NvNlLMCFJ7HpUwI3kFzkcA/wBKV7bEpdzRt7hWDll7Gm3MyLKixyCdGjB6Y2tjpVOKZUiYkhsjnHrUWI1jVgW37uQeMU7K12HLZmr4dvrnQ9ZstbhihlltLgSJHKuVJHqPSsu8uvtVzLPIArSytIwXhQWJJAHbrUZdnGFbPOetQsxOQMDHUelCuDjcikbbK+GO3OBimmMkKOvHX2pMHdzzk5qRSRGOTnsKdyYxGvGFOMjGKRgAWzz7ipnY8g4HAHI61HIpUlc8gdqpIvYiYjJx9KcpO0BcjjmmgHb9evFTQqSowAxxnGam3YzbJbXcBt2+netm0fyoSHyeuaz7VEZyu0EgevatVYwIjjO3PX3p3TMdxZJgFyx6DABrf8NjdLGpXoOMetcvc5Df/XrsvBMBmuIgeMkHig0p7nvPhNAdKIJx+7I/+tWPrcDQo6r1GHJPc4xXTaXAIdORQMljjp1yKwPElwiwugUsysVOOvFYVnofY5TB2OfmgW5sHkCgsrHIHcdK4m9t4WJEqBlXjkc4rsLOWSMzuUYRSrhVzz15rn9ZtRuMsTEh/vZHQ1x6SPZnCUUcXc6WNzCMHaSTu6gVzN1Htc9+a7aSYWzAF8xseVz0965fXLb7Pckg7kb5lIrWOmh4+LV4mJNxSLytOkGTSqu0Vt0PFcW5DEPbFDpsOKkgCmT5ulJMMux6c07i5fdIzwuaqseatS/6uqhPNXE5q+jsHPrSrwaSlFUYoWiiikUfd+oW9z4csRaKwW3imRomlbICbucHtxWhbWVvr82o2F/p7eSZA6zK/ByvDg+tbGlTW/iDTPKv0WRhw2Rw46ZHtWNGreGdbuDaI8tu8YLw5OABwpX061jyqLUuh2KpKacNpo6m2neCeC0CFoVXYHPXgdf0rjfido0txCs1tbmeac+WkigZgbru+hAxWvqurKNIN4VlEJlBaLHzAcdMdiataLqC3+nyW8EsbyxglWBzwc4H1AOK0mo1FyMzo+0w0liIrbc8WtrV7W9YXSM7Bfmc9VqzbsrxT/Z7k7t/APcV0vi3SNSk0+PWoLmCbyYRFdxj5GG18DHrwTnPpXF3pn0+5jYxjaxwce/SvFrU3Sduh9nhMTHFxunrtbzQk9r9mL3CN/pQ5I7N7VI1xJLEJJlUAqPlB6VFJfx3TbG4ZeuOoqpdyK0beXKAcHPtWG2qPThTbtzLUq3fPnEAhQcAdOPWsa5DCMYXJUDketWWvSskivhkOAD6mmB/LuCHwVdhg9hVJpnoRXKtSt58scTREsBjB9SazppSm9AzIDzz1wa3pHtvszsNu/ovua52/k3tuVSMLgk962g+hm4826NXRZxe2E1jI4JT/VbqwbiE21wfMUjJwcg8VHBPLHcI8YO7P8Irob+N9Qi84QlWeP7xPXHtXrYeomrM+KzzA2fPEzZFG0OhG49MVcW4kjtjwM569aqwokagSjhBjH40txKqDykGVwfwNdCR8quxja85uFbdkYPFcTeMFm3e/wDWuu1SGUW64PU8/SuK1GNxK2AQBwBmk0X7SysV2bO4sxyw71FlsA55NRuCOCaazliAT7UJEOZPtO3aCORmheuSOeoFC/6tvbpT1yHBPU/rTsGxNG+EBx/9amySbQA2SOpIoUq22MHJz0qJ92AAc8Hj2pXWxM5D4pBli68HGBVrTrS51bUYrK0iEtxNIBGAcVQjUspIxlcU2J5ILhHjkaN1PDA4NKyMlJmqbVLLU5Le8dQqvtYxkNj1xWnfXHh0+HrKz0+0m/tWO8nae7k4EkBVRGuM9Qc9vzzXMrKRnqe+TT13O/cE85xTaNou5KIiwbG1sjqKjKkRqSSWPatC1lgSHBODnHSq3lCSWRQwCg7hx1zSLT1IeCOMtgj8KbyFwowc96mK7ARgcj+tV+WZl7Zp31BjSWbGVwvIzipIYj0AGSM5P8qlEeIUznB/wq3aWxk2lQCowfwp6oycdCW1hbzIwy5YHv0NW5S2FIHHTI4qa2DBMcBexpJYw5BBG0A4FNpmZE8bzy4GAuMZzzzXqvw10lnm83G8lQAfxrz3SbM3dyiYOGI6V9BeC9MFjp4kWPbtXGTSbSO7C0HUmrHR3DNbxKHyNqgAe54H8q4DxRfNBos2qW8tu3+lGJYy3zsOQWA9ARiu21e9hkvIIWyYnwzlTg4FedfEO5a7h0e0SGFdO06NoVMQ5cs2SxP4fnk1x1pe6z7bL6NROMUvX01/U4mLUbqGTeJWLHPU9M9cUXutSy27I3IHc1JeWRTIVtx3ADiucvyylhziuCDkme5i2oRuQ3l0rKSwyxqndSi7jWNRyDnNV5mJIqezIjiZv4s967YnydepztooLaOGbzEIUAn0qrKQCcVs30ga1Zyfn3FfpWI/vWkddzyqq5VZCJz9aOhNCj3pzHiqMktCCU/Kapk9asXDYXiqxFaw2OCu7sUHijNIKKswuxc0UgopDuz73W8s1SG3OpxbInRIriCQESEthRj8a6fSdSt9VFzp96UN2jyQMAeXCnrXjF14OuPC1ro8pfAlYyzpb/vGjcfMMD0Fbvw5upvNdreQS6pe3LSmSQcQIQSxP1xjFccKslLlaPXrUIzp88Xsdx4nsL+y8Pyx6bC1zcREtETyNvXBri9I1yC61w2yxi1mbGBD/fx09q9TS7jvkmgglYXMKAsRwORxXEz2i2FzFejRViuC7tJIrA5IP3j9a0qR1Uk9B4KtpKE1r/mTX0Fr4h0+7sYQTdrNGZCCVYlRuwfXmvO/GsjP5Qs54y5DB0PXKnBx7iuonuk0/wAcNqHkulrPLtbDYz0ANLrNhHeaNpyR28IjtrqSdLhW6xSbiR75J/QVzV0qsX3R6uDm8JVjK2jt8tNf0PInjuEmJdypcZwO9IIiBuVnctngnpXWarpqeY+1lO0gcds8iuauka1mPUqoJ9q8lpxdj7OhiI1YpooKCyZ6Y5UfjSRbwziaQ8ABVNWGdblOAPMU8A1QvJygVCPnHB4rSEWddrot8MgZkAUnjFZ0kZbcHiIB6HOc02KUyYRiQMZBPb3qzaTPGIy8ZePPY89etbbIzkmVrCzbzEO05OcGuj0u2aASeeCITGVG4dz3qG0ZDd5UbWGNldViFdNxcukYJyc9zXRRlZ7niZhTc1ax53rFrNbu3zZVBkHH3qqQEtv3EFyOB6D1rsNWt45QSrL5IRgrg5zzmubntTbzALywAA4r04zUloz4bG4OVKWiMe+iYFsDdjp7VzOp2eZWJHKnIx1rs7qEk7s5Ytzx371kX1rvkOAPoKtps8uW9mcNdWoil+6Wx1FU3QiMjbghvSuwvbIE4IGTWJPaEOpXIHIpqLE9DOt12qQQxZu3tTz98YYY5Iz6Urq0YIbG4UrBWOWYnPJAov0DmI1f7PN6tjcCRSSMWGW6NjFWHVC6BxlQetLdKqlfJPy5wMjtQrCvcqxDcGyB270GLc+GwSD1zUuw9FAxzuFLt+csMHsfak3Ydr7DVGSDjgDBPpSqnRgx3YqaEhItp2knOPrikldiED4yBgYPTii+mhrFEakkd+MZqQZTD5wMA8+lRcZAOVOan2ggeo7elTqwkRMyMxA5PvSrE7tu9eD2qVVzjaAA3P5VPFGh4zkgc8VSYuaxDDCz7kbJUEYrTskCR5Y7VwAMdcU+1gyjEfdxyc1Nb2q7oQF4AxVNpqxEpJqw2JzIgyMqDjpVqGHLBRkgnHWpooB5CjGCDgD15rqPD2i/a5vMdPkUnB9cdv1qb2RVGk6rsjV8B6DkrPKvCrn8M16XqV6be0aGIlc9QOwFVrOG2sLBQTGjKACPWsDXtQYXC21vjMvJIPauWpU0Ptcpy7l1aNG1uLmLStTvtsbqkIjAkPzZZ9vy1zV4XlTDttR8YXGcY/8A1V0zIE02K3IXawDMT9c1gzWx+1hZjgPnAzWFW+iPocNZSkzmpJULkKSZc/NWBrVuikEZUsCefrXW6tpMTySTRPsIA5HrXLao0nktFOG3hcr3/GuaO+pviZxlTscnLExm2gGryRqymEgE7MD1zUe4qN4yWyeO1RSyyySkoTkDmuyOx8hWgr3RnzFh5kbc89/aqpXPT8a0b2NypnwPm4Yf1qBHtickkeqmrR5lVK9mU+lIxzwKfOFUZDAj2qv5vDKO4xWiVzmnJR0IpBmQ+gqOQVMw2iomOK0RxzXcjFFITzSZqznuPAopF5opFLU+8PDdjaW1hpFnFembyIT5/nHLFyM5B/E1Zn8OnTo7nU7O1jlacxlk37CirwWH4HpWbrWkXVrqara28UWk226aWZSSwIGQB7YrsfD2o2upaSslxLEweNcKWzhSK5oQT0Z6dSo4pSg7og01ZLG6Nqw3Xk5O91OQqjpWtcafFerLG77p0Xbv7ZI6GuK1m7s7LV11SyjjOMQzhJsHywc7q0LTXFTWra200zMJ8O+47lwR1z0704zjH3WROlOX7yOjOa1eOEPb2lxYtLcSXKoTn5lH+Fb9npx06xXw+/lvdSiR4sP92MZwh+lbeq6Yt6zzJj7TbsGbnr9K5PxFp9xq0vnWpkgug29GQ4YuBzz6YqHD2bvud0K31hKN7Jfn0+RQ8V24uHn1hLEwxR2kEV2MjhskA47gAgZ9K4vV7QI8WF3RzqefT2r0PQbmWd4VdUmivFGn30Zblc5Ct9Rkg/WubvtMewkudKvCDcWZwD2dSMq4+o/XNceJgnaa6/metlmJdGboPpt6f8B/geZ3NhIkgdWIOSNw7DNV5gkzbWLbuBn6Z/xrc1KTyb4FT8mwAqfX1qhfQR3BV4sxyj8jXGvI+zp1OZXMO4hMYIA+cd/anW9+YtqvjjI+uat3yMrc/exyT3rI2KxBf5W5rVajn5Grb3Ec18xY4G3AxXSWk1mkaLu8yTH8fOK4PayqGDdhVyK5kjLEHvwe9PZmTgqiszqsRzXTPHHtiUMhXOAxPem6tZlcSkc5yMcVj2eoSJgtg9+tbq3wuWVZBu2jJXsK6aVXlVjysbl6lrYwJoJRdHaudp3NVa4t1kXcAQc5xXR20AleeU8DJJA9KzpI2CyPgYQjJ716NOpdHxGPy+cJNo5u7sSxYEAN2OKxbyyO8qRj3xXdypFK27bnJyDWbd2OGUkdc/LW6bZ4k1KLszz68slLnb15yao/ZPlYngluBnrXbXGngKDtywzn8azbjTQoO/I7fL6UPQz5rHNtakK6tzgdQaiK+rZXqMjoa6BbHaNgVsdRzk1XlsMH7hOf0qWPmMzYcHhSc800ou/K5w3Sr8toVB5wegxSfZWKqpDHA4NJxLUrGbsVkc4wUGfqTQiKf9YxBKgr9a0HtXBC59BjFKtlhgCpLj5fqKpRsiudLYzo1BlGQWOcZ7ZrRWAYZR3xn3FWRp21wcEDOcelX7GwZim8EGly9iXO+5nR2u5+EHH8qtwQdFCDsBkVr2+nN8m8ctkZIrSttNyGbjAGemKOWwufojFisn2LhQMnoK0DZbFUBMYUY9611tQIH2IckcGr1hp0l40csYMikhCB9M1LtF3Z04fDTrvYzdM0lprjc8bYUfh616fpmlwWFlCuATuLFh244pthpkVmY5LlQAEyy+pxxmmahdZgBhKmIdPauepUTPscuyuMLOwt3KiR3JdlY44GOmK5fT5mvtQjkKcbTjHTg0y6mklnxESTn5xntWloUAsraSbHyqCBketcd+Zn1KoqhDTqa8komBgJVUCg+9YfiC7USrbkFTGwaOXPU+lVXusbx5hBcdf6VBG7XCN5vIB2ncM5pynd6BTocvvE9xqNrdvGigxkk78/dPHrWPqsMU0DYAOFxvB6Crd1BbyQokZwyjbnoa5XWJJbGykjeTDuw2gH+EVmr3ucuLlGETGvV8m4Ma9CxxUyRLb25M4AJOQT2FZM15KxLHBI746VT1K6nkH76Xd6DPSuuEWz5XEYlR1Q/Ur3znOOB0471lSSYNRs5OagZia6IwsfP18S5O455STRG/zc1FS1rY4vaO9ywz7qjc/jUeTT+SM0rWLdRyGHrQKKliTnJpt2M4x5mCgiirAUBdx6+hoqLnSoW6n6VywwXltcWrKpRgY3UehGK8w8UeGdQ0+40iZZLe20HT513rbZVvKHQtnrz1rrtDMVvpt/eWUTxyXMry75nz5je3PHHStSwI1vRFTUoEZZkHmRnkHvUySqK3UcHKg21seZ6t/Y+lafEdL0s6pcm4Z1VDkJGxO5m9RXXWunWaGOe3QGUhfLG8qASPb0qTUxYeH0iN1Di1kDx4jQnYo56jpTdBvBqGriWzvJXtpLbfFHsCqDn3GelY8lnZnW6rcHKN7GhpaSx3tzAZlkcEKwIwA2Mn69ah1W2a0vFuYdyOD93GVYd8Vb2efcBhZxRzqxd1aQZbcCAwI+lR6dctHokYugZ5YkIDqc7ucVqktmYKclLm+TR59Bo8KSao8F3JE8h3eWMfK2c7gfUHmsvxpf22raRa6nNcrb+JtLmjs7mHO03UTvjIHcc7ge3Ir03WvDsc1rPPArCcLuwv8AF6j+deZ+LdPhvLAXkcRW4hjB2nqfr9K5KsZU4tPZnuYOrDETjUTs0/029GYWp6fAodkO5T2IrnCiRkh1OFGfpW6k5vbCJonJONvI6Gs+6gkWRCQoVjjp14rg5o9D7HDVPd5WzGmiEzPxlcDn8Ko3FriNSVJwMjA6VfcbWyvTcQR9KVlaeHchwP7vpR52O5anOTxOrDGSoOAR0pYWPlhtpwOM1oOpkLDGHHAzUc1qyhhyXGDxVNoqMdSmdyZ7fL61dtNTMEZWT5yeo9ahMfmHGcHGOnaoTbsDx1FJNFSptmvaam6pIIztU/wntU1rM5PmThQSMcZ5zWK2Fckn5z14qJ7iVG3K5wDwK1jO1rHDWwsZXujZkl8uSVX4VvmQ9iBU0bBkVnIC7e9c+l5JK488ggcc+lXrFlaMrG+ccYIziu+GK/mPmcbkkaivBGibdZonbbhjzk9MZqCXRzKgWNQT1zirMFzwULDHAIx3zWpZu6BwjDp0I6V1wmpI+TxWXVKUmmjmH0YwoVaML68d6pnSWLMApYH+Vd2t2jqyzICEOSc/pTo4rWQeaCqgEKB6VqmjgdCSZ5zJpBBPBwDjpTG04cgADHY16SNMtmbhlYlskdqh/saJwwYqPXNGj0DkaPPF0zgZUFgOppW0h0YMuc55GOBXoLaXEsbLhctj5vTipDDYxBUZlbA54qLLoCpyZxcWjSHBzkAZIxV1NFkM27bgEDPauha5gSeKOJQVfPbtUcrvdS4XCccL6elPRbm8MLKXQzorKO3jBmI44A7j3p6qJAqbcBuOnWtBNMeTBAYyADI9f85rd0nT4QXkkG2NACoasJVUtj2MHk8p6zM218PSSbmlYRwKFKnoD610NrBb6TEDZqox1I561y+s628lw8KsyJGMbOxqxHqaPagiQbgMbQa4ZVuZn2WHyj2ME7Ghqd9a20Mkhk3MSC2T15rlNR1syO3kDAJ4HbFVL0s87mfBG3PXrWW8iqmBjI7VzzqM92jhoUlrqaGm3TyXvznAPWuh1q9EfkWkQP8Aeb0Nc3oFu810ZFK4Hy4PXmtXWU26hJNIwyF24H0xRG7iTJqU1cqs+PKG0O45wPSrELkRSI20yMxK1DZRNLIcEbtvJH1rRjsHDOZBtySdzcAVcdQqzSVjNvFS2VJWO6Zuij6d64y/SWd2ku33HG0AV12u6rbx74LdhheC+M546CuZjBlnMj5MY+bPatYwTdzw8VPR8xz02mzs6BeA3JzWTe2E6EgfOucZHrW7qetpa3LpHH5hTgHPFZsOvSu0i+XGA3r2rtgrK58TiqilJoyJ7GaBQ0i4BFVZYJIgpkUqGG5cjqPWr17dSXMh8xgcenSq0ru4UOxYKNoyeg9KpNnnzgmdT4e1XwzbfDvxNp2qWEkviC5khbT7kLkRhW+YZzxxn659q4unMOaQCtDltZiqORVgAqm3tmi2UMxJH3RmnsGlbPTNQ2dFOGl0QCPJyelShfSnvHtAAHIpcfKMik5GsKdgc54HYcUUDp09qKm5o43PrXxNp+q/D3VtQ1D7ZcXnhyWaOZbcgsYyN3y5z8o+YflXc6V4pk/sq1lFiwS5Tc7owzCcDaoHfjvWx4ZuYtW0qbT9WjilWPETiVgxkwoB3D3Oazrzw5DoMR8ucrpau8yRkZ2ucYBJ7elZqNvei9ClNN+zqLX8zstOu4dSsopQoxIm7Y3XB9q43U9Nl0WG41LVJ/MS3mH2M2+UKoxA2t69a2tPS3XUYLlbiY3U9ru2KMRlRxnH1q4z6b4l064sblPMikQCWF/lbaeh/Tr7Vq7TWu5zpulJuPw9TDuLCxkuLW7ZZopQ8e+WOQ5YKxIB9smo7eP7NdWtnp7GOI7mkiL5dgW+8PUZNVdUvR4ckFpNbPFCN620rZaNgQMKx9c561T1i9msf7O1i2tt9xDEAWAyuG6oD+tc0tGd8IuSuup39nqEM91LbwYIiUc54JyQRXGeMbVF1NYYVAE4d3XHfArT0BjBBdzLbFA8jSRuw4y7Zwfoas+KbcywWd/DGGlSQBv908GtZ/vKdmZYf/Z66ttt8z598NSyRvdW5AG2V1bJzjBNXtVDpaA4VzHnp24pPGaLpHxN1CzhVRDcIlzGwPDZ+9+oNVNRuNsZERy56j2ryJRcW4s+6wlT2sY1F11MZVYxlZM5xkMPWizxj5iEm7+/NT2CzPub7sfIZT0qrqhIUmHClcYI+tCdj2ou4x2EjNvXEisQamgQmXLMGB4HHJqpbyPLGUlyr5J+tWYVZGHByTgH260XT3NktR81soyqrhuoqsluyqenvmtQsN+HHXg1BMoZiozt55po1jNvRmW0KyPIrkbuxA6VXutPIAKnP9K3Rb4CkDPGDxUjWqyDfyPUU7dUKUoPc4yW3Kuy96RJHgBZSQ5OBjtXWTWELRnoe/vms9tKDBiHAxyCad9DB0YvWJS0a43TEXEoCg7jnvW/JIpAMcgAbqPaufubCS3Xeo3KRnIHSqInmikDAkEDAq4VnHZnFXwUJL30dfFMg3IVGAeSTSRSLM0wDgKCBgevrXOR6uzSAyoGGOfr610Ony2twsjhlTcfmycV0LEN9Tyq2T0pq8UWA4TKROP4T1qA3qNIULfMM8Bufxpl/LbWNp5rurSA4VQc5Fc95sM95JMpEZbgnp1p/WHexxrIqbex1sbiRWCPjavAJ68VJkSEupRQOMj6Vjpa29rAbia6BRhwobmmT63aWypDbIZI1Gd3vT+sSZtHJaS3RpRFHWM/fl3dcdKmSZlg3TIqHcAD3rnBrs0rkIqRIfQd6rtqExIyxbGck1m677noUMtpRs7HoNtqkcCSsxD7sbcdqz77xAgk8pVIXvXHyXskkpbdwRgjNSRKSNx6EVjKs5bHrUsLSWpLe3JnumcDHPU96SGVkp7L5quqjJbG3io0h+XJODgd6yaadzuUktBtzLvOMksW/Smw28Mjv5r7QDn60jttQIijzBnJFW9IsfNmeS7VvKVCcH+I1VrmE5IuaAgAluVByoxk8Z61JqoMpM+0cAbgT1qnqmqpp6GKAJnGMD+E1VguXks7eSV22yHBJ6cGrjaxxuolIvWRe2m3AAlh8oPbmi+vZbiJkefk54zwPas+5m8ncxkySuMVjm4xkjk9OtJb6FTqJasS+YLKNo3t6kdKTVL+ODTREhHmjjp7VmapelWPl8YJxXOX15I5+c8k100qdz5bM8dCLaILpsuzdzWc7ZJqaSU96rnrXfCNj4rEVed6ChiDUm4kVDUqDIqmZQb2EYd6ciZIBqZFBUirdnZuyNO6N5KDOfU1DlY2VLW5ViUgMQfarESbULt06Yqxb2cpIBXgdcim3pUMI4+B1NZuV3Y6oR5UQkl2pj5zz0pyrkcGl2ZcKeKLltXQ1AANzDjtRXXeCPAOseMb1IbG38u1VwslzICETNFLmRHNY+lfh7HY3ms6ld6qo23V27WqS5QOynA2+vrXo1vcxatb32m6/DCYDL9nRGBHmjA/qcZHpXl+s6/4cgutBuMXE72V5bkKDnEQiOXwPdhnvxXU6frmk+K9AkuLjUJYoi8sMb42MjbjhwfbAqacktETVjzaszPHlnq2j+JdOvoYI2022UW1kEkKqm8hWEnc8Z/Ksqw8VWytMp12O2/si7CPJCN6ugyVVj3Xkj8K7/wjrMGr6BZafrjRy3UqMgYncs6jgMD6kfrXByfCbS/C8zrEl1dadcyAuDyF5z8x9BU1INe9A0o1F/DqLX8z1HS9a0zxZpMgspRPFINu8IcY5G8Z7ZBrJt4msdPh0XxEGvfLJMV0se0HaMgnHfFZEF7eaZ4XtprOK30xYJRBGjMM3MIJ27B+NdxL9l12xVUlKSrhsA/Mhx0I/GtVLnXmY2VJ/wB2/wBzMy7VdIjaRQbixmZcyA5MZPAJ9qvWTRmWGOSQujhgUb196zU067sPDuoW9/cJdqGVlZRtJTjIPvwaq+av2ZdpDeZArrIDgoQVH4nFK9nqaRj7RPXrueMfGfbbeL9L2JtaFZYGYcFiH3D9DWDpsq3jAM7IXbBOM4rvv2idOig0zRtWWM7zeqkko6cqRj9BXm9lthaB5ATE2QvqDivOxEeWZ9jlFZVKCsaerKLOZTE5+f5SD349KpAC7JwR5Q+8anubCO6s5LiKZ3kQEhWbpVa1mhW3CIvBGW9R3NYrzPdpzsrE8UJSAtjJBIBxzUtuhuSHjG3A6VcKRbjIOUKjdz696jt4/LlPln92OeD1FUkmzeM2PILKMr35OKiKIih2+6e9XIHWWQgDKgZFJJF5rKqjIJwR+FPqCnZ2YqKpUbMc/rSSBlVgB97pgdait4jBLIrNhgcqpNSTSHZkYyDkDvWiSaFbXQpXa4QHbtzk/jVEEgEseM9q3mSO4iUP93H5VkXWnNGy7HJUnmlKmt7HRRqRfuy0IhLuRwQCNvBz1qtLYR3EQ3ja45460K3kvsJytW4nWQtg4bHH4UlGFmbThZGDLpbq7qBuA6HNZ00E8JwysBnFdYELYJzu3Hv602S2XfiRd23BJpJHHUpXOOlLt98E/WolznvXaSWcaiQ7VIPyncKxrnT1EhRVwvUNjH4UNNHNKi3rcxpJHIwSSPTNRpv3ZPSrstqylgeq4yBTY4epb5RUuVjP2Um9Rq7iMVZVWEeOeaiVQHIB4q0rAr70tjqpR7sS2UBju6YNaEE0aRHdnPTkVSZ1C8im+ZgjHIpJ2OqLUFY047tlDlBk9uKltUV0VpSI9vbuaxvNlZSwO3B6UqSFQHkcseoGavfYhzudnpFhasXlKpIUHp0rL8RatHbRbYwMkHCjimaZqhNtfSkAIiDpXF31w11dPI5JB7D0rRJWsjz8RVcNURTTNNIWJPJrfeYR6DaKD8gfLfnXONwBwRXQQrHPpPl4ZvLGVxVKOhwKo7tsztQumeUMpwMccdqypJmVS7HljxzVi9kd3AwRgYH0qnMEWBsxliOAaqEEcmLry3K107zHfhQo4571i3RHmkq27k1PeXEsv7vOAvYCqDtheDz1zXdTjZHyOMrupJ3I5z82OKipSakgheeVY4lLO3AArbY8pu7uRgZPFaekaXPfSFUBUdiR1rqNO8Ltb2IeVCZ5eDnsPau10nTbXT2DyxZAXHpWbqX0RpCNtTmtJ8H28CCW+lByu7HpUN9LC6vZ2yA2obIOME+1dHrGoxzW0yRQ/wCwpH61yOpajawQ+XAOehHpWL3O6CbWpn6sxtSEDgv3ArGOeSeTTwZby78uJGkmkOFVRkk+lex+D/gF4k1S1t7/AFMwWcDHcYHb95t9x2qrco3JHkunWF1qFwlvYQSTzseFRcmvfvh78BLjyhq3ieeMqqho7VATk/7Rr1j4b/DW08Gxlzb2zvKcmQnLrntmu41GW3s7Z3edooFAHC8A54NOMXLVmcqt9ImFptpBobW2m2lnGbN8O6RrgRnHU0Vz8mrXC69BDJqSTpKT8sQ7ehoq1ZDdJPdnluoeAr2w1yTStAlVIbiRvKkuiQS4H+rJ9Diuqs/DlxqzSaZdW66Da2UqqZEl3pIWj+bH/Aq19K1641jxHLZ+J4DaCRzLp9xJtV/KDEKOONxBzV628ON4ba+eS7muLGbdl5W3EtjcD9O1c/IlqjTmb0ZXgtYNLhQPOsuiaHp0iRzoMeZLlRj3PJrrfDninTbq+t/DVxc/adRNn5xbaSkqZIOD3I6EVn+INI/tbTtITT2hsrODbcTIp6jHygj0z1zXN2wg0fVNXuGuYIrFLR0jAGDCzyg8N1watS5GZuHtIk3i3SNN8G3KazrE9xLp8A8u2Zl3iBmPGB6AV13gjy9QjjviEbKvsc8PIhI2uR6YqaC+0/Up5NA1hIZgYo5YhKMidWGeh7g1Jq2n3EOmfZoJ2tFjaOO1ktxjgAcP7ZBoUFF8y2E6spR9nLc0NcV4bUSjHkKNkqA9VJ61ydnBb6dII7y4lmtYF89CF5VZCV+b1wcV0Gm3kV4l3vuUeEMYpoW6o47iufeATWSi2LNcsTFNEw/1kYk+XB+v86U5Ju6NKCcU4sg+IWmHXfAur2Ua+dJ9mS4iGM7XXnI98V82f2g13ZQMcqiDBb3HWvrPw8pLrw3lOGyjc7QPlI/Ovmjxfoi6F421rS3wLaSRp4FHQKxzisK8OdKTPaymuqdR0/n+hmWN/MIXIJWPIGRV1ZYQPO3DO3GAODWSts8B8pshC2T6CtOOzUWb+WPnYnvnFcfKfXxqpq6HLMZMiEHZkc5qzaXjrFs4GD830zWbCkkC7Dx0ANXVEZRDuwTjNCR0xlcuG78sgQsRgg4x71uR3KXSoGUI2fvdCa5i8RYohcMTgHGe2fWnabfK8gAk3OvY9DUJ2Zo4Kor9To7uGI/OJMOOM5qiC3mSAsCVxjPeoJ50mPlsNhI4PvTEbYgDkHjrn0rRPsVCm1HUhnllWRuw7elWTdMApcAj0NMZoXZRIfvYxRcNE4ZFIJXpxWl7K5ro7JooShZH3ggjtTok2Me2DmiNflKhCMcg+tWIPn3F1wSRnIpKLZvKVlYekYXAZRzQQRKMAlzwc9KmXdnAZfpTQOBubgdTQ0c/MRxyje4ABI4NMAZkYsisQ3r1FPjTeW2lQW4BxVZNKleR1R3ZzztU1Dk/hSCSj1LQ05JbcsUAZz1AHSsu40mAHIYZ7c118Flf22nSzCBGhVFDA9VB71h38Plaj5Udq8cyKfMVweOhq3Cyu0c1OcZSaTOfTR5pCCjLgnnnpVe6tmtbgxHkjvW7cRujFlbYS2DzUkBjjdnvG8xs8cdKh2N+VLVHNrGzKWYgexpCP3JAU7siuteO0uHTcqKF5AFV5LEZ2xKEJbg9aagZylZanISuQOTjNOR/MG1BkkgCuot9CgEjNON6KeSTjP0q/pek2MI+0zxBdh+UE8U0mccqtmclrGdO0tbXdl5TvfH6Vy+/v3zXoGvaZDfzK6qRtHPNY0mgwRQbnYocnk960irHnYiUpSuYA3EZccdMGr+m6iYNwVQUA2+2TUO/zFjHlqfKP3wOW+taTSW95p4gKLCAwy6jriqS1uck61kULs2853wlctwQexNVr3SPs+lNdzTgMHCrH6g9/wBK3tN02xt0JdWmcDn8+K57xNLLd3vkxLshi6ehrWKR52IruWhzM6lVkccHOB71nCF5WAA79a3ZtPwqMzO244IC1Pbaf5ke6T5Io/zJrpg+iPBxEL6szI9JRAplkDFv4VrpPD9gNOmaR4gHPTPYe9JYWZgjbUZkdraBwrNtOAT0GfwqR5JNYuJmiYxxA/N2zScn1OaFLmdkjuIFke2W7iaCaRlKhQ2dp+lVdUujZwtE7/P905PSuWutYS3svsum5imXIdgeorn9R1GW7Mj3Ny8kr4rNM7lQUVdmnrmofZY1NvL856AfzrDsNO1LXr1Y7C1luJpWwBGueTXbfDD4c3HjfUfLmMsNrsLKy4OeentX1/4O8I6X4T0iy0+2t4jJEMO6p8xPqT61pHfQyqS6Hl/wq+CVpocNpqmpXIk1VoSdu3Kwv7Z6kV7BbvDZMljdOZbkAEynPzc9KsWc5d7mFLZi8UpAYjAHcc0/7KbuznSRNlw5J3kdD2qlDqYuVt9ic3aypJJHDvMTY569O1NngnljiVijQEHzEZeTmmW+nw2D+b5p8xyMljwcD0q4JxIrbEZkLbAw7+/0rVeZi2l8Oxzc0WlaZcSzm2hFxGNxOOQDRTNWtcXrCWPdvj8vkZyT0oqG3fQ6lGLV2eAeLrfVvGPjKDT9CuzeLp4lEDuphVCpOeT1Py4r0/QvEy3f2Hwvr7L5t3aL5c+MeYxX5hnswqzqvhTUTrOhJoENna2hmbUbqR3YuzIOEHsS5zXIy+GNPfxvJZ3t5cNdtDJLHsyBDcZztX0UA8VzrmiaXjLY7fUNVs/B0Gm6MtnNIJQ1u99Im5I4gSQXb6HFQeO9L0r/AIRm41O8mijidlkURDAlUDAHuao2HirSdZvbjw1cx3DQpI9pFNJ8xkKKNxP41H/wjGvT2GoeGxrCXXnRedA11ECI8N8qjH50N8xNuXUdNdw63p3maXqFpJIL9p3lf5WtlCKEUg843YzXoHh+/HiLw8bfVlRbzYIbqNDgByoJK/nmvm298N3Go61baGbxNP1Ryv2iZckThiefl4GCg/OusvfE9hpElhpZjujqE6s5uYpDxKibc89egpQqNboudFSVk9TfuLrUvDfjMaNqpklikhZ7DUUtyEOf4JD0yMda6rS7qe48Qb50jV4reFgijjG7k/ia2/Dl+niXw/HBqEJW7+ywtcrwQrum7g/rXn/nTaF4xvrG+nkkuGQRQmIAAW+zIz75pThyNSWxVKp7VOEl7y/E7Pw/cXaSa1NdoVW2uWt0THVSwO4fnXA/H3QksJbTxHGkTIXW1mWT+6x6/XNej6MZraSVp5knheFCnykEnBLbvWsT43266v8ACXVJE5VYkul7Z2kMK15VKmyKdR08RF9HoeBqsUyvGuNu7PzdQKp2MkkEp2nfGmRjuQa59NXLqsqschFUn3xzV6y1LYT5iluc59a4ZKPU+toVWtLmrcXqSs27g8fL3FQOxAQR4HrUWpFZ4GmhA2Ej5cYquQWG5SFjx071DXRHpU8Qi296xheBjlSSDnoPSswoYmDISD2Ip6LtkVBnDE00oVLgcqOTms2jsp102TpeTAYLE961I79Wc5wP9k/SuaE2JMKMZ6VIXKnnOM9adrbHXDELrqdOlxG4UY57fSoLiUwy5RCRisHccZjc596kh1OeL5WO5fQ0m31NvrEUdHBcB1DEgH0JqcSA7jgkVhR3cUwZvmU7MbR61bsppSgVcFSev4GtIyuPmUtUacCxzXQO4xbQOtSraXBjlmlkGzsR3NZgkfzVeVSTn161dQBnciRlQc7OwPerSuYzqOOzKXnPC0hZTvDZA9atreyozBCI5gvBB/OrdhdzRFlt4Ina5KwfvFB+8e3pVzWdNSwuLmxu49l8lwIRGuCDlQc7vxFaeydro4p46PNyMpS6zdW8zeQ4l3RKxUvgEjBwfyrU8U+KW1rVpr8WQtorgxnaWDNkIFJGO3Fc09tbzlmVmBRGQg9iMim26hiE3FlHIzUOUvhuV7OjKaqpapW++3+SNCYCeLeCgV/0pv2KVrbICt1NPsI1lPlxoCqnvV5RKkKFMDopGaFS6sqWItojDWGRZFJj9T+VI89zG5by2PHGR0Nb8oMVvvlPIHp0qgZvOIVB84PJpOKvoZutzblNFlmKvcSbYl5x6067vkuYRFEDtUgZJxk0yZnR5N20rnHSqqvFAnmMoPI7dzTi+hyzmiSSdlVgnqOves7UrhpC0cTIyAliD6k1HfXSvlgcBTt4BrODCSNlPyR85PU471qoo83EYm2w++FtAZROVMpIO1D2IzWBqWpDeNi+XH1Wp/F2vwahq88thbLBGEWJQB2VQM/U4zXJXU7Skl2JrVU0zxMRjGkdD/wlEiK4RR8454po8RBxmaFWauTLnPFPhb5iSAT0rX2SR5LxUps7NdRaS33mNVwDjFUPtk8uEDYYgFB7+9Q2UktxHHbrtwo4+taQ0tbOLzr88HGFWpTs7IrkcviHWGo6k2i3OkG4ZtPuZhNIpA5dQQOew5NVLu5FlF5KsCzDkIanga41K5MOnokUJ+Qtnk10ml+EEgRDMgmlLdDioej1NopR0RxMOn316ryRRsIzliT0r034V/CyTXtRLXJ2COPzV3qdrnPQV6zpnh7SntUaxtVSF0AdHGTk9QK9ZsdPk06xWC1kijghTbtWMDPpRC8hV3yWvuxngzQ4NB0lbaK2tomBJd4kC7z3JreUqyq2Mk98VVgjuZPKkkmA4wyqODVxQFGAMCuqOx5VR3dxsQIUl8Ak5NUbvUGzJHYILiePG5c4Cg1ZljacsjNiEjayjqfxqnHbw6YBFZosasD6k5+ppsIpN67kV1dXIZzLbllTDIyr1zximrcyW1xDaRw7C7HkngcZqi9nqWp30b3N41tbryI4T98A960Lm7txEzDLyoDlsYPAqPM3strXG3VtdY8y8nixuAUxgggUVymk3l9rqb9Q3ww7cxhWBJ59qKXN2NFFrRs//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bullous, elevated sub-conjunctival hemorrhage is shown in a patient with an underlying scleral laceration. A hyphema is also present in the anterior chamber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carolyn Kloek, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9137=[""].join("\n");
var outline_f8_59_9137=null;
var title_f8_59_9138="Patient information: Polyarteritis nodosa (The Basics)";
var content_f8_59_9138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/41/26258\">",
"         Patient information: Hepatitis B (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/39/32370\">",
"         Patient information: Hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/42/22178\">",
"         Patient information: Lupus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/20/37186\">",
"         Patient information: Renovascular hypertension (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/49/12051\">",
"         Patient information: Vasculitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/22/44389\">",
"         Patient information: Vasculitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Polyarteritis nodosa (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/polyarteritis-nodosa-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H116244754\">",
"      <span class=\"h1\">",
"       What is polyarteritis nodosa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Polyarteritis nodosa (called &ldquo;PAN&rdquo; here) is a condition that can cause problems with the kidneys, skin, and other parts of the body. It happens when certain blood vessels get inflamed. This can damage the blood vessels and keep them from carrying enough blood to body parts that need it.",
"     </p>",
"     <p>",
"      PAN is a serious condition. Often, people who do not get treatment die from it.",
"     </p>",
"     <p>",
"      PAN can happen in people who do not have other health problems. It can also happen in people who have certain diseases. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lupus and rheumatoid arthritis &ndash; In these diseases, the body&rsquo;s infection-fighting system, called the &ldquo;immune system,&rdquo; attacks healthy cells.",
"       </li>",
"       <li>",
"        Infection with a virus, including hepatitis B, hepatitis C, and HIV &ndash; The HIV virus is the virus that causes AIDS.",
"       </li>",
"       <li>",
"        A type of cancer called &ldquo;hairy cell leukemia&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H116244768\">",
"      <span class=\"h1\">",
"       What are the symptoms of PAN?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Losing weight without trying",
"       </li>",
"       <li>",
"        Muscle pain and weakness",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Joint pain",
"       </li>",
"       <li>",
"        Skin changes &ndash; These are more common on the legs. They can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Red bumps that hurt",
"       </li>",
"       <li>",
"        Red or purple spots on the skin that do not turn white when you press on them",
"       </li>",
"       <li>",
"        A purple pattern on the skin, which might be raised above the skin around it",
"       </li>",
"       <li>",
"        Open sores or blisters",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Numbness, tingling, and decreased feeling in the hands or feet &ndash; At first, this might happen on just 1 side of the body. It usually spreads to both sides.",
"       </li>",
"       <li>",
"        Belly pain &ndash; Some people have other symptoms of belly problems, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Diarrhea or blood in bowel movements",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain in the testicles (in men)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      PAN can also cause high blood pressure. This can be dangerous for your heart and other organs. Your doctor or nurse will tell you if you have it.",
"     </p>",
"     <p>",
"      Most people who have PAN have symptoms in several parts of the body at once. But PAN sometimes affects just 1 area, such as the skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H116244783\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and learn about your symptoms. You might have some or all of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Chest X-ray &ndash; A chest X-ray creates a picture of your lungs. It can tell the doctor if you have PAN or a different condition. Some other diseases cause symptoms like those of PAN. These diseases usually affect the lungs.",
"       </li>",
"       <li>",
"        Electrocardiogram (ECG or EKG)&nbsp;&mdash; This test measures the electrical activity in your heart. PAN sometimes affects the heart.",
"       </li>",
"       <li>",
"        Biopsy &ndash; In this test, the doctor takes a small sample of tissue from a body part that has symptoms. Another doctor looks at the tissue under a microscope to check for signs of PAN.",
"       </li>",
"       <li>",
"        Arteriogram &ndash; For this test, the doctor injects a dye into an artery in a part of the body that is affected by PAN. The dye shows up on imaging tests, such as X-rays, CT scans, or MRIs. These imaging tests create pictures of the inside of the body. The dye can show problems with the blood vessels.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H116244797\">",
"      <span class=\"h1\">",
"       How is PAN treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors give medicines to control PAN and keep it from getting worse. Many people can take pills by mouth for PAN. But some people need medicine through an &ldquo;IV.&rdquo; This is a thin tube that goes into a vein.",
"     </p>",
"     <p>",
"      Treatment for PAN usually takes at least 6 months. It can take more than 1 year to get rid of symptoms. The medicines that treat PAN can cause serious side effects. Your doctor or nurse might give you other medicines to help keep these side effects from happening or make them less serious.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H116244811\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some medicines that treat PAN are not safe to take if you are pregnant. If you have PAN, ask your doctor or nurse if it is safe for you to get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H116244827\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       Patient information: Hepatitis B (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       Patient information: Hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=see_link\">",
"       Patient information: Lupus (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=see_link\">",
"       Patient information: Renovascular hypertension (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/49/12051?source=see_link\">",
"       Patient information: Vasculitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       Patient information: Vasculitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/59/9138?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83628 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9138=[""].join("\n");
var outline_f8_59_9138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116244754\">",
"      What is polyarteritis nodosa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116244768\">",
"      What are the symptoms of PAN?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116244783\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116244797\">",
"      How is PAN treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116244811\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116244827\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=related_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=related_link\">",
"      Patient information: Renovascular hypertension (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/49/12051?source=related_link\">",
"      Patient information: Vasculitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_59_9139="Management algorithm for violent patient";
var content_f8_59_9139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 648px\">",
"   <div class=\"ttl\">",
"    Management of the severely agitated or violent patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 628px; height: 770px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECG: electrocardiogram; IM: intramuscular; IV: intravenous; PT: patient.",
"     <br/>",
"     * The safety of atypical antipsychotics in geriatric patients remains uncertain.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9139=[""].join("\n");
var outline_f8_59_9139=null;
var title_f8_59_9140="Vulvar deep anatomy";
var content_f8_59_9140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Deep anatomy of the vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9140=[""].join("\n");
var outline_f8_59_9140=null;
var title_f8_59_9141="Reference values for pulmonary function testing";
var content_f8_59_9141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reference values for pulmonary function testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/59/9141/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/59/9141/contributors\">",
"     Paul L Enright, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/59/9141/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/59/9141/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/59/9141/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/59/9141/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/59/9141/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correct interpretation of pulmonary function tests requires the use of appropriate reference values with which the patient's results are compared [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/1\">",
"     1",
"    </a>",
"    ]. Unlike many physiologic parameters, for which normal values do not vary with the characteristics of the particular patient, predicted values of pulmonary function depend upon age, height, gender, and race. Therefore, interpretation of pulmonary function tests performed for the first time must take these and other factors into consideration. In practice, this is usually done by a computer using linear regression equations (reference equations) for calculation of \"predicted values,\" as determined by published studies of large numbers of healthy individuals.",
"   </p>",
"   <p>",
"    Even when anthropometric factors are taken into consideration, the \"normal\" range for measurements of pulmonary function remains wide, often 80 to 120 percent of the predicted value. This means that large changes with disease progression or therapy can easily occur while the patient's values remain within the normal range. Therefore, follow-up pulmonary function tests in adults should be compared with the patient's previous (baseline) values, not the predicted values.",
"   </p>",
"   <p>",
"    With children, the normal growth of lung function is fast when compared to the changes observed with disease or therapy. As a result, the use of growth charts (looking for trends across percentile lines) most accurately reflects changes that cannot be attributed to growth (",
"    <a class=\"graphic graphic_figure graphicRef79707 graphicRef60080 \" href=\"UTD.htm?32/20/33103\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on the standardization of spirometry, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTS OF AGE AND GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;During childhood, the lungs grow in proportion to the increase in height. This growth results in an exponential increase in lung volumes (and maximal flows) with each year from preschool age through adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/2\">",
"     2",
"    </a>",
"    ]. On average, girls reach both their maximal height and their maximal lung volume earlier than boys, but boys achieve larger lung volumes. Additional factors may affect maximal lung function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young people who regularly perform aerobic exercise (such as competitive swimming) develop larger lung volumes",
"     </li>",
"     <li>",
"      The growth of lung function may be retarded in children regularly taking oral glucocorticoids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cross-sectional spirometric testing of large healthy populations shows a plateau of lung function between the ages of 20 and 30 (",
"    <a class=\"graphic graphic_figure graphicRef54935 graphicRef66761 \" href=\"UTD.htm?34/19/35134\">",
"     figure 2A-B",
"    </a>",
"    ). However, longitudinal observation of individuals shows that some have a lung function peak in their early 20s, while others, particularly men, may have the peak in their mid 30s [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/3\">",
"     3",
"    </a>",
"    ]. Healthy nonsmokers without exposure to air pollution experience a gradual decline in lung function throughout adulthood and old age, apparently due to slowly developing, very mild, subclinical emphysema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FEV",
"      <sub>",
"       1",
"      </sub>",
"      falls approximately 30 mL per year",
"     </li>",
"     <li>",
"      The vital capacity (VC) decreases while the residual volume (RV) increases, leaving the total lung capacity intact",
"     </li>",
"     <li>",
"      The diffusing capacity (DLCO) declines linearly with age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cigarette smoking (starting during the early teens) is associated with an earlier peak in lung function and therefore an earlier onset of decline. In addition all of the changes due to aging are accelerated in susceptible cigarette smokers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTHROPOMETRIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other independent factors besides age and gender affect lung function in healthy persons. These include height, race, and weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Height",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taller persons have a larger frame size and a larger thoracic cage than do shorter persons. Consequently, taller persons have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Larger lung volumes",
"     </li>",
"     <li>",
"      Higher maximal flow rates",
"     </li>",
"     <li>",
"      A greater ability to take up oxygen and carbon monoxide per minute (reflected by a higher DLCO)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, the predicted (mean) vital capacity of a 40 year old man who is very tall (6ft 4in) is six liters, while that of a very short man (5ft 4in) is only four liters. Therefore, the accurate measurement of standing height (to the nearest half inch, without shoes) is very important in predicting lung function for a particular patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy African-Americans have spirometric values that are approximately 12 percent lower than whites of the same gender, age, and height. Most of this difference is due to a difference in the ratio of trunk size to standing height, ie, African-Americans have longer legs for a given height [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Predicted values should be obtained from studies of healthy persons of the same ethnic background as the patient being tested. However, if such studies are not available, Caucasian predicted values should be multiplied by 0.88 for African-Americans, East Asians, and East Indians, but not for Hispanic or Native American patients. Ratios such as",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     RV/TLC",
"    </span>",
"    should not be race-corrected.",
"   </p>",
"   <p>",
"    Predicted values for static lung volumes (TLC and RV), DLCO, and maximal inspiratory and expiratory pressures (MIP and MEP) should probably also be corrected for racial differences, since they are strongly related to standing height. However, the data are scant for these non-spirometric measures of pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body weight is much less important than standing height when predicting most pulmonary function values; as a result, weight is not included in spirometry prediction equations. However, extremes in weight are associated with lower lung volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malnutrition causes reduced diaphragm strength, so that the patient cannot take as deep a breath",
"     </li>",
"     <li>",
"      Truncal obesity restricts expansion of the chest cage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When total lung capacity is reduced, maximal flows such as the FEV",
"    <sub>",
"     1",
"    </sub>",
"    are proportionately reduced.",
"   </p>",
"   <p>",
"    An excellent index of the degree of obesity is the body mass index (BMI), which is obtained by dividing the weight (in kilograms) by the square of the height (in meters) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Mildly reduced lung volumes in patients with a BMI above 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    may be entirely due to obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/8\">",
"     8",
"    </a>",
"    ]. Subsequent changes in body weight result in changes in lung function. As an example, some of the improvement in FEV",
"    <sub>",
"     1",
"    </sub>",
"    due to smoking cessation is countered by the associated weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PULMONARY FUNCTION REFERENCE STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1991 the American Thoracic Society published a listing of pulmonary function reference values and recommendations for interpretative strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/5\">",
"     5",
"    </a>",
"    ]. Unfortunately, a specific set of reference equations was not recommended; in comparison, specific recommendations were made by the European Respiratory Society in 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/10\">",
"     10",
"    </a>",
"    ]. For spirometry testing, a survey of American pulmonary function laboratories showed about equal use of equations from the studies of Crapo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/11\">",
"     11",
"    </a>",
"    ], Morris [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/12\">",
"     12",
"    </a>",
"    ], and Knudson [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/13\">",
"     13",
"    </a>",
"    ] for adults, whereas most used the study of Polgar [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/14\">",
"     14",
"    </a>",
"    ] for children. However, the NHANES III reference equations should now be used for Caucasians, African-Americans, and Mexican-Americans between ages 8 and 80 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/4,15,16\">",
"     4,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criteria for selecting studies of pulmonary function reference equations include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population sample (with a wide range of age and height) is preferred to a convenience sample (eg, using volunteers or patients referred to a clinic).",
"     </li>",
"     <li>",
"      All subjects should be never smokers.",
"     </li>",
"     <li>",
"      Subjects should be free of heart disease, lung disease, and chronic respiratory symptoms.",
"     </li>",
"     <li>",
"      The spirometers and test methods should meet current American Thoracic Society (ATS) recommendations. Almost all studies performed prior to 1981 did not conform to ATS standards.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared to spirometry, there are few good studies of static lung volumes, DLCO, or maximal respiratory pressures which met the above criteria.",
"   </p>",
"   <p>",
"    Reference equations should not be used (extrapolated) for patients whose age or height is outside the range of subjects included in the reference study. This is especially a problem when equations from studies of adults between ages 20 and 65 are used for adolescents and elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/17\">",
"     17",
"    </a>",
"    ]. Good studies of spirometry in children from ages 6 to 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/2\">",
"     2",
"    </a>",
"    ] and spirometry, MIP, and MEP in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/18-20\">",
"     18-20",
"    </a>",
"    ] have been published; however, they have been added to very few pulmonary function laboratory computers.",
"   </p>",
"   <p>",
"    Reference values for the six-minute walk distance for adults were published in 1998; this was followed by an ATS guideline on the subject in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Gender, age, height, and weight must all be considered when interpreting this test.",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on the six-minute walk test, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     UPPER AND LOWER LIMITS OF NORMALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A traditional rule of thumb was to use 80 percent of predicted as the lower limit of the normal range (LLN) for most pulmonary function test results. This standard works fairly well for FVC, FEV",
"    <sub>",
"     1",
"    </sub>",
"    , DLCO, and TLC in middle-aged adults, but gives a high rate of false positive or false negatives for",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC,",
"    </span>",
"    FEF 25 to 75 percent, and maximal respiratory pressures, especially when used for adolescents and adults over the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9141/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is now recognized that the",
"    <strong>",
"     fifth percentile",
"    </strong>",
"    is the best LLN, and should be reported by all pulmonary function reference studies. By definition, only 5 percent of healthy individuals will have a result below this LLN. Static lung volumes and DLCO values are also abnormal when values are above or below a reference standard, so that the normal range for these studies should include both an upper limit of normal (ULN) and a LLN. Categorizing results as \"borderline\" abnormal, if they fall near the LLN or ULN, is also a useful concept. Only the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FEV",
"     <sub>",
"      6",
"     </sub>",
"    </span>",
"    below the age and gender-specific LLN should be used to determine the presence of airways obstruction. The use of other indices increases the misclassification rates above the accepted 5 percent level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Correct interpretation of pulmonary function tests requires the use of appropriate reference values with which the patient's results are compared. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healthy never-smoking adults without exposure to air pollution experience a gradual decline in lung function. &nbsp;The forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) falls approximately 30 mL per year. The vital capacity decreases while the residual volume increases, leaving the total lung capacity intact. The diffusing capacity (DLCO) declines linearly with age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects of age and growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Predicted values should be obtained from studies of healthy persons of the same ethnic background as the patient being tested. They should not be used for patients whose age or height is outside the range of subjects included in the reference study. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anthropometric factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lower limit of the normal range (LLN) should be determined from the fifth percentile. Uncertainty should be accepted when results are near the LLN. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Upper and lower limits of normality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airway obstruction should be determined by a",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      (or",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FEV",
"       <sub>",
"        6",
"       </sub>",
"       )",
"      </span>",
"      below the age and gender-specific LLN. &nbsp;The use of other indices increases the misclassification rates above the accepted 5 percent level.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/1\">",
"      Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/2\">",
"      Wang X, Dockery DW, Wypij D, et al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/3\">",
"      Robbins DR, Enright PL, Sherrill DL. Lung function development in young adults: is there a plateau phase? Eur Respir J 1995; 8:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/4\">",
"      Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/5\">",
"      Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/6\">",
"      Korotzer B, Ong S, Hansen JE. Ethnic differences in pulmonary function in healthy nonsmoking Asian-Americans and European-Americans. Am J Respir Crit Care Med 2000; 161:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/7\">",
"      Babb TG, Wyrick BL, DeLorey DS, et al. Fat distribution and end-expiratory lung volume in lean and obese men and women. Chest 2008; 134:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/8\">",
"      Sutherland TJ, Goulding A, Grant AM, et al. The effect of adiposity measured by dual-energy X-ray absorptiometry on lung function. Eur Respir J 2008; 32:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/9\">",
"      Nides M, Rand C, Dolce J, et al. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. Health Psychol 1994; 13:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/10\">",
"      Quanjer, PhH (ed). Standardized lung function testing Bull Europ Physiopathol Respir 1983; 19(Suppl 5):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/11\">",
"      Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/12\">",
"      Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971; 103:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/13\">",
"      Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/14\">",
"      Polgar G, Weng TR. The functional development of the respiratory system from the period of gestation to adulthood. Am Rev Respir Dis 1979; 120:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/15\">",
"      Collen J, Greenburg D, Holley A, et al. Discordance in spirometric interpretations using three commonly used reference equations vs national health and nutrition examination study III. Chest 2008; 134:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/16\">",
"      Hankinson JL, Kawut SM, Shahar E, et al. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest 2010; 137:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/17\">",
"      Garcia-Rio F, Dorgham A, Pino JM, et al. Lung volume reference values for women and men 65 to 85 years of age. Am J Respir Crit Care Med 2009; 180:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/18\">",
"      Enright PL, Kronmal RA, Higgins M, et al. Spirometry reference values for women and men 65 to 85 years of age. Cardiovascular health study. Am Rev Respir Dis 1993; 147:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/19\">",
"      Enright PL, Kronmal RA, Manolio TA, et al. Respiratory muscle strength in the elderly. Correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 149:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/20\">",
"      McDonnell WF, Enright PL, Abbey DE, et al. Spirometric reference equations for older adults. Respir Med 1998; 92:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/21\">",
"      Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998; 158:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/22\">",
"      ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9141/abstract/23\">",
"      Cerveri I, Corsico AG, Accordini S, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC &lt;70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008; 63:1040.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6971 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9141=[""].join("\n");
var outline_f8_59_9141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTS OF AGE AND GROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTHROPOMETRIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Height",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PULMONARY FUNCTION REFERENCE STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      UPPER AND LOWER LIMITS OF NORMALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6971\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6971|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/41/5790\" title=\"figure 1A\">",
"      FEV1 growth curves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/32/15886\" title=\"figure 1B\">",
"      FEV1 growth curves I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/4/22605\" title=\"figure 2A\">",
"      FEV1 and age in females",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/33/28189\" title=\"figure 2B\">",
"      FEV1 and age in males",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_59_9142="Aliskiren: Drug information";
var content_f8_59_9142=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aliskiren: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/43/27317?source=see_link\">",
"    see \"Aliskiren: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4412572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tekturna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5586777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rasilez&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4412576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Renin Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4412613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Initial: 150 mg once daily; may increase to 300 mg once daily (maximum: 300 mg daily).",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation, correct hypovolemia and/or closely monitor volume status in patients on concurrent diuretics during treatment initiation.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4412614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No initial dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4412615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: Initial: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial: No dosage adjustment may be necessary (Vaidyanathan, 2007); however, risk of hyperkalemia and progressive renal dysfunction may occur; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ESRD (requiring hemodialysis): Initial: No dosage adjustment may be necessary (Khadzhynov, 2012);  however, with chronic therapy, risk of hyperkalemia is increased; use with extreme caution.",
"     <b>",
"      Note:",
"     </b>",
"     Hemodialysis eliminates a minimal fraction; does not significantly alter overall aliskiren exposure.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4412616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild-to-severe: Initial: No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4412622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tekturna&reg;: 150 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4412574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4412618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time daily; may take with or without a meal, but consistent administration with regards to meals is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4412577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other antihypertensive agents",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6263976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of persistent proteinuria in patients with type 2 diabetes mellitus, hypertension, and nephropathy despite administration of optimized recommended renoprotective therapy (eg, angiotensin II receptor blocker)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4412723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tekturna&reg; may be confused with Valturna&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4412587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (monotherapy &le;1%; may be increased with concurrent ACE inhibitor or ARB)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Creatine kinase increased (&gt;300%: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: BUN increased (&le;7%), serum creatinine increased (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, gastroesophageal reflux, hypotension (severe), myositis, periorbital edema, rhabdomyolysis, seizure, Stevens-Johnson syndrome, toxic epidermal necrolysis, uric acid increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4412582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Concomitant use with an ACE inhibitor or ARB in patients with diabetes mellitus",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canada labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to aliskiren or any component of the formulation; history of angioedema with aliskiren, ACE inhibitors, or ARBs; hereditary or idiopathic angioedema; concomitant use with ACE inhibitors or ARBs in patients with GFR &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4412583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur (rarely) during monotherapy; risk may increase in patients with predisposing factors (eg, renal dysfunction, diabetes mellitus or concomitant use with ACE inhibitors, ARBs, NSAIDs, potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Anaphylaxis and angioedema have been reported. Since the effect of aliskiren on bradykinin levels is unknown, the risk of kinin-mediated etiologies of angioedema occurring is also unknown. Use with caution in any patient with a history of angioedema (of any etiology) as angioedema, some cases necessitating hospitalization and intubation, has been observed (rarely) with aliskiren use. Discontinue immediately following the occurrence of anaphylaxis or angioedema; do not readminister. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Early, aggressive, and appropriate management is critical.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: During the initiation of therapy, symptomatic hypotension may occur (rarely), particularly in patients with an activated renin-angiotensin system (ie, volume or salt-depleted patients). Prior to initiation, correct hypovolemia and/or closely monitor volume status in patients on concurrent diuretics during treatment initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes mellitus: Use (monotherapy or combined with ACE-inhibitors or ARBs) in patients with type 2 diabetes mellitus has demonstrated an increased incidence of renal impairment, hypotension, and hyperkalemia; use is contraindicated in patients with diabetes mellitus who are taking an ACE inhibitor or ARB.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution or avoid in patients with deteriorating renal function or low renal blood flow (eg, renal artery stenosis, severe heart failure); may increase risk of developing acute renal failure and hyperkalemia.  Concomitant use with an ACE inhibitor or ARB may increase risk of developing acute renal failure and should be avoided in patients with GFR &lt;60 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Avoid concurrent use with strong inhibitors of P-glycoprotein (eg, cyclosporine, itraconazole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F4412594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4412593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Aliskiren may enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Aliskiren may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Aliskiren. Canagliflozin may enhance the hypotensive effect of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: Aliskiren may decrease the serum concentration of Furosemide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the serum concentration of Aliskiren. Management: Avoid concomitant use of aliskiren and grapefruit juice. Separation of aliskiren and grapefruit juice administration by several hours may reduce the chance for interaction. Monitor for decreased aliskiren levels/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4412597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: High-fat meals decrease absorption. Grapefruit juice may decrease the serum concentration of aliskiren. Management: Administer at the same time each day; may take with or without a meal, but consistent administration with regards to meals is recommended. Avoid concomitant use of aliskiren and grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of aliskiren (eg, shepherd&rsquo;s purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4412578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4412579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4412581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4412617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food; however, a high-fat meal reduces absorption. Consistent administration with regards to meals is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5062513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tekturna Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $118.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $149.89",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4412620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum potassium, BUN, serum creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Enviage (EE);",
"     </li>",
"     <li>",
"      Rasilez (AR, AT, AU, BE, BR, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, FR, GB, GR, GT, HK, HN, ID, IE, IL, IN, IT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SV, TH, TR, TW);",
"     </li>",
"     <li>",
"      Sprimeo (GR, NL);",
"     </li>",
"     <li>",
"      Tekturna (EE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4412600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aliskiren is a direct renin inhibitor, resulting in blockade of the conversion of angiotensinogen to angiotensin I. Angiotensin I suppression decreases the formation of angiotensin II (Ang II), a potent blood pressure-elevating peptide (via direct vasoconstriction, aldosterone release, and sodium retention). Ang II also functions within the Renin-Angiotensin-Aldosterone System (RAAS) as a negative inhibitory feedback mediator within the renal parenchyma to suppress the further release of renin. Thus, reductions in Ang II levels suppress this feedback loop, leading to further increased plasma renin concentrations (PRC) and subsequent activity (PRA). This disinhibition effect can be potentially problematic for ACE inhibitor and ARB therapy, as increased PRA could partially overcome the pharmacologic inhibition of the RAAS. As aliskiren is a direct inhibitor of renin activity, blunting of PRA despite the increased PRC (from loss of the negative feedback) may be clinically advantageous. The effect of aliskiren on bradykinin levels is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4412602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Maximum antihypertensive effect: Within 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Poor; absorption decreased by high-fat meal. Aliskiren is a substrate of P-glycoprotein; concurrent use of P-glycoprotein inhibitors may increase absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extent of metabolism unknown;",
"     <i>",
"      in vitro",
"     </i>",
"     studies indicate metabolism via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~24 hours (range: 16-32 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~25% of absorbed dose excreted unchanged in urine); feces (unchanged via biliary excretion)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Khadzhynov D, Slowinski T, Lieker I, et al, \"Pharmacokinetics of Aliskiren in Patients With End-Stage Renal Disease Undergoing Haemodialysis,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2012, 51(10):661-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9142/abstract-text/23018529/pubmed\" id=\"23018529\" target=\"_blank\">",
"        23018529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parving HH, Persson F, Lewis JB, et al, &ldquo;Aliskiren Combined With Losartan in Type 2 Diabetes and Nephropathy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(23):2433-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9142/abstract-text/18525041/pubmed\" id=\"18525041\" target=\"_blank\">",
"        18525041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Straessen JA, Li Y, and Richart T, &ldquo;Oral Renin Inhibitors,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 368(9545):1449-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9142/abstract-text/17055947/pubmed\" id=\"17055947\" target=\"_blank\">",
"        17055947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vaidyanathan S, Bigler H, Yeh C, et al, &ldquo;Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskerin Alone and in Combination with Irbesartan in Renal Impairment,&rdquo; Clin Pharmacokinet, 2007, 46(8):661-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9142/abstract-text/17655373/pubmed\" id=\"17655373\" target=\"_blank\">",
"        17655373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vaidyanathan S, Warren V, Yeh C, et al, &ldquo;Pharmacokinetics, Safety, and Tolerability of the Oral Renin Inhibitor Aliskiren in Patients With Hepatic Impairment,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007, 47(2):192-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9142/abstract-text/17244770/pubmed\" id=\"17244770\" target=\"_blank\">",
"        17244770",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9282 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9142=[""].join("\n");
var outline_f8_59_9142=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708586\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412572\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5586777\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412576\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412613\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412614\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412615\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412616\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412622\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412574\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412618\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412577\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6263976\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412723\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412587\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412582\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412583\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412594\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412593\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412597\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412578\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412579\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412581\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412617\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5062513\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412620\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038890\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412600\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412602\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9282\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9282|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/43/27317?source=related_link\">",
"      Aliskiren: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_59_9143="CT with extraluminal contrast from perforated ulcer";
var content_f8_59_9143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Perforated duodenal ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Decubitus computed tomographic scan shows marked thickening and inflammation of the duodenal wall (white arrows) with extraluminal contrast material and air (black arrows) due to a perforated duodenal ulcer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan B Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9143=[""].join("\n");
var outline_f8_59_9143=null;
var title_f8_59_9144="Takayasu arteritis aneurysm 1";
var content_f8_59_9144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62264%7ERHEUM%2F70960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62264%7ERHEUM%2F70960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusiform aneurysm and wall thickening in a patient with Takayasu arteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 277px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEVAW8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwhyzZwSQMsg68/j0/lVgyDe2zLHgnapBb6/l06URRM48qAs87g4CdM9ODn1/xr0rwj8P5o9t7qqNjKrsZxgP2GB1YAdKsVzlvDfh6fU5InlKx2vLFwPmC8/MB/dzxkdK7EWllp0PlKBsxlUePGfQ7s8DIznueK1NWuIdPWKGHdHGMpEAwHAxuC8cHgZH864qea91JJZlMgBB3Fs7TzgDuR6YoEW7zW/tV5EkLNx8q5gxz9B26j3xnvWfqepxwQPHeT4kKhRCE+brkkHoQR+XrxVHVtRt9Jd4LECW7dAHkLhwjHk4I69/oP0515nlkkaQeYfmBJOcDrnJ5oYIvXOpPdPiLEFurAAK/U44yeueetVg5HL43gliWHLEdT788VVXKkg7PmwGDDJ4HcdfyqTegBUDPBOV+9g45JpDJndFbCuR8o4bp6nH+Hv7U7exhXk/6w4U8ZHpgfzqu3XLBVRcOT646E+nehg4beX2EuQOcsDjv+YpgP8xwGeQ/w9T6/wCcHFSM7b+rlByMHp3bHp0qCQqAAwkDMrbtwGMcYx79c/hQ7uCctGGA5Bz15HI+n8qQEolOSCGVSm445B5PPuenHv8AjTQ7I2GG3btDdTjP4fpTGycxtwgOA27HJHXH07/T0pqqzNgA5B5wSB7cHmmBIXAlGCMEkAt0PH4c03cdkjAsBjBJ4PUDp09OP8KjZXKImQ429xjn/INJIpK8hSevXuOPx/WkA4zEMmWbHpjk56centTg/wC8VTwAW2nGMtj9CaZkhRjnIzyfp69+tEilQAFJVeOegPTn/P0pgDOHO4FQSc/dOR6U6PAOWyDtyMA85B598ZpEA34w+GXjPHy9Dz9aZwYZBhWJHUrjcR06dD/SgCQk/eXlgVXdye2PzNXtC0u71zW7TR9NffcXcvlqGPYjqePrWfv3OzNhc8jjH5e+a9w+Avho6cr+IdQi8uWZGjtQ8e7bGR97/gX6gUAec+P/AAXe+Eb0LdASWbg+VKpyAf7vsfwrj180KCpHznB9sHj/AD+dfVvj7WdMuNMn0+9tluA0WF82MkA9lz0HSvm3WbCL7dIlm2VDbdjKdw9Qc/lSAxXJSLhmX5R9cf1GaCdoCln4PVMHOe4PY1vR+EvEFxbGePSZ5Y9uS8fOQO/8qrtoWqiURjT5gWZgFIA+bHTHqadguZWBk7Qy4GQfYnv/APW96VsFSVyqYGRg5XoAf1/XvU11aXFvcCOeJ4JBnaJU2scDqB3HvVZc8MSpQDPynPXrj0/yKAJGk5xHyp5KseG9Me38qC5xGQxI3EhwM8YOKjl3CTcVwwbBbA5/+v8A40KQM4/2gSSOvc5/EUugxQWWPBLbefTAwRyP8KdIQQz5CndjGRgnGOn9feoHGSQF7YHv7/59acxZ2f7pyRuwMYOOuP8APWgB0hCpkkhQSNx57e3+eeKTedjZIBH3gRgnI/KjawHJfc2TwBkcdB7Yz+FC7gQFGdpxgdMcY/n39qAJACrnOWXAXb0yc9vSnZMnKKx28Nz17479gPyphbgqS33vmCjBPPf0NIm4Stg7T0OM5I/qPemIUuQm7nJXGMA4B/8A1f8A16UspYDkFU45x+Pt34+lROrKpHA44Geduew/xprk5wSCuAc7cYJH+eaQHvvwI+Lz6ZNb+HPFM8k2nmQLZ30rEm2c8CNz3Q9vT6dPqNW3JtIK5yPlP8jX5wDaUKuMAnaTjr2xX0Z8Avi2QbXwv4ruUJ5jsb6aQYZe0Mjdjz8rfhQB7b4o8OR3dvJNZh4rgLn2OOeR6+leS3+jwX/nWV5buCGKlQnIbPQe+MfTBr3sSZAww3YHKNkgHv7j3rA1/wAPpcObyBZUnzyqyDDDnp70kI+PvGvg2bSGM0eDAy5JVOAPwHX/AArhJCNg2kHK84Hc9z+FfVvi+yWWCWIhgp+V+OPbOenJr538W+H5tMuXkjBa3I3biR8o7gZ7g9hVDTObYnKku3Y5B7+ue1JuDfKqjdjOQME8/WmFOASx6gYHQ0sZI3jJC4xz356ZpDR9B+DPB9rp0cd1fpGk20M3mjHzZGM56dh29K0fEGo21hYPbQPCsjOVHlr0GPx5A7+9aev6g8SrBbq7u7+Wpj2n8c/179Kt6H4Kk2x6nrAYsT5ixOmPl7den6njFMk8misprpWu7t9okR2CliVK54DDoo6HPAz3rB8SeIRbWy6ZpcgZI1WKS5KAc9TjIyRz1rU+JPiPzNQn03TPlVMJM6oFAHGEHt6en1rz2NyhUgjHDDgZBA7Z9qEFhwZCct/q3zgqCMn8O/SnRqJFLLsDgDcQT9OemQen4UjB327i6ABiCPmY5HJx+AHp0pBJK6xrtK7WwuVx+H0pDETasbZGDjJXPOP8/lTnACggsc/OMjnp/npUasW3fKdzKcALwff1zihGMgAI3Dtgfn7fjTAmULIMrsX1wvOOOooiVjtDIeuBjqv09e1MG8sHdQ3XI/p6e/4CnklVyyE4ycdmzj3oAYVCkMytwPvBcZ9cCnRAhGB3KrZU8cDJyQf04oQfdYBXXBzt4IA55/OgErv/AHTKzY8tixyMen+e1IBMKGZRyGJGShGcdAPXP/66cquSdwGArAZGeT/KmgFnG3Cjr97gZ65/xojIKDCgJgqWwcAHsePU/wD66YCsBgfMQCoHIzwP6fWot+Q5B4zuB4PH9P5U5yPLI2sAvUYOBz29fp9aQOdzFWb5flOT36/p+NIB6AOwBO0H5clc59Oh/wA5NMIVhxkSMATgdP8A63HWnxyKpGVIJDYHQgd+fpTCrqqeWcADgqvAPUAZHv8A/rpgPYLvO0hsZwCMbiO/+ev41GxKkchIyMkjnkHn8f8ACjaQ55woJBUpjJx0x36Vq+G9Jm1a8jjAkSFM7nRc7QAM4Hc/WgDp/hR4UGu6zDdagmNItfnl38LKy9EHqPU+2Oa9wn1UTRmDTIH2mP5BnAxj7uR29P5isjR4FstItLOJI0tEUlY1Qkjpnr1Of8a07Wa3F1DHKwWNlXqjK2e/9cDtQIy73QL+8lfzC2XCjIbkAc9Oh64B9q2PBXwusH1SO8vYQywk4Rs8c5wc9K6sTQ+SxWNBEzgblTcD/wDX9+1dj4bVfsAdeD0yTn8Se9K4ya00q2trZIYogioCFHoD1/D606TS7ST5Xt4yMYH7tcD6HGRV/oMADj0owNxI649am4WOO8VeA9A8Q2bR6jYQvkj94IgHXpjBHT618s/Fv4ZXXgq+863ea40mR9olKH93wAEOPY8GvtZxkAc5z2NYviPRLPXNMuLG+gEtvOrBgRnr6ehzg/hTTCx+fUnEigNkj1wCD/I1FCGZcnGTkjjkj2/Kt7xnoF14X8R3+j3kcgkgkOxifvIejfiOx5rFZdiHnjABYHIPPf8AKmBGpBAZ3Gw8YPJY+n69ae6sHKeYdyvtAz3Ge/p/n6x8hnLMozgfKP8AORgfrSHdHlVJKqfmGMA/l6igYrK2QXIwwLAsQOmf8/nQ5ZEQhgN6g4/+v1P+fSm/MFL9egIAA64601i4xw2QQDhelAibPy4EjY9Gx78/SkDYbIY4zuXJxketNEiMXLFs8kMi9T268D/69J1LKSzcfl/j/wDWoGI21GcNkkdx1pzMA2GLMCBt/wAc/gPyphLM27C7j0APGRTQ+4k7SeO3H5UxDxkEFkbg8/zApEccscdhtHGfbPrQ5Eh4GRnIAP6frSYco3ByAQxx0yRSA+m/gT8X0vBa+G/Fl3uvw4jsbyTrMAABFI3Z+mGP3h15r6AiZXjZW8s/Mc5HQ9OR2r85AxWVdhYfN8uOox3B7civpP4IfGYTR2ug+MLtkvF/d2uoSMGEozxHIezD+934zjuAdL8XtPm07U0vV8kWMseNp+8Hz1+vcE8fnXkN/BFeK0M4BiOELE4+gz2OK+pPF2kp4g8PXlg25XlTMbEYKN2I/Ht718xapaT2mp3VvP5qG3cpInl7ioHXIPUH8qEI8w1ewaxvJopRuUDf24HQA4/DpWfEMkbsHHGGP9K7/VLRbyPyZNwkXAOFGDkdF7jr0Hr9a4y+s57K72OhcEtjb/F9DTGmfbXhHwmlqkV5qcY+1Id4HUJ6H379Kw/jp4lTwz4LdIE/0++kNvbgNwhP3nz2wP1Ir1O5AaQHKgqS/wB7BXHHHtzXxJ8YvGTeMfGdxcQMTp1k7W1iOoCK3zMfdzz9AOaSA4iXczGV3ZnIJ3Mdx69T70rBARuUdskjr3yf581DkgfIq4OSBv8AUj+WP1p+SF3IB8o2Zbtn1/xpgOwWiK7W3D5snsP8/wCcUhIUlzjAyu09un/1v/r0xgArDIyV3DOeg7fX1pz70zuIIPRgfyH/ANb2pAIMhQrNjOCAOc+vPr9f0pwAIz8ucMB7e/t1qNM7s8jnazKevf8AH1pyBhgxHbgbuv8AU9T1/wA5oQD1JIeQ5IOMkg8ntj/P4U+PaV5ZQB3A7Hg47gjuKasmAMKGbgDIzk4I/Dg/pQ5KgYcFl7d+o/w7+vpTAE+ViM7QwJLhOhJ5Prj/AA9qfIybsbwCTknHX39PwqCNz5iv3IyduRx6/hTlkkZ3kUjqTyM/gPwNICXaFlQuWBwF/dryQQTx7Y/r+CYUxqVyoJ2sc+nXGf8APFMJCxgvgPnnIPOOvP49KQsuCznc+8cY7cZINMCRxknc/cHOMD2/n0qIAfMnytljwRwv9Kc25phhRnHZc5FChym47sZwuMZPuKQCklypBIydoOfTnikARcM3GWDEn0x6/lQseHROwBGTge/Gegz2p0ERuJIljCscZY+gH+eTTAm0+ykumJUkRJwxxyMjjHr9fcV654F8Ny3o2pG8MK4bJGc46fh+vBrlfB/hbUPEOqLbWMH7mIgh0bC89W6dcHHAOM19O+C/A66Vp6LKFDFBlMn5PTHtQI4G7sptNEkkju0apz8oOce4HAridc1eeHZDPK6EjbnIYox65xz9en9K+idX8GWl7YvBt5YhclsZ4/8Ar15V4l+EE5hmawkaQjDYYcg8/h07DH1oAyvDPjKSeCLTy/lPG+4FRu3IDzjuefX8a+i/Dskc2kW8kXKFRtPtXxJqdleeHtX8uOOQfOQFIOWHfjsfb2r6z+DOsx6z4Gs2VsywjZIuc4PWkxo7oZwOf0pMjPuMZ4peCOenvQOp69e9SMawJI+7wajkX5H+UFT1ycVKTzj19qa+CMnGO+RQI+dP2qPC6PaWfiKzjQSxAW9wy53GM5Kknp1zXzS6qQQMnqMjnPv+lfe/xE0ka14L1uwfDGW1lwrdmxkYP4cV8EksyhmAyq/fC8n/AD6VSYEEipvI3HOMZXp/9elO3aSSf7xGMf5FKgdl34Y85OTkZx1pZNwZlxuyMjJB/M96AAYJZk+YjBJbrg8DrUfGPlOS45/L3/Glc4J45IDYP8vX3pCwG9nwx4xk/wCf8igBNymQlj1IzxmnbkDHAZx94Bm/Tj2poGAWIAA4xnpQHIIwCB2z6f8A6880DByNnBXG3/8AX/Ojq3BBJIwO3IpvIPMZY9MBeM9eKRnyw6YAwSefxoAccKQQMg/h+OabIeCWPXGMjnj+XSjccH/ZHHHTNIRg5weODigB6lThVGCcnJ6njpQGwGJbk4YsO/8AnrTASScE7QM5bikVjsOD1HPfFAj3X4MfGG50y4g0DxVK8+nSN5UNzIctEegDZ6jtn3r0L4vaZC3kavar5qOoWQxN97g4bPQnsAOua+SDkMQw3Y4KnpXpHhH4gXX/AAj48M6rIs9oGxbPKcmMdQu79B6UAy1qwlumLxoF5B+6OpyOcfhVXUbI6lY+WqNHMoUFjhcHPIPp/Ot3T4jcQGKNgxdSVboMnr+HA7djjmubvzcafrM0ZaRYycKW2nHHP9KYj6I/aR8Xt4f8H/2bp8wXUtVDQjbw0UH/AC0kHfnhR6bvavkaFFG5TtwAdpAI4x7f57V1vxd8VyeMPHOp6ixb7NG32ezyD8sSn5ce7cse2TxxXKKwVwdrEYyEJ5I9Rn3/AJ0kMQIRv3AAE5J2ZIx2I61KiDarK6u28EhQTg4/l7j/AOvTSXy+5Xy+S2B1H0/r1p0ZYEEuq45BbnefU/X0pgJGN0YC4YeuOn/1qV9pxhfvAZG0/j/+v2pfnUlCrEEY5GDzTC++Ulz64JIOeMYpDGqFYKXbEeGUDPc98e1PMRBKPhs/K3bGBz/+ukXDI6ZwzHjp24/D6VIchw4JA5yOwGPT3oEBKqCpbbgZ2Bc5Pofy/nSshAZd7hd33uDz7flnt0piEyKi/IMJj5QMnnPJ4pW+V/MCE7SFABJzn0/wxTAbtDSqCvzdOPukD696eqlVG0Z55DHOAegPp1NKS25MAbUBxzkNjHUH8qZJJkFmyBjkFeo9/XvSANgDFG3hlXOCO/YflRsVlRfOKv04HHrnrSq26QbdrMxAJA6n6Hr/APrpykvJw428rgEKT7c5xTARwUkTYDggn7uc+2Op/wA9qbJ84OBnHGdp/AfhyMU/cwyQWKjggYJH1H+elLIQJRkEZ5Lgc55wOfxpANA3MCOSenofc+v+eK7TwBoxuVguJEz9rfygSmcID3+p4A9q46NS7bVOWkIRffJAA6e/48V9J+C7K0tPEekaUFjAtIVx8nVgDzn65piPUvA3hi00TTAIYtryDL5UAk98jt611q8EKBhQOlRwKAnGdvAwQTx/nPNTAZAzyeufSpYxrAMpBwcnvz70nloQcgben4DtUmOMD86Q4zz27UgOU8VeBtJ8QxObi2jW5OSJcZOex9/oa4r4N6Vc+GfFWtaPcsxRlDqMYHB/LPJ9K9h6gEkVzFzsh8WxSRbQ5UKxX7xHoR6e9MDqaT1paTnB9fakMO/ekJ+YDml7mkIz19c8GgCG5TMTqcfMCOB0r89Nct1sdRv7Rw+2Kd8I33iAxAHtnt7V+g2rXQs9Oup3ziONn4OOgr4B8TSm61a5umCD7TKXysmVPI5z17fp+FNCMZyY1ITJUjdkkEf56ZxULvucfxMTuJ9vb86m3YAAJwCcYPU+vt26/wA6hIJwSMbgD9R6k/4UxiHG9gcMegA+tNLKPlU5UZByOP8A61PZQUUgDnJOOMgYx9KQchcY5HQdPp9PrQAhI2tnls5HHX6+v4+lOCqoLNJhiACoPJHtxj86byMoAegYAHn/AD/KpOdmUzg5zxjsPf6/5OKTAaeWyTypIJLcnvTFUyYxu3AH6exp+CIVJKsMfezyBjBBpFBGVCjnGD6cD+tACNjaDkk8kr6H/GkZRg4J25ALDkjI/wA8UvII3Z4yOMcegpr84GMAEZyOR+FMAACyBmHA59ePpTCAV5JGORkc0qZDjYOQeijr1o4yMg7gAeMf5xQABc5IHOMYH4U1ly/qM9TgilJ3KSVAHfHC/T/PtRtOCePqeM/n1oA9G8F6wzafGgkX7VEcMpyMqff3wf8AOK2PENlFdwrdqwVweCqkZBxn26k15jpF62n6nDMjOCCFIB5Azn8T0/KvT7XUI5IUjEu5ZeVYJjpzkfy596ZJ5Y7KzdcjgDOOvf8AD0oDYwJFOzIVh06etNyzSORk89dmcH6e1SQkEHIGzORyMcDIB/OgZZIPJ+U7ixIDfhjp8vBPPembfMDDplRx97rxxjv3NISxDlhgnByy46jpnPX/ADjvTWclnOF+fK56ZJx/X060ATqpAJAYbyVDcgHA5/DmmumYfNUqDxuI52+vB6jJoid0RgRtC4Gc7uO3HfnH5H0pjo4wCnAAwoxuGB169+ppAOYqckH7pAx79zTwzncpyGJ2Eg5JHP6f4UwCNciLYWPQgYAz+HuOaejl2MkgT5cfKcgj6flTAVTIIlyWBB4+X68emetCKTglkTng4z2P4fjxUaLmZVIBO7oDwp/zipSzquQSSGAIJ4JH/wCvNAEYKqyMOUPKsowcZzx/9enoD86lio3591z0xnr/AJ6U9zIkinbjGFztyTx0qNNzc8Z7Lt6kDpn16jB9fpSQD48SEMrLuGCSDjPp+P8AntTXQkhSFwd2Rxu/H1/+vTQvLZU7QvzZGe/t2GTzmpcFRtZZNuMHKg4xkjFMCJypbcoUZAYAn0GB/LPNDfvGyTwRkdgM9vSpA7BdqodgQjGCFP8A9b3/AJ1G4HzkkY4TJPHGOe/t+QpAdP8ADvS21XxpplodzD7RvclsNtX5j29R+Ve+eHFEHxEkmud0asGHUYXoMg988npxn1rz39mzQ5NU8a319LGotLGHazcEGRz8oB69AT+FeofESBrLULa4stjTKS+wKeeQcjHp+tAHsMB3wKQTz/d9O34VMRznAzisjwvdte6LbSugWTYNwxt57/Stj8qlgIOOgPJoIHpzzx3ppkAcKeCegIrN1XVoLKFnlljCgZO5toP49jQMvXVwtvGXckAcD3PYVyGjM2r+I5rwsfLhbam4EN06n1FZ91qlx4inVNPctaBsFweT7fka7XRrBLC0jjRXUqMYZt3609hGhwD70p6HvSZ+bvj6Uc47Z/OkMDkg4ADY4z60nIU7tuM/hTj0qhqV8llFvkLKu7lgoIHHegRw/wAadXew8KXCR+W7yBlwD84GD0HfivkDV41ZDKWUkMB8i8Ef0r3T4r63NrM/kEMYo1LhWXrnnk/w/wA+1eOThv7PuQwlcFRvG0DYcjGf06VSA5EhSS3DvnPHGeemOMjvTXjRGAQYBO1SDnOevNATa5Gcj7oBBBx1yP0pVwp4KjJ4IGc+1AwQAooRlAx6Y5GMUm0MpJ5KqTjGMe/0pzEbQOHUDjjHBPXHp1pMqZCcMWAwR0zwM/T+tAhAmWILo2SOQenHX9cfjRtUKCzttzgjjrmkOGVivI3fePb34+n60BiMkfKxJwuBgc9f8+9AA4LIgYcAHAUDI9s9+lRhh8427hwQAeR+P+etSH+8MHPp0GOPw9KZIeAdpAB+8R755H5UAI+dwI+VtxGOhP4fjUeRhRg5C8d8e1PY7iANox26jH+HWmsuFCkN06Ht1oABydq5OCV6d/WkLMV5HbdnIpAe59Qc9h9aQ8IDjgA9OMH3oAcR855PPU5/z+dIg65ODjp149qGJJZtoHHbt9BSZxwDj69unShjH9NrfdyB3x3/AEPFdr4bvvNso5mZxLGNm8HG4+pPUcfnXEnuDgdi3tXR+Bp1jvpYWXAlTdn0I/yefwpoTMN/mkcyqWbkgdDnOBmpI8YIVVEp+UAA5PHemzMCSy7lAZTnOefb+lSou2VlUE8hgN2Tjt9D7+lIBx5ZgNy5P/1un8/606Iv8u5n2n1AHbI69u1IUI3liTkZy2VGf8/l60i7s5IYYHOT26nn8D+famAiERjCgqw/h2leh9fxqQFEkLHLcMQGGeTnP6U3BMaHd93qCcA/5zSOQseAGJAycjofQ/SgCR8Ih+ZsnI9B1/z+dOEgOHXlS2cnuR7jmozl442CgktuBAPPp2zUu4rHjYyJtJ2g5A9M8cdaADuFJ27geq8Hk9aCQzyEqQSMfN16ev4j9KH3AEhDgA4O3px0Iohc5UhQy89s4XOMigBN+4gqTuxlgrEAjHUGlY7ck+YRt3Zbuffv6fyqQuoGdoUMAAByCfU9een50x2IVRGh3A9c5IB9aSAXkyPHtIOQPU9e4/P9aCGGTIruMHadw5Hp+tMO8OoC4JHDKc46c0oYDeB5ZPl7QB0Pv9aYCyNIS7EuRtBIXocHGT6dqEdWuR80gBzgBQSBgcgdx1pNow5wWKkkfNg8jH5d/wAvWnRLJuAjA2sAF2kgHp+P4Y54oA+pP2WbVU8AX1wHcmfUpAwAHyhUVQP159K9Yk06CfUE8zfIyxkjKjbjPY9q8+/ZugA+FNhIiBWluLl855J8wgN6ZwBXqcabSQAcH5evX3+tSA5EWNFUAbeByOv1qtq8t7Hak6dEsk2cc/wjHUDv9KtnIAPzdcnFZPizW7Xw54c1DVr2YRQ2sLPk/wATY+VR6knAApDPD/F/xyk0hpdN0ezikv4t0cksmSsbc5wOpP6dK8rttb8S+O9ehWe7kuLmVeittCg4yRjH/wBb+fOabY3+v6xHCoeS7uSXcNz8zcnn8a+oPg78Ov8AhFbMTzKWvpEXc4wNp9s9jk1RJ3Hgfw+NE0mGAqquigdOc/4V0yjGeAOex7UiDaMDpnoOlKOQcjue1SxjqO3HH0pON3QZArG8R+IbHQ7Tz7yWNUz/ABNjPP8An+VAzQ1C9is4TJKwVeeSfT0rzXXdebUZzEscgjZmVW38dDn69/p2ri/FXj4a7O8Kqj2pfARWPzk9AfQ/4c0eHh9r+zKYbZXlyN3mEs34Y47/AF5600hGRr9n5ck00sMoj2MFCtk4Pb6dc+/rXA+LLWGxi8tF3OFGAGBxxjI56Dt+fFem+Mby3t7OWOV1by1ALKeSAeoA9uMDrj8vK5bddVkeRWAd2DbRhQRjjb/PHseaYjgLlBFMyjcCrnAY59M/0pucbjJz8o6jHB5H+f8A61bPidLZbiL7GYy6o3n4b+PP+HHFYyR/ORtYDJJCnJwOvXqe+KBiZ3e7tnoMf5+vWmlgD0yp6HPH/wBb+dSMSAexYk/MxHHY5/xpn/LPu7E8LjOT649KEMbznKrx69MdKdl14OSucgHPUnqKDywJUkqCR1wfx980qjyn2nb0BIDd/TPrz29aACR1IYnB3AZxz6/5/KmEnllQnPzDJJxj6fXvSNhmX+I9WbGMnGelIpYbuoB+YnGMj3x/L2oAZnjBOTtJyDSHOAFxg9/cU4jnGXO4g4UZz6j8KaeenA7kcfpQAKxLfKCE5xnp1py7R2O4KRgDkYFIpG0ksvHr1NBAGcngjgA5x+NADSxJwBjIAOOv+eKOWJKqWPX1/Gg5xgAZJxkHjtTtoTJLEd+Vx27/AOelADfZjnHoO57Zq9pNwbW+imjVjtzg7tvYjrVVI8uIwDv68/XoPXrSJ8rkL6456n6UAWBIu9iWO04yQOCP8PapYm3BycKq4OSDt6d/8+lQSOSHBw3fd6/4U+Fztmx2UZx3GfTt/wDWoEWowGznIO5RnA6D6d+M9PajI3sAo4Iwq8ZxzgHpz6Go1O3G9wpb5snOTz3HpzQ7NIxIJIUkcEDtzjmgAXBjC78KCemM/wCcfTrRggty7cht3cfgPpSN87hGc/KMIQvYcgfQUJtYjsox8oGM9c+vPWmA9C5xhjk5IKZwOR/n3p6yAg8IpLBRz1Hrjp1pFIlBU7sMcBeQDk8UnmEO6qVYDLEBePTr3/8A1elAEu44VWBwVI77uemP88U0OXVfvAkAAZzg57cUu5m2llXd5fAHIOfT/D86bliPlBByOcZx/wDXoAlb5pFDsSP4sjgYxjmmBh5qnzcsDkMVIPf1/rTZi4nBTdz2J6+/+f68GCyhd2NxBDt93tkk9u/50AIqAcKArZAAAzz6f5//AFSMq543bee3UY/p+GajjztBJYLk4wMZ4yc++OfxqSJmQuiqwC5JZT83fpkevb60AbHg7w7e+LPEVnpFhIi3MuSZZR8sKKMtIx6kDHT1r6Asf2fdDARLvVdRnfaDIRsTIH91QOOehzmvOv2brV7n4jmch1S2tJWfYR/EcYH+fWvrSCKNAVKoOMHHr7Hrj29aQEGgaRZ6LpNpp2mRCKzt4/LiQZ6Zzk55znOa0zgE528jJ9azZNOhuNTivZml3RptjAkIUc5LEDv71pg9eSfbHSkwFwcDpmuP+JXg2Lxtplrp11PPFbRziZ1ifbvxxz9M11uSCo3Dknt19qzrPVFmvZYJdqPGcAnjd7+2QRxSA5Lwn8KPDHhe7jutNt5TOqjL3D7z19O34V36Rqq7VAAB/KlxgLng0YGO3tQAp47jnigde/40h5UjIPHUjI/Guf8AFfi3S/DdiZr64jBPCRhhuf6UDJvFfiOy8O6c1zfShAM4B7/T6V8veKvF114k1g3J+0iENuQEKent/dyBxjOai8ceLLjxZqUslxMywM2UtwSNqjvjoSenoOawYbtLSWKRIhJlt7BWG1iANuD6j0/xqkI6XRdMebMyvP57E/LJGARkn73PJ5/HINddpM3ktkS7jEnlgeUV4HI79ff8O9cQmuiKJXhV0KHg5HXGSQe+Mf06mpG1yQt5jLdbGAY5dWPl9jwAOeMDsTQIh+IN79phjELqzH58ldpU/wAJyPTNcwoubZfOmJLht5PQlm65A6N9PxNbl9Hc3pXZFcSOx3KwX5dxyVCn6E+3tzWhB4R1K5hMUVvuMvAAPBHcHjOPemB5xpeh6l4l1g2mnQyXNzLnG5cYHHBP68c8VZ8UeDNa8L+W2q2wEbHdHJH8ysRjjPYj+dfUHwj8BW/hzR5JpbdEvpflJIyV5+77fUV0Xjnw5ZeIfDl/p92EYSIcOEw0bDo4+hpAfDgzhd2CgIGS+Oc/p1/WmNjlfnAGQFGMpz39RXqMXwg1dJ57jUL21ttNtw7NdD+NB1IX9eteYXKAXDqkm+PzCI24yRzg+wPXHvQMYTjhskkZ2sPve2fwH50zcUDllxjjIIBGRTnIJ/i2gYwO468ClAJUt5ZJB5OOPX9aAI5GXd8hbgcEnpmmOCUyOfUAZAwB0/z0qRgT0xyOgX+Xr2pJFIUliGyuQRjnPQf560DIjtAcEMxOQvelck9cAbcGkIbovzZGMk56/wCetKV2MVG4DqT3x65xQA1RkZOdu7I4/T270hAG0MSevKjI+o/+vTt20/KrBTwQD/n/ACaU7l4jJUH26D/PehgM2guMcHHyk9P85NKDuAY9euOOPpmmgkjaC2SOnXANIMBjnOPrQBIMAL90g++c9+lEWA4OT3yR/SmgMRgk844FOAIJJ6jGRjpn2/CgCzMgWTK47ryOuO//ANf2p8YLKxclguGOf4j1wP8AP4U2baGxu5JwfXHQ5HpinjYiFhhXYbh8ufunt+VAgwGGA2ZOSecY9e3v0pTwcMdoI7Hj0/CgqnQ4DfmTz1HHHNKNhXazAkna+DnGBx/+rmmAnCnoRnkMOBjsac25QyEllK5weR9Rz2oBTBJcbgQCB2yPfv7U8IsmACSerMTwO/T/APXzQA0KrTALgH3bqccfT8aUfwnByFOOOB9MdadG3OwhgFbOSPb8/wCdKVKMm4jGOFAwvc/4mgCR1YMoCA+q8gcjJyP6AUzJwdrDgAsxJB9efXpS7gGIPAC4HbB+h6n/AD3obaFkZQegB/LqP0zSAYUUhRsPTd6EA9vf6/SgqGY7cAk8hTjH9Opppld4vukFzxkcn/6/vxUwA+VVwDsKr8oGAOPx/wAKYByBjk5XgHPP4f8A1+9aVhotzqOpLpliizzO4Azlecc854HHU+lbPw38KzeK/EQgiQeRBiWY/MduOF6ep9/XOBXvPw/+HqaBrdzeXDxyTSO2XKHIH9Rzz9OlAjZ+EXgK18IaWu9UfULgBp7gHk8nG30HTFelruUHOPl6dAuf8ap2Y8sLIdh3Ak7BgEDp9KmeRF3HILKBl934ZI/GkMtLyOuDgAt1+oxT1Y55OAScelZGra3p+k2El5qV7DZ2aPteSdwgA9iev0Ga4iP41eB2YqdZGQTuzbyKvrwcccc0gPUMsT0O3GfQfSs+5gC3XnxFsthSFTOPr7Vwtz8YPCEO0Q6nHOWj3KyBjnuc5FclrPx30y382O0067cYUo5bb1PTvn69KAPd94YgdDyR79uPzpktxHDEZJGAQd8cfj6V8/n9oIMjGLSXVgxUKz5yQM5rzzxr8U/EHimM2zTm3s5QSI4nC7gPp+WSe3aiwz234hfGfRtBiubbSbhL3UFBVQq5RW9Cehr5u8T+KNS8T6hNc6hdyS5YbQTkDuR07YrBGAjOFk4YHf74zgj1rRsrGBoy9xP5TrgZALMOmSB354xTsIdp9tIQ00hxEhJXk4I9R9P6itCGFVhQnaCRjknGT0X/AOvxmtu0tbKG0jj86HcxZm4wm0ds+5/Ij3pmqanoOnLmS7Z5vnJjjBYlivy7s/wjP1+lAjEkCsP3nlEKwxtYqAO3v+PtRJHHGI1hVGUkNvhkJ3ADqM8jqeP8MVmSeJIznyrVtrKfncYwOMkc+596b/wlU727pHY2SrIQh/c84XGM5/Dnv360xnofhS9iQoJIQFVvkLOTjAx0H06e9euaJNDKDJFEHC4DYk+Vj9ew9vevlQeI9UjmS5+0BZd5YkIOSB3x1rp9E+J2uaRbsFWCZcEEuuCWByScDnp29aBH17p16Bb7TvD4wwPJBPr68jrVa/ae5lMLq6w8AjIyTnrn0r5/0X47XiyRR3tlARuAOwcjI5PX/HtW14h+M9o2jOumxMJXx94keXn8OBwMn9OakZY+PPjW1sNB/wCEb02Vn1C9I+0GLH7uIHnJx1bgfQ54r50toVuLqOAsiiR9odj90Y6jP4+nOKn1O/n1HUpLi5cvczvv+dizHOfbp1xx3qB7WeOKJ54JUjmKhSU2GTrwAeeo60wIZDlmAbep6N/fOMcjtim4BIDZyBggEHoP/r0hGX24KkhSRgZFRoSgUBipOCMNTAlkUBiTnI+f0yO3HbqP6VAyqGIILNjODnt/+qnzOWQ7yWzznr+ppsgVd3Lc/wAPPBz060AMyFU7cEE8epx/n9KTI2/KDkYBJPWnEYXKqv4A9Pr3BpFXG3BbGMcnt3Gew4pDA/K3zgKduMHt35pGG1UHOc9yT+Q9KVXLMT82WA5J5FBzjlMKOuD1PfFDENIUEfKT3OOlNUbuinr+ZzTjkHp0HIIIGM9KaACp+7kjGQeevpQMU5xjgN0ODz/9YU9CA43A9ORn+dMZTktjCdz9KlhGJuqBh39KAJHYEsNxHA7cjjpz6VLGD5f3RjowQHr/AF/zmmM3OzaxOe2MgY+nXj86fCgUbWPUYA4469aBMfu2sP3i/wATEgHkD1z2PNNLMrHexXPUN1A6YOfY/wD6qedgTK989OMj3/n/AJzSqWHyjjdgBRx19+30P6UwGLu3qhboc5ZcEdO3t0/pT9rfKdyt2yQcj1/nTDv8xidyvj6c9DT3BJVtxTIGDgHgc5HtQAwHgljwG5AOMew/M8U7cysWAK9+p4PTn2p0i5ALZGOrfX6daRmQkjOOMMNx5/x7UAIWdnUsSCT1z07f096cAygK2CB8wAyMEen59/1p6oS5YtuIPKlRg/40oVdzPHtGBwSPbkk9c9v84oAZCxChQxGVIGSASTz/AJ/pQv7ze0jswVgD83C8dM+tA2jawfjnfuHQnv8ArzSom4q8eApztwOgzj8qAPc/2cPE1nbfaNCuGkS5uZzPFIJABKNoBB9SOcj0r3L/AISHSYrgW7anax3LMSIzMu7juOeDjsa+HUwMNFId4J5VjlTwPX9aPLVt7TAMe7EdfqaQH3LrPiPT9HsDd39yRGse/gDLdf4R3614B45+M95eyyppIeC1RjhjtPmjHAz19xXjLyy+UqK82wrs8sMQo5BJ61JDaTzwS3MaM6R4818D5AQMEqOgyOpoAta9r2q6/N9q1S8lvGQHaJG3Kg6nC9h79e9Zfnu0aKrgnGQ23p2J3dfwpHG0iTJ5GQR9f1/+vSBdkaKMk4B9Qf8APJoAUOhdmQFcgckYxxySO2f5dK1LBFvEkgYMZg52CLkuOhBz1APP8qzCHMhP7wkAHdjHTp3xyKt6VFK9wJoNxVVwvOOuRgH6ZpgXNPgjluxEc4IOGLbQcY/L6VvtpVuixiYxlSg3FsguQM5YZ+UnH0546ViG3ZJ4ZHfabhictxuz3OOPr+GK3UMyhZPMfb5ZZpHG09APmPfv0/rQIx9bsntbkgAqx+bAO1hnoOOpH+elYM0nLI7MCPugHPTrz7/l0rvbS1fXGkgZA0gwqo6Fjyf4T/PP6VW1z4f6na2M1xFDvAJ42kBwP4s45GCaQHDTXUhYhGfaT8yDj0B4/rUJfHIbJCksQOvpn17f5NTTxvbyAOjo64YJIMH69Pf8qglyuM/j655J/wD10xikfeJLRknIA7cYz/ShXDMNytt4ycdR/n+dDAAFgVXce/PbkH/PalRfmPC4A3Hac8enPv8Aj+VIBDIGKjcTtH8OMgk9PfiiR1aQiN9yjIUuApOfX0/PtT0GNgbdhjkkEHjnpnvzTfkGFJXYTwG7/wCf5UAWdKsJ9Qu4bSxillkkOwLGM9TjB+vNfSHgD4K28dnb3HiF1ndv3hQgHacnjPYdOa5f9nDw4YNfbVdStzsKeXAXGPmPJIP5dK+pkXCgZbOMliAD+NFwOR0vwJ4f0rLWWkWcUijJZYwxQnuM9c4HPtXg/wC0/wCG5rPU9K1lYx/Zssf2Zio+VZOvP+8OnT7tfUxXCNuyDngNgfl+FcB8aNFi1j4d63auQSluJ0kC5IdDkMB2PX8DRcD4l8vDbQSQG6jOSfY0MpwRu6rxk/59O9WH2n5shSTjkcc9/aoWCtI2CrZJPTA/L8u9MBvJzn5d3G3seemPWozkN26YK/0qQqWPBYMecjgZ9fekcKNxBAzt7dPX+tIBhbbnJbrg4HH86QjYxbaFOCwUE9OTgZ7frTzhhkj5Q2Pm6Y561GVIAVt2SAfUjgnpQMTlZMdCOQB/nrR/Au35SeBx17YpSuX25BYcfdAo+TBAUMABggkHOev6/p+YBGykEdc9QT3oViDt9urdqeqY6kLnByeg+tSMyKY4/LRPKPLLw75OeTyDgdPb1oAizlRxtAOQfUe1PXBypICkYIPAP40wN8mWwOcnjvT494GFyGPU+lAEsm0swwAoLHnjOOlWIC4kKqQATtGTzz14z+vHSoJyXMjRKxDMQTjk57VNAxAyhy/JB5xkd+n86BEitiUBTgOM7g2D7jPPPfj/AOvQqCSVMBX4AKnvwT+eB+OacZG3jcjHAUjbx7c/SlRtqAMpYqcZAAB4PTv+NMCMA/Kq4C7l5G4nkE596cuG/wBZgjGVUN93JHB/Pp9aRJG2q2WXBX5dnHAxwKFC5TDINu0AnjuOp9RQBL820sWwCBjr0zjp37D8aYMnZuLKoP8ADgn0P4+49KRyxt4yrLtOAFJyc9sD0p4lw2VChsbuBn34/WgBSu5QAQGwxHOfy9DkD/Oab5LbsBsHjBGM88cj+mKkaRQNoJYFW6Ehj9f1pssgMZ2jCb8qc4x9f1oAbEhEabiAeecdMd+vp0GPWnhN2RtGATnqMj/69NBVsKq8E8nJUZ+vHr7evNDs6MdxcjpkjP4+9IBv8W8MFTO0kY5HPHPP/wCunSQsAQWYkZIA4Hv+P/66eZW29CGBOQfy/H6e9RmRkDbSMtx82QfXH06/X8KYC+XndH5jMc4znJxwTnPT6/8A6qn0zULrS7g3NhcNBO7FeD/Dx8rA8Hp0Iqq8+5/ug5yee4ySc/j/AJ4NIGPlnHDHOTnnnnvzj/PekBce5inDyXdijySBhuicwk5PUAZB/QVf0+Tw1gC8tdaBz0imiKEDGOoB/wA/hWJl8DBO0NgAr+PXtTldSVbhdq/NgHB9sdv/AK9AHXRXHgqNZB9i1aWQFvnlIYgAcDg4I6fUn2qTUNa0WeFY7KCSEZDeXMgUbj/dIPHQD/GuKLFl4VVBJIHtjH9KN3XhVBUqCxyBznJ96AsdPIHnR23xxxlSd2OCvTB9+4PuBWnpMs08QtjveSIAFFYOu7qAPb1/+tXOeHdVWFhBc5I5xJgHaOcgjuD1Hcc11mkSI9zHIqxBXb5mHK47EA98dvamI2vDsFzb3r+Srod4UYQeWx9R+H49q9hsJ2/soeWVSRgpAIyc+pPcZri9PtHNvC8YSN1+fmTHGcZx/WobbxPHpVw1tcShIYwSBIwJbGeR7n/CkBmeLb2NXmIsoWlUgHfGGA9CMdv1HPpXmushJJZ2eOKNvmYuOATjn6Y5/wAa7nVfE+lXwDW7zNK2SqRghhzjHPGfbniuZm0OfU5mD8Ox2cZHX1HfgU9wONS3iefy1Vo4xy/UuAOTx9P0rotA8HNrDl42lUMwPEZA+n+eK9b8FfDPdbM9zHOrlg+VG0oBwCTjn/CvYtC8LWmlW3l2aEfw/OgJ9ye5+vagDw3TPgrYSwILh7l22glVJ5Y9c++OmOPXNegeHvhT4b0yBPL023aduC9xlyxHuenrgjtXqcOnopXKsVAzt/hX6VZMCsm0MTk4baOD9aVwseS6/Zz2N2j2ZRreEk4AK57/AIDIr0Lwnqy6tpsL7dsgXlSwJH09f/1Uazpn2hWKZz1yyBvxx0Nea+Ibm68N3SXVmdsf3m+TgA+3boKNw2PZGJAdsnGO/Kk/zFeefGrV10nwJqspWR2kTyFVcDLMccn8af8AD7x3H4mlktjAIrhQCzAHDjpmuK/ah1e3tvCdrp7RK9zd3IMe48Ig5J/lg9OaQz5dkjYLjeS33sd+hOT+I/lSEMct5iruGDkkf/X/ACppdtzNghj/ALI54Iz/ADppYqW2kAYAOCT37Z+vSqAcYgzbmHLED3yR1zTTEwfJOQcfw9Dg8ke360F3UnALADcCxPJB7UBXKsVz5Y/DBPbPfjt7UADAr5fQAgHGM889fb8emKiwfLXkA4wM5x6ZpWJEag9+cjvn/wCvTXLKAxb5O4x1xyKQAuRKkhyWXpn6d6O45xuIwDzjjrn8aEbaQD93qcjI+goDGPD5BA5x1HtmgBCS7DzDhs5LnjFKNrhSq7OmFRie2OM1GGMZHCngYHUD2pMkEbuMdMjp9aBkh2gBycnAO0jj2HWnRp/DncRyc1GCxXuzHoD2x3rQ0SBrzVILWMcyE9V9FY/0NAFeTawbeMndjKen+cVOCSGBJwW+8fr+lRTxgh9wXJG4YGBn09uD1qxCFMwVQgT0b8uc8ZoESKSCQCy9eSMHIOM465/zxTCCMYDZGeAeemfTn1oZVIJ3q7KSGBON2O/4UsiHkFw2CSpYdOn+fegBNqMpBwm0AMM8D345I9e4pXZ2DLgl124wOCccccZ/GnbSsR3KAN2MKeDjnt/gOvemvnG05AGCfQdeRTAiUgtyoZWPGE5P4+5qRCNrFW+/1zjk/n0znmlEToNpJw/HQHtnNCxyBQPug+mCQO/8qAFVlaIFmyW53begGMD6UbtrFlJBYnBxke/FOZFJAZvlJxkZPP4/TpSzxMqKzDIBwT0H4+tADCH/AHfUt/d6k8e//wCqmIQMAEZB6luc89fenNA5QbM8HBbGdp9wfxoSMOoKhiXwq7eP07fWkAittQs5QHPyhe2epB/Gn4bYrSP8o43A4A59OtRiMHG5lUYB4XjJ657D6f40/YB95Cuccdxzz+IGKYDFYPtLSAqF5GB0HTn09KT5c/M7A8kEDrnn+XrSpHuLZBTBwNxz+VPCKrjaNrYGflx1+lAAjZMvzDa3bkkeg96jdxIcZJIbjjP8Pc0sik5U4ABC89R+Xb9PpTCGLKjBShA3DgAfh04xSAMxfK24FiSx3DGOMU+EY8wkknABCnn68+1BiZgXLfMOeW75xz9KeYiGc5YLtJPIJHOO55/+vTAYj/PFgE7cEEABs+gPfivYrLRYU0hZC0jM0fmFlTack9cDofQH1968dSF3CRsoLuwRR2Yk9M/T+de9QXDw6ZHBDk/u1VGPORt+9SAms76NSImdWiUFSdgG31OfWuK8S+GI9V1F723nP+0rgnbnHc9Dgc1e1TVP7Ht4Ypy8MoXcqh93HOMD1PUjp2rIvvGCCzVLdJQWwMYBUk8gA9sZP+eaBGpawaTbSJFBBCZ41C5yQCTwT9f8+teofDbwt9qnGoSxKFVv3aFsspGRyema8T8H2t3q2pxzTSqMMQoKBgxz82R+OB7/AEr7B8NWQs9HtothVwgz8m3nHQ96ALllYRwjCDBGBw/Ocen+eKvKnyJtGB1wp9qaAnJ+QcYyV5/GpAm09FILd/8APWkMcoCjAAwKQ8yAEdOQ2cZ65GKUfLyxPB5NU9X06HVbCSyuWlWKUD5oWKOjKQVZWHKkEAj6UgLLgGMgAlcZ+U1zPi7SIr20lQqC0i46Z9ufTH4U/R9Tu7O8TRvErxvdyHFrequyO/ABOMdEmAB3J0IBZeNypuXEXmISRkEdj09v/r0wPNfBPhqHS7pZYw8ZywYfdCjt+nOB7V43+1DLO/jewt5R/o0VmjRqvQEk5P5Yr3rVr9tPvWI3KF+785IOMd/rXyl8V9Su9e8b3tzeOpaJhbxBTjagGR6ZHOM+tPcNjitxZcKf+A4x3OO9NByHUA8kg45IyemaRAGZdpwCpP178+vSpAhwMjkjaASCCPTHfqKYDHZSigcgjPPOOlNXb8xGDydvGc8EdqeeZGGRv47/AJdDSNGFkyQTnJ68jnFAEUp5BOwDAyvYHGCKc8iEYBbJ67T7d6JlKHL5xxjJ7/5NEi+WApUABiQwHJJ6fhSATEZyuWBxwAo6bTkk/wBMevTFRsw2nufc8f56UqAEDcTn1H1/r1pu0bgOvPbv2z/KgYjEY3dSW7cYpqMVQ7ep6gHHf0pcDABPz9eP60rsTxtCncW4OPwFAApy5Y/w/MRjOBnr+uK9I/Z70n+1/ilYQuAY4IZpmAAHGwr/ADavNU2ggk9OOO3517z+yZpm/wAT67qbglba1SBc+sjZP6IKEJnikjgPkAuFJIIGfYfhU0MoBAwhYj5Sy4yM9M9s4JqCZiZXC79+443nvz1zT3TAPl5KEfNk/n+XH5UwJwVfO5QVboccD2z+NKsjSgIH+bYdwAzuPPB4pFXAyobP4fpn/wDVRt3KwT7y8N6Y6/U9OgxSAlaXMu5RgbcsoYHHtz0/pTC2VIyNuQDnAx7fhzTlCFk5Y7ckZY/KBzjimbnXeo3HPII49M/jj9KYDy/7vAH8PLDn9PwpA+QAigZXjPbHQDH1P5UrlnLEtkYGCxHY8D9ajHlkFiqnYcqWGCevf8uTQBJ5uCzs3PBI3YzgYHPvTSSQ65UDhWbgAc+n+elOES5ZhggcLlsY796dgoQNhBz1OBtHJxj34/KgBC7OXIO4HDLu7dj+HNRk/KEK4wfTr6/nwaVhmAyY68kdQee57jGKGG0gH5RuAOei560gI3ZNjRxk+WQMAjHA98dfepQ7AIhDBhlmOTzyefcU2SPduZAGY5GFOSvt6UAnj5OMfKS2R+HOOmP8nFMBqEF8jO9ySctnHqM/5/WlxuBJOQCCwP3cA+mKcI90gKs7EHacDOe3ORikbbuIVG2g9GOcHuf50AR525R1G0HcVPGCf8c/5FNhCkYZiVwFIHGT1PH+elSbRHG2fmUeg2jpn/GgkfMQG28gkdCMd6AFRk3jGzJPp93vnH19KVpFlGFAI5ACdBznjPc00IFcDYGIBHHfuTXZ/DLwVd+NNdW0gWWLT4WDXdwnJjQjO0Z6k849vwoAufCTwVP4lvRcFT9itm2jaA3muDwBn0zz/kV9D2XgEyRwnEaRp/A5zvBzwR0/w9+ldj4Z0Gy0LSbWx0+3jit44wgVV5bHfPqTya3M/KW3DPJ5HHTvU3A+cPiZ8LL26nuNQigG7aFIQ5bbz27/AOfSvF9Zs5NJKwTjeeoJ4G4cYI7HFffLIGLLjnGDn0rxj45/DOLVdIbVtCsx9vhYtJFGcBk7nA6njkU7gcJ8DrKG+vLVstJHEMqpOAT7D05GTX04EMaDcDuwB8zZGe/H4180/Axv7O1MwybE6qFL9emceoJPP4+tfSyELtACEZAGznp/P1oYE4z6NgHgZH5in7s4I6fSo+qZAHUn5Tmn4xzzkD1qQEbaowOO3rTsD3I68msLxBPqmntHeabb/bLSPP2iyiAErLuyZIj3Yc5Q/eHQg8G/p2o2ep2S3ljLHPbuOHU9wSCpHUMDkFTgg5BANADNd0+DV9LmsrtR5co4JGSjjlHHcMrBWUggggEEHmuT8AWnirRRf6N4qvjrEEZM9nrCgbpEYndDLGeVZTyMZBU4BG3FdwoIYZAx0wD0qvclVjLfMBtySMZAx1HrTA8s8b3MMWoK0kkatkYABx1PI9utfMfj8CPxnqeCTmTOG4IyOOT2xXuvi/VTdeM4I33HEwxlscYJz9OMfga8Q+JEgufHGsMXUBbnAYfxKFH+f51Qjliy+ZtUJtHf7q9Ohz3pm52BXaEDDnHUAe/071LtwIyFCqpbEm3I9x/L+vSomABKqwJHfkenr1HFIYjuDIDzvHOSQfyHTv0pgYMVB4QNnPQEeufXvU0jfLJtfcW3AkemQep9xTAg8xvLJUcnew6ngY/GgBm4gYLNgdVBzj8fems3G0EsBySccmpm2+SoBxHkgZHDAjqB/nrTGwXDbQGA+U544HWgCJTkjJ2npkCkbqpJzkYznr/nmpIwGmAVMdQMDrxn8KURHAWMH7uSMYJwOpH4UAQKo2g7vqvShDvflgAeuRnH61Iqj93liQ3AGM8EdR+lAUFcOrhvY5HB9fpQAxTmXrk4AyfT6V9Y/staU1j4En1J/wDWajdM4LDBKINgweP9qvlKIMSNmWZuiqCSzHgYx3r7y+H+kHw74I0PTcNvtrOON14GXxl8Y9GJ5pgz4SlhPm5xgjj5uc9ev6/yq1GpLEBC54wueefT047VXnjZZGQqxVZNpUckEZB+p4qSGQkh5XXBUZyN3qP69/ahATsrFmI2qQR8wbOfYd/r/kUMCfnTAAG1Vz29f581F5jI4fJUrtGJOn4/405sphCgwpYkIcnJAJIPTP0IoAsGIMFB+VyTyowAcdB+FRtGWBKkM4YHhu/ce2AaSeUBJT5ZCfNkAcHd6+nbmlDqzuSudz72O3GTjvjt7f40APRH8xCTuUvkZyMjBzj1qN1Ybg7Abl3MVGcgcgc89c5A/WnNNgoQEZcltyj5W4PTHf8Az7U/dkKWQAYxuIzn/wCvQIRQ28o3yvwpOOuRwP8APpTRk7GACIwJXJJPB5x2z6/SpEkHmAjzFCrkMB0AGCf5UxwWQjBVCoUE54z/AProGCoVY84/hODgEYzn2piRPMux3Bbdnnk9AOQOex/WpXwzSHOQCcFRjAwOajPLg/My4DAjghf8P8KAEYAMSzqeOgHQZ5x69utKsISRiQpBGBgkg+wx3H+IpCSDgZ8vYIsZ7ZySD/ntUuSrAKrHgfwD19uo/wDr0ARoBlZSWG9j07nGMn8M/hTlBiYKAxGzblei4wc/yxStJ5caLvTKk4Ycbec8f3v1qKMKcCQKQcnGcZwefpgikAjLgEIowuCTjqR6DsaaVbeyELgjOM4xn1xxjnvTt8Rd95UkjIYjB64wf8KGdThUHRQCOee+T+PPPpTAltbaS4v4YIIpTcSyLFGo7GvtD4TeDovCXhC1sUTN3IfNupFYAvIefocflXzp8AvDg1rxzZ3EoEltZylyCOd6gnIHse//ANavsEKBCCVRlOSAOmPUelJgTKCrZJO3GfbjvjseaeARjG4cDPAJHtx1702EjGXwWCgMSMNj3HpUwxx047A9KkZG8fzgg4JPTP6igbZI9pwc53DGM59R71K3PvTQuX3DggYoEfP/AMR9FHgrxhDf6ascdlqTBhGUyInBG7Dds549ele0eHdQTVNMtrnIIYDj3wOlYXxh0dtZ8C6hHBuFzaqLiLb329R7gjPH/wBavMvgV41WSd9Mup5Q2QEjfGFwcHHsf0p9APfsLt428H+7j8x/n1p2AJBwucdhzUUMu9FPzj5j16/j61I8mDj5shc8Lx9QaQxrNuVejDIzk4H4f4Vx/jfTdasbe91bwJbwPr8+BLazMFguhgKJHBIHmLgYbIJACnIAx2MjKcAlfvBfmHf0+tKXwwJ3YyT0xii4GD4T1xtc0aG8nsZtPvUBiurO5jKy28owSnupzkEdVKms74gaumlaHcmXYSU2sBzgHqf1rc1fUobC1aWeXYuw4OOB7g9v/r14J421+fxLrZtbJg4OxGKkjbk9V9eOCPf2xTEM8MwW8t9d65eMY7azRmBY/KoAycE9M+n0714Dqd21/qt1eKpdbid5Rz1DHI/TFem/E3xHYaRo7eF9EZDMzj7XMp4UHqnrk46fzryXcHx5mCUzwx4HHTHfpVAOVmkXb85XHJHJ9fyx/WmxGR2RQzsRhlwAeT6ClYFH2txImCWDDPPYHPPBpiMTGUGSzjgDn8P0oAaFL5C4AJBwOnPt/Wg7lc5HKgDBPPUcH8+1Bf5GEnGMDAA9T1z9f1oVmVwCNrdSPyORn6f5xQA5AAPk2qnfAz36Djtmo2jfcPlOeflx3BOP8aexIQn51Xb8xBGCTjNNZnYMrK+7OG3cikACHd8hGSMhsDd+AHelaEbGyNwGc7eOhxSRlsL1IBY4C9/r+H8qZhPJHfg4PQNz/MUAKY9hPmHB6/XHuPzpNgGBI6ZGScngf5/rSEku4zglueAOaTed4b73BPze/XPrQB3fwX0I698TNIgMTNDbObyUl8DCcgEjoNxUfjX1n8QPEi+GfDUt6XxK7oke89TnkYwc8frXkv7MHhr7Do2p+JbqNIzdEwwGQZHlKcnOf4Sc/l7VkfGPxU2veI0sbGU/ZbIlIgjcu2DuYD8x6UPsI5X49+DZfCvjSW+tYpE06/kaSJmG3D/xLx2z+f515vEpCsF3EEYwueMk84xzX3D8T/CFv4v8M3GmSCJJdrPbzFs7JecEe3Y18VatZ3WnareWGoRNFdWshjkjY8jHBH44B+nahDe5EfK3AnockktjnscfTJ/A0KqJlSBncy9+eOP5n9ahU8qNqOM9A3ykfzpVcbWPyYJPJ7DpzTAmypDeYSFwSdhwTgd+eRn+XtTQ7bWZlbamc7cZBAGOfSo5jtxjKllACsMk9Mfh7UrKnlKVYhd4AHYnHX260AWJH3y8kNknqMnGMjOP50iMwKMSQckAk4JGM/pUchBO5htUYbGM9cYFMDN8u59vy9DggD09vWgCyGO5AhHGSu2THJHUE+9M+8+0nhQMjt09KZIodlZioUr/ABevuf8AH3oaZvMyThuQSenT+vr+VAE7udxVj84Oc4y2R1+v+fwaqEnG3A5B5wq9On5mq8bspVQACCPlX1OMH1HX+lKpIYksdpBXI6dD2/woAfCcomx/MIOCUPtwT+NKW3bVYnJG4DPXjjB/Cog3zKC2NqjGT9ensfX2oc4V1GyNuvA6e38+tAEivt2Kh+bJI3LwRntnp1oUkghyM88HBOAOOPTP+elMEi/MwySGw53cnPOB+JohiMzxoiGSQMAdvU/5yOKQIllY7o94GePkJxx7enNLbQG6nSJC2WPBHKjHU8854+lV2CAMJQMMN4PT3z/Lj3r0bwd4aktIfPv4Qs0mDt3kbVIBAP1GDu96YHqv7ONokE98F3ebGgjAI2sOp4Pfp9MfSvd4yNkZIJyvJwMZ9x6//XrxL4FiZdf1x03G0ESooOSuSflGewx37dK9pjGQMklgoA45P4f1qWBbDHJHzEjHHcfj3pJZVQoGeNd74G7ufb3qPeqlj0UfP14wO9cXqvxC0O0uxHHdvO0QJJiUNnHX/wCv1oA7wMNvJyOmf8acB0z1x6159p/xT0G6vUt2kljLkbXZcjnp05xXcQXMU8IlhkR43UMrKeDn3pDJZUWRGRlDK3BBHBB4P6V8Ra3b3fhzxtfLpwlRoLyQIseA33+FAPsa+23bIPIHzDt+hr5n+OvhuLRtZbVAtv5F65xFI3DPjn88Zz7U0I9B+FfxBi1fS44tQJhulGAZG+/1+564wevHXHpXoUupRhGcSOTsU53gKcn07V8hprMOh+ErSKC0Qy3L/NN324/p8vI/xrGvfF2qwSGL7QSGVT9/k+4OeO4x3osB9g3viuzs7hVmeQbmwMYZguPTuDWHq3xAs7WDzASgVmAJYYHGMD2zgc+1fL0Pjq4bUfMvQrLG+45PDcY+oPfP8qxvEfia91gxoZDHaoG2xRH1PIPqMn34osB6Z4w+JsOprLE887qyfOkfPzZ4AJ47H/PTzy88YX0kDxWLfYI5CpYoAJGOOPm/h+g/WuY83/Z+8AFHPHcgH35GKazlnH3cZz97J/z70xk7tmWSSRw7EszSHqx6k/nnv1FM8wBV4JABAAPI49fTp1pm/wAtcsCF6cn2zjFR7hk/LkY4I4yPahCJdy7xuKZ4wTwOBz07+mP07kjh2DbkC8AbgSAcdxUJLORkn7u3PGP8+9OCEMdo3H2APA/p/OhjBypBPO0EgDPIHoB9SaadoI3gY64HU88/TjP6UwHCqAQV6gEcH6UtvIiTK8iNLGCN6bym8A5xkdPwoEPGG3c4bGCT0PPSmNIpIJ5GB3z3/UUwgjoWLZ5OAD9f6/lQ7NyMHnlqBkrOflzlnCgdenpikZlDsCWxnnacjr/jUS5BBHyEDt3pBu4DIc+59fWgCUFx94YIOGJ9cdPpWhoWk3GtavZaZaI5mnYqMAAKOrN+AGay+rbTncOMd69L+Fdn/ZobWnhQSSIY4Nx5XGCT7ZxQI9t8Ra5b+DfBcWiaTMEeCBYUfaRtX+Ln1x+OSK8OtU+36lO8Y3Mx3MynH5/n/nmk8feIftDywxSNl2BZgchuP0PerHhSBjamcGUurZfHPUccfj+dNbiPsq4aKZfMV4zHInDFOCDyDk9K8O/aD8A/2rZSeJdHhVr+14uYoYSWlj6b8Dqy9yB0PtXSfB/xFNLpUWjX8m6S2j2wyhgwePrt+oyMe1ekMOoBlxvBGcDHToe/0pLQZ+fpIdic/KxB5yARnOT/AJ6UkjL5EJA+bGQSM59/p14/rXtfxy+F0uj3Fz4h8PRO+lSM8l3bomPsjdd6gdUzyfSvFT88fOWUnI5OW/Dpj6UAOl+QPkdRnOQwBI/SkaQoCWAyxwQRgHHt60+Z1DBhtYHoxBA6c8fj+lM84vgDK+4I44/z1oARXIABdSobG5RkZxx/KkRmyvnDK7Txnt3z+NSRggEghgSdvGGI65//AF1ChGzduAycFsHnOc5H49PagCYs+7CswyMYK5yOP/r0i7hwrdAQpxx/n9abEQ8iE7NufvLxgY9u2R+H40AAKXLDcBnOOAx6DFMB+8kAq5APzDIwvHT/APVSrIVHzHcDxkDrUJyy4AUEr1znJ6knP1PSjPAXaCFyhUkHP+fekA8uxcIPmIA4Bxz/AJApd5SV3LM3JOcHlu/bmlCvjJB3AbT8owCD0PTAx35pr7s5C/Nuxlm544wfWmA6NwBMnl7pDtCuMgKOhGP4s/Lz22+5poKleQpyCOD1wR+fb8qbwq/MOqEKCeh9fqf50A5YM3yrvGfkyBx+n/1qQFjTokm1K2WUgwmZRISByoIzxX0dqlqj6YNTha2iWQFeU+YDpkAeoxn17V85QPGqySyOpy4UDZgH69q77TPG0o8OGw1CU+Sh+XGD8vufqKYj6D+DVvDbaHdvDJE7yTYLIuc8dCD/AC9c9K7vU9QttN06e7vHKQW8Zkb12qOx/pXzJ4J8VXum6zZPb3Dw2kzKrDywQQRjB44wPT8a9l8ba3Bd+HZYoclpEBxtyo9M/wCfb2pAeYeKviVqOuG5Rw1tBNnyrSEg4UcZYjOWPPtXGWc/lPEztIxZOA7lVyeASe3bjp69a5PXLqK21hpLUZxhQVGFIB/h9PpWhb6zBNG8jO0BPRM7s9MA55xTA27e8CXJKncVOCH6DA7gdT6Acnmrtl4z1XSNYhbSb2aNw+4wedvWVe+R0YHpnFcmbyECaSa6ChEPJOSc5yPcA1jatf8A2+/zbRLGuVIxk7uRjgd/b/GgD7Gi+J+iR+H7XUr+SWN2Ub0ij3YfHOD0Iz618/fGn4ix+NWtrfT4Jrexg3EiRRuJOOvoPauK13U54LG3sZ9oPJd0wNzE8BvQ9+fX3rC2MylFJkZ4ycBu46H69R+NKwzotAu/tGnvY3DfIgBXgk7P7uOeen6+1YMEkcF3It0CwaX5lDE/U9Ofx96fpyPa3sEsm9V3ADaQNw/uhun9KqalG0d1PuyfmYBg3JJ7j1HFAHUW2mWnnrIhdmA3tKFyBk8njrxnoPyrjp1Ebygl8AkcrjjNbGkaoY2iS4CiLBRXDY8vjnI9Of5dcVQ1m1aO5DKoMbrvUAg+mRxxQBSYrJuJYZC5JGQGIPanlVbJPzA8kg4Pr19aYUxuOQwBAHcc5IH+fQ0gXnkkuD1x2xQMUhfn+YgljgA/T86UHYOMbuh+XqP58HPao0UAHeN3fjt9Kkb5+DyRwecjp69+9AhpHXkk9Nw4/H6UjEgg85GMZodxuyVByOmehpjEbiB0P4UDF3ZCjkHPQY4oZuDuJ3EfKehH+e31prDKjt3z0BpF6EbiM/xEUAPZiWGGzj+7/Dz6UMxJYAnjI6+v403ORkBvl/T3z9aZtyBtBAGTn1oAkUhSRydvqOD7Uwnrx0OfrSkLvxyOOAeauaTplzql4ttb9QNzE9EXPX3oAdpFidRvViKNszljjr7Cu81bUxpVmbSNoS0ShAFj2Ae59M+/T2qWO0tdGs9tpGx2rg7G5YjOXyenbivPtSuzdXryCWQxjhC4GQvv/j70xFmzjk1K/DsnLSDJBxx7joa7u3zbotui7nCgny3798df8+lc94dtlRIpEfc/BYCMggc8c449a9r+F3gb+32bUNUhENjtxExTmTr909h/OgRzunzT2UyxRSBVTJEkT7CCO3/1+2K948Ea9FrlinmBI76MATxeZ1wPvAds/QDNeHasscF1uiRztLnbKdoOep45z6n+tavh/W5NOu4poDFHJtwAFbb34x3B9vekB73LGHEivGCjIVIYgqc9iM+9fOPxa+DlzZPNq/g+3861YtJcaapBeHuxiH8S/wCzyR2z0r3nQdas9YgklhMSThEWRedyknnORjrxmtc4Zl4GQeME8ADoPUfnSGfn10+ZVwBwT2HYj2oXeAy4GM4245/LHTivrj4h/CfRPFscl3bAabqrZb7XBEAsjE9HTpk8DPBr538XeDNa8J3UiavanyVG1bqPJhYdOG7dR19aYHKAr5RyzYzn5R8pJ9fbr+VNB+XfwCOcZA7deeKmaM7GLje7DHzDjOfT8KUApNkNyG5ZcdhwB/ntQBG4y8mWJ3PkAg8Duef880zad/70NwvYdj0/GpSgO9i5CgZUd88n/I96cjbRhdzLjJx1z3Ge9MCuTuKbVDZzgY6/X/PFSJnDElTuHGed30P+fWkPJBZ2YliM5/PPqe1Eal8hCOucDscY+gP+FACqr5HUMByT0BH05B/yaYwAhTPHGB1HHp/n3qYxkuCUkLDqfXjgf5/xpUHLbiCCOCRnv/OkBXyXZQCTkAY5AWrFrbtJ+8ZSIVYklh1b0INXVtdkAurnKqMgDGCxA44/rUE9xLOiqo2RrnHJ4+v59ef8ABLiVDIojBJQf3Bhfz9P0rQ0XT571/tDW0oiXjI47ZJHbHv0r0D4cfCafXbcahrbta2JCvDEeGl75PoD9K9nt/BFtcXEQiigt7aFQqxRLtHsff6etAHjfw08N6tq3iGLyLNRCkm5pC5CrjqOepx+WK+jf+Eaja1aNxGJGjIzjA6YA571oaHpVvpVn5NvDGibs/Kcgkd/r6j/AArXGcNnAJXO0/1ouFj4w+KXg/VNK1mYtaSG2xuV41yCOxPH09BXn1xA8cjtKrhzgHcu1smv0C1LS7XUFKXUKyqGU/dB5Hf3qKPw9pSgBNPtGVeAWRTkD6/z96LiPgW3sridg8NtI2WwWUHoB/LFdP4O8M6jrGomKyRXuFJZVeMgYxjPYdq+1n0HTzCFWyh2Y5VYlAP1GKr6V4a0rR5pZdOso4JXPLInTOeR7UXGeOWvwKGq2sE3iDVJY7gRAoIFBZecnJ7nPFebfEr4P6h4Js59RtrwXumKcGQriRO4DY9+mO9fYJb5V5/hB6YyM15h8fNds9L8A6jZSzJ9uvlEUUePn65zj0wP1ouKx8q3EMmo2UMsXEsRwy/dzzgEZ46d6x5/N2ZkDgEkFmGMY/8A1/jUtvdPbOGjk2qT8xK7lbB7+tbJmS5szczqqFfkaTJbHIwDznjjp7dKYznGIZwx3AHOM5OTmralJ7T5gpdeRlgB6D/Pvz61LNZQlpvs0hYAnCspJYYPOcYHaqgV0cFs4K7vmHoM96QFUoQ5UBkycckL7Y/nRL1IIPT7oPIA/wA/pV6byp1DR7Q6DB28DH+GMVTkADJh9nHUcjHHNAxm0ryeTwM454pcNgltzA8sAeh9/wAaRQG5IUBTnOf8ml56oCG+tACKNuCQw7jHIPWkyByp4A3beo6dKex+c4QE8AbTxx70xiy/d3ZVT6celADHJC5yD/td6DkHGfQ+tKzleuAM9B2HXin5O0HgA5IPTIoAiXIGMAH1I60pz16AnjHQ46inHJyDIzEcnvWnpmiXOpzxqm6OAkjzSpbge1AFPT7CbULqO3tlLO3GScBfcnsK9I0rQE0y18kMfN6yMzDMhzg7eeBx/kVLouiW2jwBuGmZQxY45B9//wBfWtJpGu/OMflK5P7tlHyseefUe4P50xGHdWct3GY3P7osBiTABHPPP49BzzWLf6ZDC7W8dsCyjJKnJb35zn69/wAa7Ywj90CUREyN2cqe5Le/9B3rnNXMqXoaJYpSx4wuAOTjHT5fTPY0CPW/hR8O0ubaG/1qFhAQpjiLHLt2Le3H/wCqvZtTvbHw7pSTTt9mt0wiiMhfbAFeHeE/iXe2WmQW0sNqwUKi4OcqG6e+f0zWX428UXOqSrJczsFZyEj4Kj1yOxoYFGy8RWt/GzGRxcbuFA3YzyOO5Gep/U0pgByYGJIBZWU4xnIzjnAI7cdq8bLypclondCCcOCQQc84I/mK2NC8SX1ijKXWWPtHICAwz0z/AJ/OkFj1bRdZ1HS5WntHlglVeJFUbHAP3TnnHTrg969v8J+K7TX4FXKw3ygiSF+endT/AE69K+a7DxlaXKmO+RlYtnzOVywGBkeo9O/4Vu6XqMZYT25lEiqxj2TAFMAcqc89+PahgfTLM2xmOewO5cHHoR2P/wBaq93aw3cT291Gk0LAq0UiBh9DxyK4Hwt8QFlTy9VhbagAW4X5u38S8kjqSfSvQLW5iuoWntpA8RAO5JAw554P49KBnkvi74IaHqINxo9xLpV0eVSP/UkHtt7DPOAR0rx3xL8K/FOitL/xL2vYFBxNaHcOO+37wPfGO9fYQwQVG4At0YAggev/ANb0qtPCFJ2kBlXAynI7Yx6dPwouB8JSxvb3Leb8jqAuJEKkevXp+NN2blbDAcnO047+/wDn8q+2tR0e1vMrNZWk64AXzEBB5zxn361yGq/DvQbtHEmhWStnl0G0jHbjpQB8ooWVQCFOcHk8dzUhSSR28sSyEk5VFIxnnoP8jI/D6JuvhrpFrueDRrdiBkrKWOFHQ9Tk84zWtpfhIRKjQ21rbKM/6nv7Hjt/WmI+eLPw5qUrs1xC1tCse5nuMKR9B1P0/wAas/8AEr04eXCWvpwQ3mMwxx3X8ccf5Htuv/D9dXuJZZZDtZVAUSY28nIx7jpn1rCHwssoXaSTaY1bGxnwG745x7/56oDy6xs7nWpJLm4aZhHG2GOcADt9P1ziuy+DfheDUfFtst9CrRxLuUPHnkds+tTajd2uiQvZ2qiMNnJB6Zz3/D9a1PhxfS2l4tzBG8gA27C4KlScZB/p25oGfQtpYRQIxX5cADKrk/iPX6VfnkitEklnkREQ7y2PQda4e28fWNtlrxHRWfhkPPbrzyBWP4l8bWWrWlzbwyeVEM8uep6ZAH0/KkMTxB8UWtLx4NLtrSRIyxLybssOcYHTOB1GaztJ+Nu1iNd0jyOMebbSZ3D1APH615rrEltHA/kwyyu5ZtwkGAzcnHPufYDrzWPf+H3lk3xTMkCKI8RrkcnkcninYk+i9J+LfhTUXhSO8a2ZsELMu3aPXPpXeW88NzCJoZIZYpFBDoQQ49yK+GLu5e2v3SRNhBLMdpzx0J4x+lesfAj4kS2Vynh3VJkWzfeYXYY2sTnB9j1/zwWGfS7A4GOqcnJww471xnjX4ieHPCEZi1PUEN2eBbW775ee+P4R35rm/i/8UbTwpoX2fS7iGfXLpdkaIwfyAeshPT6D8a+WbKzvNbuZ7y4eSSWVzJLLjcS3qR1IH/6hSA9j8Z/HfWNTBtvDdsmnRSrgXL/vJyCOGAHC/Uc15u2l3Oqu019dXs1zKWMsryhzIe2ST8p/w460NpKWwVLZyx2+XuUcseOmO+f6U7StOlkuEZpYzlCDufawAzgkdsnH6ZqhHM6rpd1p8rZid0HO9xnAI6EHvj8qi0y6EIkjclopFB5GQfTiu4ubXzozaTCSQPHliknI3D3OMdfY/XFceNIkuNYS0t18xC4UOhyCMcnPqM80DLnhyAXN4xRN0Ldl5RmA755HrjvW9feHF1W3jls2eOTYQw4IznAJ9xnHHrVMW8+hwx/aFQxHPzDkgd+M98H6EVt2+s2bpHKCXm2gbVkAx7Dnn9PwxQBwep6Ff2Um6e3kKk4LovT8uO9ZYZiwXG4k4AbJPPXHH6V7Za6kzyFpogxbhQHBz6H36D36fhLeaZoGqu0txbKjupG4cYPXB/z60gueGm3fysjDIemDkjv07jr+VMkUxkiQMrFgdpOD04617T/wiGmTyr5VwFlA6bcMuDjj6DqPWob7wVHEwR3Rgfu98A9fqDjnNMLnjYC55K4xx/8Ar60hIdyVI5PHPA/+tXp0vgaIXG8LGq5w5Jx6dvrRZ+C4be5X/j1KgZO9SwB/usD14z045FILnmKxSHesayOAcfID0PStKx8P6hdMpEIVWxgt39gPXIxjivUodDt7eMpOImVSFDb9jYxn/OcVZMduyFRLbuvJIiJXp3GeuOcjvQFzitO8LWsLIbl5biXj7uFAHTp2/PsO9bsUsEHmx24kRQPnZRvIA5578Z49jTdRvngbZa20czuCGY9iT19O+Pz9qki059qMUQSqvzBGwQPz5zj9aYiBWbUhIVkCfMBtC4HQcjH1HvzWjkBcRFWm3ZboFcj0P978PWkEdva3G+F33H5mIPB6+p4GP8jNV7zU7SJQY5YDJuJZ2kUbueQyjv16HnBoAilu5ZihjjjRMEtIvOOmQR3J/wA9apyqZEjQokwGGbKlQ5z7nkd6z9V8WxNEoiQM7DaxjIH4ehHJ56msLVPEl5dx+UuIYs8qpJJH+RRcZpeINcMVx5VrHGuwYG36/wD1h+B4rBudWuZySzBcgBtp+9iqDtuLuxBZiSWPc0iEgsU4PfFIdi4EDkBicEhMcfX+n60+3jDl2yQBgYH0z/SiimhE3lKZIwRkMc9T649fb9aswXM1uzCNyMEYPQjPOfqKKKSBG/ZeLL61kKlY3VcO2MgtjjGe3bJHXFdz4d165hP2zT3ltJpFE/yykjGfukdxyaKKa2EzuYvifqNioF3Z2900ZALAmMsCcds09fi4zKd2i5+Qni7PYj/Z96KKkaOisPHj3doJf7PVN65K+bkZ5H92qWteO7u3QrDaQL8+0HPYgn8elFFNA9DCv/G+pzqzQrDAybgpUE44zkZPBrF0rxtrbJIjzxEFc/LGBjkdPzoopoEct4g8fa1Gm8TnewHPTAA4HHbirGn3+pX+hi4mvPmdWG0plemScZ68cHtRRSEzjnjnuJEMtxkykH7vCnJA7/8A66674eQyDUJlMi8IV4THzE/e68fQccUUUxnRR2UUJllYF5pifm3NxjPbPt+tZ1vDDPKsTIQvzt8pxg7mHGO3HT+VFFJiJJYbZ7RUjt1QZKdSe/J+pPNMvtOhF5dxguBvAJDEEj0P5jn2oooGyumnW/22MFSWG4hifXt9K4fxxp8Fjra/ZV2OFVtw45PcY6dqKKYluczcRF2Zp3Mkg43nqRz1/Ku88EWMLaVHJgq0r5LKSGAVhxn0oopAa+oW8dlcusQICMcgcbiRjPrn8azrmzWWYxMVC7CQQuCORnkdf/1UUUMVx8VhFbxA/eEkg+oKkY579elLYQw2l258pZNsxAB4wScEjHQ8/lRRTYybWrKO9aG1l4RwSWA+bGD39eBzXKTeG4lvIFWdts+MZX7m30574x9KKKS1AtPpTW80caXUnlgDC88cnnr15/StSxgk+0swuHxGc4IyW57+/FFFAXKviaa6tLgS291ImwLjHXpzz711+nO72MDs53OqjoODjqKKKqwMS704wb5EuZiVG/5sdCcY9uB1qN7GW4WONrn/AJZlg2zngnANFFJCI/EVv5WmlCyujEYyvII9TnmuU8O6chu/PuXadlIAV/ugegHboKKKXUDq7tVsneKMAqse4/7QPY1xWu+JLpgLeOKFEdsE4ycj39PaiihDOWuri4lyZJmxuJIQ7ef8mqcsC7QH+YnOSe+KKKGNiywiPIY7jgAHpjNR+SrEAjHKg470UUkMRowFbB427sfrT44fMLJu6AHJGaKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enlargement of the descending thoracic aorta and thickening of the vessel wall (arrows) is apparent in this contrast enhanced CT scan. These findings suggest an active inflammatory process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sueyoshi E, Sakamoto I, Hayashi K. Aortic aneurysms in patients with Takayasu's arteritis: CT evaluation. Am J Roentgenology 2000; 175:1727. Copyright &copy; 2000 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusiform aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enlargement of the contrast filled descending thoracic aneurysm has occurred despite treatment with glucocorticoids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sueyoshi E, Sakamoto I, Hayashi K. Aortic aneurysms in patients with Takayasu's arteritis: CT evaluation. Am J Roentgenology 2000; 175:1727. Copyright &copy; 2000 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9144=[""].join("\n");
var outline_f8_59_9144=null;
var title_f8_59_9145="Captopril: Drug information";
var content_f8_59_9145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Captopril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/49/25365?source=see_link\">",
"    see \"Captopril: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=see_link\">",
"    see \"Captopril: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Capto&reg;;",
"     </li>",
"     <li>",
"      Capoten&reg;;",
"     </li>",
"     <li>",
"      Dom-Captopril;",
"     </li>",
"     <li>",
"      Mylan-Captopril;",
"     </li>",
"     <li>",
"      Nu-Capto;",
"     </li>",
"     <li>",
"      PMS-Captopril;",
"     </li>",
"     <li>",
"      Teva-Captopril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dose according to patient's response; use lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute hypertension (urgency/emergency):",
"     </b>",
"     Oral: 12.5-25 mg, may repeat as needed (may be given sublingually, but no therapeutic advantage demonstrated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: 6.25-12.5 mg 3 times/day in conjunction with cardiac glycoside and diuretic therapy; initial dose depends upon patient's fluid/electrolyte status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Target dose: 50 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial dose: 25 mg 2-3 times/day (a lower initial dose of 12.5 mg 3 times/day may also be considered [VA Cooperative Study Group, 1984]); may increase by 12.5-25 mg/dose at 1- to 2-week intervals up to 50 mg 3 times/day; add thiazide diuretic, unless severe renal impairment coexists then consider loop diuretic, before further dosage increases or consider other treatment options; maximum dose: 150 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Usual dose range (JNC 7): 25-100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      LV dysfunction following MI:",
"     </b>",
"     Oral: Initial: 6.25 mg; if tolerated, follow with 12.5 mg 3 times/day; then increase to 25 mg 3 times/day during next several days and then gradually increase over next several weeks to target dose of 50 mg 3 times/day (some dose schedules are more aggressive to achieve an increased goal dose within the first few days of initiation.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diabetic nephropathy:",
"     </b>",
"     Oral: Initial: 25 mg 3 times/day. May be taken with other antihypertensive therapy if required to further lower blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F145389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=see_link\">",
"      see \"Captopril: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dose according to patient's response; use lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Infants:",
"     </i>",
"     Initial: 0.15-0.3 mg/kg/dose; titrate dose upward to maximum of 6 mg/kg/day in 1-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children:",
"     </i>",
"     Initial: 0.3-0.5 mg/kg/dose; titrate upward to maximum of 6 mg/kg/day in 2-4 divided doses (NHBPEP, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Older Children:",
"     </i>",
"     Initial: 6.25-12.5 mg/dose every 12-24 hours; titrate upward to maximum of 6 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents:",
"     </i>",
"     Initial: 12.5-25 mg/dose; titrate to a maximum of 450 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F145370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Manufacturers recommendations:",
"     </i>",
"     Reduce initial daily dose and titrate slowly (1- to 2-week intervals) with smaller increments. Slowly back titrate to determine the minimum effective dose once the desired therapeutic effect has been reached.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Alternative recommendations (Aronoff 2007):",
"     </i>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer at 75% of normal dose every 12-18 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer at 50% of normal dose every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute; supplemental dose is not necessary",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 12.5 mg, 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F802614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unstable in aqueous solutions; to prepare solution for oral administration, mix prior to administration and use within 10 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension; treatment of heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F145409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To delay the progression of nephropathy and reduce risks of cardiovascular events in hypertensive patients with type 1 or 2 diabetes mellitus; treatment of hypertensive crisis, rheumatoid arthritis; diagnosis of anatomic renal artery stenosis, hypertension secondary to scleroderma renal crisis; diagnosis of aldosteronism, idiopathic edema, Bartter's syndrome, postmyocardial infarction for prevention of ventricular failure; increase circulation in Raynaud's phenomenon, hypertension secondary to Takayasu's disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F145421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Captopril may be confused with calcitriol, Capitrol&reg;, carvedilol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril [Great Britain] may be confused with Accupril which is a brand name for quinapril in the U.S.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril: Brand name for captopril [Great Britain], but also the brand name for enalapril [Hungary, Switzerland]; lisinopril [Malaysia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angioedema, cardiac arrest, cerebrovascular insufficiency, rhythm disturbances, orthostatic hypotension, syncope, flushing, pallor, angina, MI, Raynaud's syndrome, CHF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, depression, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bullous pemphigus, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Alkaline phosphatase increased, bilirubin increased, gynecomastia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Pancreatitis, glossitis, dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, thrombocytopenia, pancytopenia, agranulocytosis, anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Jaundice, hepatitis, hepatic necrosis (rare), cholestasis, hyponatremia (symptomatic), transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Asthenia, myalgia, myasthenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal insufficiency, renal failure, nephrotic syndrome, polyuria, oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, eosinophilic pneumonitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (1% to 3%), tachycardia (1%), chest pain (1%), palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (maculopapular or urticarial) (4% to 7%), pruritus (2%); in patients with rash, a positive ANA and/or eosinophilia has been noted in 7% to 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia may occur in up to 4% of patients with renal insufficiency or collagen-vascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria (1%), serum creatinine increased, worsening of renal function (may occur in patients with bilateral renal artery stenosis or hypovolemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (rash, pruritus, fever, arthralgia, and eosinophilia) have occurred in 4% to 7% of patients (depending on dose and renal function); dysgeusia - loss of taste or diminished perception (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, angina, anorexia, aphthous ulcers, aplastic anemia, cholestatic jaundice, eosinophilia, erythrocyte sedimentation rate increased, exacerbations of Huntington's disease, glomerulonephritis, Guillain-Barr&eacute; syndrome, hemolytic anemia, hyperthermia, insomnia, interstitial nephritis, Kaposi's sarcoma, peptic ulcer, pericarditis, psoriasis, seizure (in premature infants), systemic lupus erythematosus, vasculitis, visual hallucinations (Doane, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to captopril, any other ACE inhibitor, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F145325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts.  Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Captopril has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients. Onset of neutropenia is usually within 3 months of captopril initiation. Neutrophil count generally returns to baseline within 2 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F145407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F145358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Captopril serum concentrations may be decreased if taken with food. Long-term use of captopril may lead to a zinc deficiency which can result in altered taste perception. Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Take on an empty stomach 1 hour before or 2 hours after meals. Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of captopril (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, yohimbe, and licorice. Avoid black cohosh, california poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Captopril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F145374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6195942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Captopril is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F145349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at least 1 hour before or 2 hours after eating.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F145346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Captopril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $72.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $79.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $131.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $181.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F145335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN, electrolytes, serum creatinine; blood pressure. In patients with renal impairment and/or collagen vascular disease, closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F145350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ace-Bloc (TW);",
"     </li>",
"     <li>",
"      Acenorm (AU);",
"     </li>",
"     <li>",
"      Acepress (ID, IT);",
"     </li>",
"     <li>",
"      Acepril (GB);",
"     </li>",
"     <li>",
"      Aceril (IL);",
"     </li>",
"     <li>",
"      Aceten (IN);",
"     </li>",
"     <li>",
"      Adocor (DE);",
"     </li>",
"     <li>",
"      Angiopril (IN);",
"     </li>",
"     <li>",
"      Antasten (AR);",
"     </li>",
"     <li>",
"      Apuzin (MY);",
"     </li>",
"     <li>",
"      Asisten (UY);",
"     </li>",
"     <li>",
"      Bloc-Med (PH);",
"     </li>",
"     <li>",
"      Capace (ZA);",
"     </li>",
"     <li>",
"      Capomed (PH);",
"     </li>",
"     <li>",
"      Caposan (PE);",
"     </li>",
"     <li>",
"      Capotec (PH);",
"     </li>",
"     <li>",
"      Capoten (AU, BB, BE, BM, BR, BS, BZ, CL, CN, CO, CZ, DK, EC, ES, ET, FI, GB, GR, GY, HK, IE, IT, JM, KE, LU, NG, NL, NO, NZ, PH, PK, PL, PT, SE, SR, TT, TZ, UG, VE, ZA, ZM);",
"     </li>",
"     <li>",
"      Capotena (MX);",
"     </li>",
"     <li>",
"      Capotril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Capril (KP, TH, TW);",
"     </li>",
"     <li>",
"      Captace (PH);",
"     </li>",
"     <li>",
"      Captensin (ID);",
"     </li>",
"     <li>",
"      Captodoc (DE);",
"     </li>",
"     <li>",
"      Captoflux (DE);",
"     </li>",
"     <li>",
"      Captohexal (EE, LU, NZ);",
"     </li>",
"     <li>",
"      Captolane (FR);",
"     </li>",
"     <li>",
"      Captopren (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Captopril (DO);",
"     </li>",
"     <li>",
"      Captopril Pharmavit (HU);",
"     </li>",
"     <li>",
"      Captor (PH);",
"     </li>",
"     <li>",
"      Captotec (BR);",
"     </li>",
"     <li>",
"      Captral (MX);",
"     </li>",
"     <li>",
"      Cardiagen (DE);",
"     </li>",
"     <li>",
"      Catoplin (SG);",
"     </li>",
"     <li>",
"      Cesplon (ES);",
"     </li>",
"     <li>",
"      Debax (AT);",
"     </li>",
"     <li>",
"      Dexacap (ID, SG);",
"     </li>",
"     <li>",
"      Ecaten (MX);",
"     </li>",
"     <li>",
"      Excel (TW);",
"     </li>",
"     <li>",
"      Farcopril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Farmoten (ID);",
"     </li>",
"     <li>",
"      Gemzil (TH);",
"     </li>",
"     <li>",
"      Hartylox (PH);",
"     </li>",
"     <li>",
"      Hiperil (PT);",
"     </li>",
"     <li>",
"      Huma-Captopril (HU);",
"     </li>",
"     <li>",
"      Hypopress (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Hypotensor (GR);",
"     </li>",
"     <li>",
"      Kapril (TR);",
"     </li>",
"     <li>",
"      Ketanine (SG);",
"     </li>",
"     <li>",
"      Kimapan (MY);",
"     </li>",
"     <li>",
"      Lopirin (AT, CH, DE);",
"     </li>",
"     <li>",
"      Lopril (FI, FR);",
"     </li>",
"     <li>",
"      Metopril (ID);",
"     </li>",
"     <li>",
"      Midrat (MX);",
"     </li>",
"     <li>",
"      Minitent (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nolectin (PE);",
"     </li>",
"     <li>",
"      Pertacilon (SG);",
"     </li>",
"     <li>",
"      Prelat (PH);",
"     </li>",
"     <li>",
"      Primace (PH);",
"     </li>",
"     <li>",
"      Properil (CN);",
"     </li>",
"     <li>",
"      Retensin (PH);",
"     </li>",
"     <li>",
"      Rilcapton (SG);",
"     </li>",
"     <li>",
"      Ropril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tensicap (ID);",
"     </li>",
"     <li>",
"      Tensiomen (BG, HN);",
"     </li>",
"     <li>",
"      Tensiomin (HU);",
"     </li>",
"     <li>",
"      Tensobon (DE);",
"     </li>",
"     <li>",
"      Vasosta (PH);",
"     </li>",
"     <li>",
"      Zapto (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F145324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F145343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Blood pressure reduction: 1-1.5 hours after dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Dose related, may require several weeks of therapy before full hypotensive effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 60% to 75%; reduced 30% to 40% by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 25% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (renal and cardiac function dependent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, healthy volunteers: 1.9 hours; Heart failure: 2.06 hours; Anuria: 20-40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;95%) within 24 hours (40% to 50% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p. 28.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doane J and Stults B, &ldquo;Visual Hallucinations Related to Angiotensin-Converting Enzyme Inhibitor Use: Case Reports and Review,&rdquo;",
"      <i>",
"       J Clin Hypertens (Greenwich)",
"      </i>",
"      , 2013, 15(4):230-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grossman E, Morag B, Nussinovitch N, et al, &ldquo;Clinical Use of Captopril in Takayasu's Disease,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1984, 144(1):95-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/6140907/pubmed\" id=\"6140907\" target=\"_blank\">",
"        6140907",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis EJ, Hunsicker LG, Bain RP, et al, \"The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. The Collaborative Study Group,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(20):1456-62; published erratum appears in",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 330(2):152.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/8413456/pubmed\" id=\"8413456\" target=\"_blank\">",
"        8413456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DR, Oliveria SA, Berlowitz DR, et al, &ldquo;Angioedema Incidence in US Veterens Initiating Angiotensin-Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2008, 51(6):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/18413488/pubmed\" id=\"18413488\" target=\"_blank\">",
"        18413488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(12):2643-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/9193433/pubmed\" id=\"9193433\" target=\"_blank\">",
"        9193433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Veterans Administration Cooperative Study Group on Antihypertensive Agents, \"Low-Dose Captopril for the Treatment of Mild to Moderate Hypertension. I. Results of a 14-Week Trial,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1984, 144(10):1947-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/6237623/pubmed\" id=\"6237623\" target=\"_blank\">",
"        6237623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/59/9145/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9196 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9145=[""].join("\n");
var outline_f8_59_9145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708658\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145364\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145413\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145368\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145389\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145369\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145370\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682459\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145337\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145321\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802614\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145340\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145409\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145421\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145411\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145344\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145325\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145407\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145330\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145358\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145333\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145347\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145374\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6195942\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145349\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145346\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145335\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145350\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145324\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145343\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9196\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9196|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/49/25365?source=related_link\">",
"      Captopril: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=related_link\">",
"      Captopril: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_59_9146="Coronary artery stent thrombosis: Incidence and risk factors";
var content_f8_59_9146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary artery stent thrombosis: Incidence and risk factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/59/9146/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/59/9146/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/59/9146/contributors\">",
"     J Dawn Abbott, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/59/9146/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/59/9146/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/59/9146/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/59/9146/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/59/9146/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/59/9146/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery stents are used in the majority of patients who undergo percutaneous coronary intervention (PCI), as they significantly reduce the need for repeat target vessel revascularization compared to balloon angioplasty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link&amp;anchor=H2#H2\">",
"     \"Intracoronary stent restenosis\", section on 'Incidence of restenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stent thrombosis is an uncommon but serious complication that almost always presents as death or a large non-fatal myocardial infarction (MI), usually with ST elevation. It is estimated that less than 10 percent of cardiac deaths after stent placement are attributable to stent thrombosis, with most of the remainder being due to disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/1\">",
"     1",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link&amp;anchor=H348517385#H348517385\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\", section on 'DES compared to BMS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stent thrombosis can occur acutely (within 24 hours), subacutely (within 30 days), or as late as one year (late) or more (very late) after stent placement. Stent thrombosis within the first year appears to occur with similar frequency in patients with bare metal stents (BMS) or drug-eluting stents (DES), as long as patients are treated with dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus a platelet P2Y12 receptor blocker) for the recommended duration. The period of risk requiring dual antiplatelet therapy (DAPT) is longer with DES, due at least in part to delayed neointimal coverage. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Very late stent thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    General issues related to stent thrombosis will be reviewed in this topic. The prevention and management of stent thrombosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The randomized clinical trials that have evaluated the frequency of stent thrombosis have not used a uniform definition in their protocols, leading to difficulty in comparing the different studies. The following definitions were used in most studies and, for the purpose of this discussion, will be called the protocol definition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Events occurring within the first 30 days were considered to represent acute (first 24 hours) or subacute stent thrombosis if there was angiographic vessel occlusion, any new Q-wave MI in an area supplied by the stented vessel,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unexplained death from a cardiac cause.",
"     </li>",
"     <li>",
"      Events occurring after 30 days were considered to represent late stent thrombosis if there was a new MI with occlusion of the stented artery on angiography. This definition underestimates the incidence of stent thrombosis since unexplained MI in the territory of the stented vessels and late deaths, which may have been due to stent thrombosis, were usually not included.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another problem is that, in most clinical trials, stent thrombosis occurring in a patient who had previously undergone repeat target lesion revascularization was not counted. Since this is more likely to occur in a patient with a BMS due to the more frequent need for repeat revascularization, there is a potential for bias against DES.",
"   </p>",
"   <p>",
"    In an attempt to standardize the definition, an academic research consortium (ARC) proposed the following criteria for stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite &mdash; Angiographic confirmation of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent, with or without vessel occlusion, which is associated with acute onset of ischemic symptoms at rest or ECG signs of acute ischemia or typical rise and fall of in cardiac biomarkers within 48 hours of angiography",
"      <strong>",
"       OR",
"      </strong>",
"      pathologic confirmation of stent thrombosis determined at autopsy or from tissue obtained following thrombectomy.",
"     </li>",
"     <li>",
"      Probable &mdash; Unexplained death occurring within 30 days after the index procedure, or an MI occurring at any time after the index procedure that was documented by ECG or imaging to occur in an area supplied by the stented vessel in the absence of angiographic confirmation of stent thrombosis or other culprit lesion.",
"     </li>",
"     <li>",
"      Possible &mdash; Unexplained death occurring more than 30 days after the index procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the discussion that follows, studies will be identified as having used either the protocol or the ARC definition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of stent thrombosis fall into broad categories of procedural, patient, lesion, and stent characteristics as well as the cessation of antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Each risk factor is likely to predispose the patient to stent thrombosis, which is characterized by platelet activation and aggregation, by one or more of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent slow coronary blood flow (local or arterial) as occurs with dissection or hypoperfusion.",
"     </li>",
"     <li>",
"      Prior to reendothelialization, exposure of the blood to prothrombotic subendothelial constituents, such as tissue factor, or to the stent itself.",
"     </li>",
"     <li>",
"      Failure to suppress platelet",
"      <span class=\"nowrap\">",
"       adhesion/aggregation",
"      </span>",
"      at a time of prothrombotic risk, as occurs with premature cessation of antiplatelet therapy or drug resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TIMING AND INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of stent thrombosis (up to 60 percent) occur within the first 30 days after placement, irrespective of stent type [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/5\">",
"     5",
"    </a>",
"    ]. Reported rates tend to be lower in clinical trials (or meta-analyses of clinical trials) than in registries, as trials often enroll lower risk patients. In general, we tell our patients that the rate of stent thrombosis at one year is about one percent and that the yearly rate following one year is about 0.5 percent per year.",
"   </p>",
"   <p>",
"    The best available data across populations with a broad range of risk comes from multiple registries:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Bern-Rotterdam registry, 8146 patients underwent PCI with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      - or a paclitaxel-eluting stent. At three years, the cumulative incidence of angiographic stent thrombosis was 2.9 percent, with early (acute and subacute) stent thrombosis occurring in 60 percent and late stent thrombosis (all events after 30 days) in 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/6\">",
"       6",
"      </a>",
"      ]. After one year, the rate of stent thrombosis was 0.6 percent per year.",
"     </li>",
"     <li>",
"      In the German-Italian registry of 2229 patients who received either SES or PES, the rate of stent thrombosis at nine months was 1.3 percent (0.8 percent with SES and 1.7 percent with PES), with 0.6 percent occurring in 30 days and 0.7 percent beyond 30 days [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective observational study that used the ARC definition, definite or probable ST occurred in 58 of 3021 (1.9 percent) patients who received either PES or SES for on- and off- (67 percent) label indications during 18 months of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/8\">",
"       8",
"      </a>",
"      ]. Of these patients, 42 (72 percent) sustained an event within six months of the procedure, more than half of which occurred within the first 30 days",
"     </li>",
"     <li>",
"      In the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), 42,150 patients underwent PCI with either bare metal or drug-eluting stents [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/9\">",
"       9",
"      </a>",
"      ]. During a mean follow-up of 661 days, the rate of definite stent thrombosis was 1.2 percent, of which 50 percent were acute or subacute. The rate after one year appeared constant out to three years at about 0.3 to 0.4 percent per year.",
"     </li>",
"     <li>",
"      In the Dutch stent thrombosis registry, 21,009 underwent PCI with either bare metal or drug-eluting stents [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/10\">",
"       10",
"      </a>",
"      ]. During a median follow-up of 31 months, ARC definite stent thrombosis was present in 2.1 percent of which 32 percent was acute, 41 percent subacute, 13 percent late and 14 percent very late.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bare metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bare metal stent (BMS) thrombosis usually occurs within the first 24 to 48 hours (acute) or much less often within the first month (subacute) after stent placement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/11-19\">",
"     11-19",
"    </a>",
"    ]. In a pooled analysis of data from stent trials registries, stent thrombosis developed in 0.9 percent by 30 days and approximately 80 percent of these occurred within the first two days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/13\">",
"     13",
"    </a>",
"    ]. The incidence of stent thrombosis by 30 days has ranged between 0.5 to 2.5 percent with higher rates in patient populations at higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/11,12,20\">",
"     11,12,20",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Thrombotic events with BMS are uncommon after 30 days of treatment with dual antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/10,21-23\">",
"     10,21-23",
"    </a>",
"    ]. This observation is consistent with angioscopic studies that showed complete re-endothelialization by three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) of over 94,000 stent implantations, the cumulative incidence of stent thrombosis with BMS at one year was approximately 1.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very late stent thrombosis (after one year) is uncommonly seen with BMS using protocol definitions; using the ARC definition, it occurs most often after a repeat procedure has been performed in the stented segment. In SCAAR, the rate of definite stent thrombosis at two years was 1.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Drug-eluting stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to BMS, most episodes of drug-eluting stent thrombosis occur in the first year and many of these within the first 30 days. In a meta-analysis of 10 randomized trials of 5030 patients comparing PES or SES to BMS, the 30-day rate of stent thrombosis (ST) in patients receiving DES was 0.58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/20\">",
"     20",
"    </a>",
"    ]. In a report of over 94,000 stent implantations in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), the cumulative incidence of stent thrombosis with DES at one year was approximately 0.4 to 0.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/26\">",
"     26",
"    </a>",
"    ]. In a 2006 meta-analysis of 19 randomized trials with 7060 patients, the risk of PES or SES thrombosis was 0.7 percent with one-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Events continue after one year (very late stent thrombosis) for at least five years. In clinical trial populations, the risk has been estimated at 0.2 percent per year after the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/28\">",
"     28",
"    </a>",
"    ], but a number of studies have demonstrated the risk beyond one year is higher (as much as 0.6 percent per year) in routine practice settings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/9,29-32\">",
"     9,29-32",
"    </a>",
"    ]. The data supporting these observations come from studies of mostly first generation DES. Lower yearly rates may exist for newer generation DES. (See",
"    <a class=\"local\" href=\"#H283851917\">",
"     'Very late stent and cumulative two-year thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following studies illustrate the range of risk beyond one year for patients who received differing DES:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2012 publication from SCAAR, the cumulative rates of definite stent thrombosis at two years for older DES (SES, PES, and the Endeavor zotarolimus [ZES]) and newer DES (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      and Endeavor Resolute ZES) were 1.3 and 0.6 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Bern-Rotterdam registry, the annual rate of stent thrombosis was 0.4 to 0.6 percent for up to four years in a population of 8146 individuals who underwent PCI with either SES or PES [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a subsequent report from the Bern-Rotterdam registry (cohort III), the incidence rate of very late stent definite or probable stent thrombosis (ARC definition) per 100 person-years in a cohort of 12,000 patients with unrestricted use of DES (3819 SES, 4308 PES, 4212 EES), for these three DES were 1.6, 2.4, and 0.6 percent, respectively, during follow-up of up to four years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the data for very late stent thrombosis after DES presented above comes from the earlier SES and PES. The yearly rate of stent thrombosis after the first year may be lower with the newer zotarolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    -eluting stents. This issue is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H283851917\">",
"     'Very late stent and cumulative two-year thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165352083\">",
"    <span class=\"h2\">",
"     Impact of ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intracoronary and systemic prothrombotic environment accompanying an acute coronary syndrome (ACS) has led to concerns regarding a possible increase in the risk of ST compared to patients with stable angina. This concern has been confirmed in analyses of the ACUITY AND TRITON-TIMI 38 trial databases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The range of rates of early stent thrombosis (&lt;30 days) in patients with stable angina or an ACS according to the Academic Research Consortium definition (definite or probable) has been summarized as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bare metal stents: 0 to 0.5, 1.4 to 1.6, and 0 to 2.9 percent (stable angina, NSTEMI and STEMI, respectively).",
"     </li>",
"     <li>",
"      Drug-eluting stents: 0.3 to 0.4, 1.2 to 1.9, and 0 to 3.1 percent (stable angina, NSTEMI and STEMI, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis of individual patient data from 11 trials found that the long-term (cumulative) rate of stent thrombosis in patients with ACS was not significantly different between first generation DES and BMS (5.8 versus 4.3 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/36\">",
"     36",
"    </a>",
"    ]. We interpret the available evidence to suggest that patients with ACS are at greater risk of stent thrombosis than those with stable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All risk factors for stent thrombosis likely work through one or more of the mechanisms discussed above. All of these promote platelet aggregation. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Mechanisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Early and late stent thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most important predictor of early and late (at least up to six to nine months) stent thrombosis is absence of platelet P2Y12 receptor blocker therapy at the time of the event [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/10\">",
"     10",
"    </a>",
"    ]. In one report, the hazard ratio for premature discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was greater than 50 at nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes of and predictors of premature discontinuation were evaluated in a study of 1622 patients who received at least one DES. In 234 patients (14.4 percent), one or both antiplatelet drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) were discontinued for at least five consecutive days during the first year after implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/37\">",
"     37",
"    </a>",
"    ]. Clopidogrel, as opposed to aspirin, discontinuation occurred in the majority (11.8 percent). Among the 218 patients who discontinued any agent and in whom the reason for discontinuation was known, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major causes of discontinuation were bleeding events or invasive procedures, medical decisions, or patient decision (50 percent, 32 and 18 percent, respectively).",
"     </li>",
"     <li>",
"      Among those who discontinued due to bleeding",
"      <span class=\"nowrap\">",
"       events/invasive",
"      </span>",
"      procedures, interventions or minor bleeding not requiring that should not have required discontinuation was the explanation in nearly 50 percent.",
"     </li>",
"     <li>",
"      In patients who discontinued due to bleeding",
"      <span class=\"nowrap\">",
"       events/invasive",
"      </span>",
"      procedures, predictors included renal impairment, prior major hemorrhage, or peripheral artery disease. Long-term anticoagulant therapy, undergoing procedures in a private hospital, and not receiving instructions were causes in those in whom a medical decision was the cause. In patients who stopped of their own accord, being an immigrant, or using psychotropic drugs were predictors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best available data on the risk factors for early (&le;30 days) definite stent thrombosis in real world populations come from two case-control studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In analysis of the 21,009 patients in the Dutch Stent Thrombosis Registry, of whom 437 (2.1 percent) presented with an ST, the most important risk factors were premature discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      therapy (odds ratio [OR] 36.5), under-sizing (OR 13.46), dissection (OR 6.19), TIMI flow post-PCI (OR 5.24), CAD &ge;50 percent proximal of the culprit lesion (OR 4.15), malignancy (OR 3.06), no",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      at the time of the procedure (OR 2.82), and left ventricular ejection fraction &lt;30 percent (OR 2.71) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of clinical, angiographic, and genetic factors of ST in 123 patients and 246 controls on dual antiplatelet therapy in a French registry, nongenetic independent correlates of early stent thrombosis (not included in the list below) were diabetes mellitus (OR 1.82, 95% CI 1.02-3.24), use of proton pump inhibitors (OR 2.19, 95% CI 1.29-3.75), and higher",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      loading doses (OR 0.73, 95% CI 0.57-0.93) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/38\">",
"       38",
"      </a>",
"      ]. Significant independent genetic markers were CYP2C19 metabolic status (OR 1.99, 95% CI 1.47-2.69) and the presence of either the ABCB1 3435 TT (OR 2.16, 95% CO 1.21-3.88) or ITGB3 PLA2 carriage (OR 0.52, 95% CI 0.28-0.95) genotype.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other important factors associated with both an increased risk of early and late ST after either bare metal or drug-eluting stent placement include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/7,10,13-16,18,19,22,27,30,34,39-46\">",
"     7,10,13-16,18,19,22,27,30,34,39-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute coronary syndrome and proximal left anterior descending coronary artery lesion (for early stent thrombosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H165352083\">",
"       'Impact of ACS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side-branch stenting, diabetes mellitus, and end-stage renal disease (for late stent thrombosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Incomplete stent expansion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link&amp;anchor=H8#H8\">",
"       \"General principles of the use of intracoronary stents\", section on 'Optimal stenting'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Greater stent length",
"     </li>",
"     <li>",
"      Residual plaque burden and small stent area on intracoronary ultrasound",
"     </li>",
"     <li>",
"      Small vessel caliber",
"     </li>",
"     <li>",
"      Residual thrombus or persistent dissection after stent placement",
"     </li>",
"     <li>",
"      Inflow or outflow obstruction",
"     </li>",
"     <li>",
"      Subtherapeutic periprocedural anticoagulation",
"     </li>",
"     <li>",
"      Left ventricular dysfunction",
"     </li>",
"     <li>",
"      Nonionic contrast media",
"     </li>",
"     <li>",
"      Cocaine use",
"     </li>",
"     <li>",
"      Emergent stent placement",
"     </li>",
"     <li>",
"      Prior brachytherapy",
"     </li>",
"     <li>",
"      Post-procedure TIMI flow grade &lt;3",
"     </li>",
"     <li>",
"      No",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      at the time of the procedure",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      CAD &ge;50 percent proximal of culprit lesion",
"     </li>",
"     <li>",
"      Treatment of bifurcation lesions",
"     </li>",
"     <li>",
"      Multivessel disease, as shown in the SYNTAX trial [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High on treatment (oral antiplatelet therapy) platelet reactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/47\">",
"       47",
"      </a>",
"      ], including polymorphisms in the genes controlling hepatic enzymes involved in the metabolism of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H2#H2\">",
"       \"Nonresponse and resistance to clopidogrel\", section on 'Definitions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"       \"Nonresponse and resistance to clopidogrel\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The presence of uncovered stent struts (as detected by optical coherence tomography) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Very late stent thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific risk factors for very late stent thrombosis are less well defined but relate to delayed neointimal coverage and ongoing vessel inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/41,49\">",
"     41,49",
"    </a>",
"    ]. A probable explanation for an increased risk of thrombosis in first generation DES compared to BMS after cessation of antiplatelet therapy is delayed arterial healing, particularly incomplete neointimal coverage. However, rates of very late stent thrombosis with newer generation DES, such as EES or R-ZES, appear to be lower than earlier generation DES. Thus, any difference between BMS and newer DES in the rate of very late stent thrombosis may be small.",
"   </p>",
"   <p>",
"    Documentation of very late stent thrombosis has come from real-time imaging studies using either angioscopy or optical coherence tomography, from postmortem examination of stented segments in patients with and without stent thrombosis, or from the histology of in-stent restenosis tissue obtained by atherectomy.",
"   </p>",
"   <p>",
"    An angioscopic study of 37 consecutive stented lesions (15",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stents and 22 BMS) showed that neointimal coverage is not complete in most patients with SES, but complete with all BMS at three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed neointimal coverage in patients with SES was confirmed in a longer-term study of 17 SES and 11 BMS in which angioscopy was performed at 4, 10, and 21 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/25\">",
"     25",
"    </a>",
"    ]. There were two main findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neointimal coverage was complete in all but one of the patients with BMS at 3.6 months and in all at 10 months. In contrast, the majority of patients with SES had incomplete coverage at 21 months",
"     </li>",
"     <li>",
"      Mural red thrombi were seen only in patients with SES and incomplete neointimal coverage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angioscopy is limited in the evaluation of the extent of neointimal coverage since it cannot quantify the proportion or thickness of coverage. These limitations are not present with optical coherence tomography, an intravascular imaging technique that visualizes the surface of a stent with higher resolution than intravascular ultrasound (IVUS).",
"   </p>",
"   <p>",
"    Optical coherence tomography and IVUS were performed at six-month follow-up in a study of 36 patients who had 57 SES placed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/50\">",
"     50",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    was discontinued three months after PCI. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The average rate of neointimal-covered stent struts in an individual SES was 89 percent",
"     </li>",
"     <li>",
"      84 percent of stents had partially uncovered struts",
"     </li>",
"     <li>",
"      The prevalence of struts covered by neointima that was undetectable by IVUS was 64 percent, a finding that highlights a limitation of IVUS for assessing neointima",
"     </li>",
"     <li>",
"      Thrombus formation was seen in three stents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with those in two postmortem studies and analysis of atherectomy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/41,49,51\">",
"     41,49,51",
"    </a>",
"    ]. A postmortem study compared 28 stented segments with thrombus to 34 without thrombus in 46 patients who died more than 30 days after DES implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/41\">",
"     41",
"    </a>",
"    ]. The most powerful histologic predictor of stent thrombosis was incomplete endothelial coverage, as determined by the ratio of uncovered to total stent struts.",
"   </p>",
"   <p>",
"    Similar findings were noted in the second postmortem study in which delayed arterial healing was more pronounced in 14 DES patients with late stent thrombosis than in nine patients without stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, patients with DES had a greater degree of delayed arterial healing and less complete re-endothelialization than patients with BMS.",
"   </p>",
"   <p>",
"    Current smoking and total stent length &gt;28 mm have been identified as risk factors for very late stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/32\">",
"     32",
"    </a>",
"    ]. Whether these play a role by influencing the rate of arterial healing is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other issues related to risk",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     On-label versus off-label use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The randomized trials demonstrating the lower rate of restenosis with DES compared to BMS were performed in patients with single, previously untreated coronary lesions (on-label use). In the SIRIUS trial, for example, the exclusion criteria included ostial, bifurcation, and unprotected left main lesions, and vessels with thrombus or severe calcification; in addition, multivessel stenting was not performed and patients with a recent MI or a left ventricular ejection fraction (LVEF) less than 25 percent were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been concern whether the risk and timing of stent thrombosis (ST) may be different for these excluded or so-called off-label indications (more complex disease). At least two studies have suggested that the risk of ST in patients who received BMS or DES for off-label indications is higher than for those with on-label indications at both early and later time points [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. This is not surprising, as the baseline risk of patients with off-label indications is higher. For example, these individuals often have an acute coronary syndrome.",
"   </p>",
"   <p>",
"    In previous, smaller studies, each of the more common off-label indications was found to be associated with an increased risk of stent thrombosis. These include multivessel stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/55\">",
"     55",
"    </a>",
"    ], bifurcation stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/7,56-59\">",
"     7,56-59",
"    </a>",
"    ], particularly with use of the crush technique [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], chronic total occlusions, and in-stent restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"     \"Use of intracoronary stents for specific coronary lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link\">",
"     \"Intracoronary stent restenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Nonanatomic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of non-coronary clinical factors are also associated with stent thrombosis. These include diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/6,7,39,56\">",
"     6,7,39,56",
"    </a>",
"    ], black race [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/60\">",
"     60",
"    </a>",
"    ], chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/7,56\">",
"     7,56",
"    </a>",
"    ], acute coronary syndrome at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/6\">",
"     6",
"    </a>",
"    ], cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], elevated C-reactive protein levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/63\">",
"     63",
"    </a>",
"    ], and, in rare cases, a hypersensitivity reaction to the stent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link&amp;anchor=H21#H21\">",
"     \"Drug-eluting intracoronary stents: General principles\", section on 'Hypersensitivity reactions'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H165352083\">",
"     'Impact of ACS'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Incomplete stent apposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete stent apposition, also known as stent malapposition, is defined as the absence of stent strut contact with the underlying vessel wall (not overlying a side branch) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/65\">",
"     65",
"    </a>",
"    ]. This phenomenon, which is identified by intravascular ultrasound (IVUS), can occur at the time of stent implantation; it may resolve or worsen. It may also occur late (up to years) and in this setting has been attributed either to positive remodeling (an increase in vessel diameter) whereby the vessel pulls away from the stent, or to plaque or thrombus dissolution, such that a space forms between the stent and the vessel wall.",
"   </p>",
"   <p>",
"    Two IVUS studies support an association between late incomplete stent apposition and very late stent thrombosis (VLST) in patients with DES:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 13 patients with VLST and 144 controls, incomplete stent apposition was significantly more frequent in patients (77 versus 12 percent) than controls [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 23 patients with DES and seven with BMS VLST, stent malapposition was seen in 74 percent of DES but none of the BMS patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COMPARISON OF DES AND BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both randomized trial and observational study data have demonstrated that the cumulative rate of stent thrombosis is similar for bare metal and the first generation drug-eluting stents (SES and PES) at up to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/10,67\">",
"     10,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, the rate of early stent thrombosis is comparable between BMS and SES or PES. There may be a slight predominance of BMS ST between 30 days and one year (late ST) and a slight preponderance of DES stent thrombosis beyond one year (very late stent thrombosis), particularly for early generation DES such as SES and PES [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/28\">",
"     28",
"    </a>",
"    ]. There have been no randomized trials comparing second generation DES, such as EES or R-ZES, that were large enough to be sufficiently powered to determine the relative rates of stent thrombosis between BMS and EES or R-ZES.",
"   </p>",
"   <p>",
"    The relative rates of stent thrombosis between DES and BMS have been compared in meta-analyses. We advise caution in the interpretation of their conclusions, due to the relatively short duration of follow-up and the fact that the patients included in the trials are representative of only a portion of all patients treated with coronary artery stents.",
"   </p>",
"   <p>",
"    Two large meta-analyses are referred to in the sections below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2012 comprehensive network meta-analysis that included 49 randomized trials (over 50,000 patients) and compared one DES to a BMS or to another DES (",
"      <a class=\"graphic graphic_table graphicRef65603 \" href=\"UTD.htm?11/39/11901\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/68\">",
"       68",
"      </a>",
"      ]. The primary endpoint in this meta-analysis was the one year rate of definite stent thrombosis according to Academic Research Consortium (ARC) criteria (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      The benefit of this network meta-analysis is that indirect comparisons between DES that have not been directly compared in a randomized trial, but have been compared with a third stent, can be made [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/69\">",
"       69",
"      </a>",
"      ]. However, our confidence is not high that comparisons made in this meta-analysis are representative due to the concerns about non-contemporaneous comparisons and other potential sources of bias.",
"     </li>",
"     <li>",
"      A 2012 analysis (Bangalore) of 77 randomized trials (of SES, PES, EES, ZES, and ZES-Resolute) with over 57,000 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Late and one-year cumulative stent thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall risk of stent thrombosis at up to one year is low for both BMS and DES as long as patients are continued on dual antiplatelet therapy with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and platelet P2Y12 receptor blocker for the recommended duration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Timing and incidence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies comparing early generation DES (SES or PES) to BMS suggested that the risk of stent thrombosis at up to one year was comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/23,27,73\">",
"     23,27,73",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In the 2012 network meta-analysis, the rates of late definite stent thrombosis of SES, PES, and ZES were comparable to BMS; however, the rate was significantly lower with the CoCr-EES compared to BMS (odds ratio 0.27) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/68\">",
"     68",
"    </a>",
"    ]. Since only two of the studies in the meta-analysis directly compared CoCr-EES to BMS, this finding should not be considered definitive. Changes in the design of BMS over time and other unmeasured factors may have influenced the indirect comparison of CoCr-EES to BMS in this study more so than with earlier generation DES. In the larger 2012 meta-analysis (Bangalore), similar findings were noted, including a lower rate with EES (56 percent lower) compared to BMS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Very late and cumulative long-term stent thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very late stent thrombosis includes events after one year, while the cumulative rate of stent thrombosis includes all events. The rate of very late stent thrombosis with DES between one and four years is approximately 0.6 percent with the protocol definition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/1\">",
"     1",
"    </a>",
"    ] and approximately 0.9 percent with the ARC definition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Timing and incidence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Meta-analyses using the ARC definitions of definite or probable stent thrombosis have concluded that there is no significant difference in the cumulative rate (at two or more years) of stent thrombosis between older DES (either SES or PES) and BMS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/1,2,28,71,73,74\">",
"     1,2,28,71,73,74",
"    </a>",
"    ]. However, some [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/1,2,6,75\">",
"     1,2,6,75",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/28,49,68\">",
"     28,49,68",
"    </a>",
"    ] have suggested that the rates of very late stent thrombosis are higher with these first generation DES.",
"   </p>",
"   <p>",
"    The two large 2012 meta-analyses evaluated the rates of stent thrombosis at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/68,70\">",
"     68,70",
"    </a>",
"    ]. In the network meta-analysis, only EES (CoCr-EES) had a significantly lower cumulative rate of stent thrombosis compared to BMS (odds ratio 0.35, 95% CI 0.17-0.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/68\">",
"     68",
"    </a>",
"    ]. The Bangalore meta-analysis came to a similar conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses have evaluated the results of randomized trials (comparing SES or PES to BMS) with at least four years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/1,2,28,74,75\">",
"     1,2,28,74,75",
"    </a>",
"    ]. Results of longer-term follow-up with either EES or ZES are pending.",
"   </p>",
"   <p>",
"    The following meta-analyses had substantial overlap in the trials included and variably used the ARC or study protocol definitions of stent thrombosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient-level pooled analysis of four randomized trials of SES versus BMS for on-label indications, there was no significant difference in the cumulative rate of stent thrombosis using the protocol definitions (1.2 versus 0.6 percent) or the rate of definite or probable stent thrombosis using the ARC definitions (1.5 versus 1.7 percent) at four [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/28\">",
"       28",
"      </a>",
"      ] or five years (2.1 versus 2.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were reported in a patient-level pooled analysis of four randomized trials of PES versus BMS for on-label indications [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/28\">",
"       28",
"      </a>",
"      ]. There was no significant difference in the cumulative rate of stent thrombosis using the protocol definitions (1.3 versus 0.8 percent) or the rate of definite or probable stent thrombosis using the ARC definitions (1.8 versus 1.4 percent). There was also no significant increase in the rate of definite or probable (ARC definitions) very late stent thrombosis between one and four years with SES (0.9 versus 0.4 percent with BMS) or PES (0.9 versus 0.6 percent).",
"     </li>",
"     <li>",
"      Another patient-level meta-analysis of the same trials in the prior meta-analysis plus TAXUS-VI using the protocol rather than ARC definitions found a small but significant increase in very late stent thrombosis with both SES (0.6 versus 0 percent) and PES (0.7 versus 0.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/1\">",
"       1",
"      </a>",
"      ]. The increase in risk of very late stent thrombosis with DES compared to BMS is approximately 0.5 to 0.6 percent with the protocol definition [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/1\">",
"       1",
"      </a>",
"      ] and 0.3 to 0.5 percent with the ARC definition during a four-year follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/28\">",
"       28",
"      </a>",
"      ]. These differences were at least in part balanced in the overall rates of stent thrombosis by earlier events in the BMS groups.",
"     </li>",
"     <li>",
"      A similar increase in very late stent thrombosis with SES, which was chronologically associated with cessation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , was noted in another meta-analysis of 14 trials of SES versus BMS [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential limitation of these studies is that the patients in these trials were at moderate risk with stents only being placed for on-label indications in single, previously untreated coronary lesions. In the SIRIUS trial, for example, the exclusion criteria included ostial, bifurcation, and unprotected left main lesions, and vessels with thrombus or severe calcification; in addition, multivessel stenting was not performed and patients with a recent MI or an LVEF less than 25 percent were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/52\">",
"     52",
"    </a>",
"    ]. However, it has been estimated that more than 60 percent of DES use is off-label in more complex lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/2,76\">",
"     2,76",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'On-label versus off-label use'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COMPARISON OF DIFFERING DES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all types of DES have been directly compared. The evidence suggests that use of EES leads to lower rates of stent thrombosis compared to older DES. There is less information available for R-ZES, but it is possible they also have lower rates than older DES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616228991\">",
"    <span class=\"h2\">",
"     Late and cumulative one-year stent thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With regard to late definite stent thrombosis, EES of both types outperformed ZES and PES, but not SES. With regard to cumulative one-year definite stent thrombosis (the primary composite outcome), the following significant odds ratios (OR) were noted (other comparisons between SES, PES, the two types of EES, and the two types of ZES did not achieve statistical significance) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CoCr-EES versus PES 0.28 (0.16-0.48)",
"     </li>",
"     <li>",
"      CoCr-EES versus SES 0.41 (0.24-0.70)",
"     </li>",
"     <li>",
"      CoCr-EES versus Re-ZES 0.14 (0.03-0.47)",
"     </li>",
"     <li>",
"      CoCr-EES versus PC-ZES 0.21 (0.10-0.44)",
"     </li>",
"     <li>",
"      PC-ZES versus SES 1.92 (1.07-3.90)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings of a lower rate of any stent thrombosis with EES, compared to SES, PES, and ZES, were found in the Bangalore meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/70\">",
"     70",
"    </a>",
"    ]. No significant differences in the rates of stent thrombosis at one year were found in paired comparisons between other DES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283851917\">",
"    <span class=\"h2\">",
"     Very late stent and cumulative two-year thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/77-79\">",
"     77-79",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/28,73,80\">",
"     28,73,80",
"    </a>",
"    ], studies comparing rates of stent thrombosis between SES and PES after one year found lower rates with SES.",
"   </p>",
"   <p>",
"    The current body of evidence from randomized trials suggests that long-term cumulative rates of stent thrombosis are lower with EES than SES or PES. There is some evidence to suggest this is also true for R-ZES:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the comprehensive network meta-analysis of randomized trials discussed above [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/68\">",
"       68",
"      </a>",
"      ], no significant differences in the rates of definite stent thrombosis comparing one DES (two types of EES, two types of ZES, SES, and PES) to another at two years with one exception: the odds ratio comparing cobalt CoCr-EES to PES was significant (0.34, 95% CI 0.19-0.62). A significant risk reduction remained when the analysis evaluated two-year definite or probable stent thrombosis. &nbsp;Similar findings were noted in the Bangalore meta-analysis of randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2012 meta-analysis of 11 trials (16,775 patients) that compared the risk of two-year definite stent thrombosis between EES and SES (five trials), PES (five trials) or R-ZES (one trial), the risk of definite stent thrombosis with EES compared with pooled DES occurred in 0.5 percent versus 1.3 percent of patients (relative risk 0.38, 95% CI 0.24-0.59) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/5\">",
"       5",
"      </a>",
"      ]. This translated into a 0.6 percent absolute risk reduction in favor of EES [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/81\">",
"       81",
"      </a>",
"      ]. Similar results were obtained using the broader definition of definite or probable stent thrombosis. On further analysis, the lower risk with EES was found for early, late, cumulative one-year, and very late events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding of a lower rate of long-term stent thrombosis with EES compared to first generation stents (and perhaps R-ZES) is supported by observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 12,339 patients who received SES, PES, or EES, the cumulative incidence rate of definite stent thrombosis during four years of follow-up was lower with EES compared with PES or SES (adjusted hazard ratios 0.33, 95% CI 0.23-0.48 and 0.41, 95% CI 0.27-0.62, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/82\">",
"       82",
"      </a>",
"      ]. These findings remained significant for the analysis of definite or probable stent thrombosis. Differences in the rates of stent thrombosis were due mostly to a lower risk of stent thrombosis beyond one year (very late stent thrombosis).",
"     </li>",
"     <li>",
"      In a 2012 report from SCAAR in which newer DES (EES and Resolute ZES) were compared to older DES (SES, PES, and, according to their classification, Endeavor ZES), the cumulative risk of definite stent thrombosis at two years was lower with newer DES (adjusted hazard ratio 0.57, 95% CI 0.41-0.79) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a 2012 prospective observational study of 6166 unselected patients who received either EES or SES, the rates of stent thrombosis at two years were similar (hazard ratio 1.16, 95% CI 0.47-2.84, comparing EES to SES) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/83\">",
"     83",
"    </a>",
"    ].Rates of stent thrombosis between EES and R-ZES have been evaluated in the RESOLUTE All Comers and TWENTE randomized trials, neither of which was powered to detect differences in these rates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link&amp;anchor=H15#H15\">",
"     \"Comparison of drug-eluting intracoronary stents\", section on 'Everolimus- versus zotarolimus-eluting stents'",
"    </a>",
"    .) In these two trials, the rates of definite or probable stent thrombosis were low and not significantly different in the two groups at one year or later.",
"   </p>",
"   <p>",
"    In a study of 8791 patients who were randomly assigned to either E-ZES (an older version of ZES) or a SES, the rates of definite or probable stent thrombosis were similar at three years (1.4 versus 1.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/59/9146/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stent thrombosis is an uncommon but potentially life-threatening complication of the placement of an intracoronary stent. While it can occur at any time after stent placement, the majority of events occur within the first month irrespective of stent type. Stent thrombosis with bare metal stents (BMS) or drug-eluting stents (DES) has been observed as long as five years after stent placement. The presentation is often with MI, usually with ST elevation, or death. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Timing and incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The premature cessation of dual antiplatelet therapy is the most important risk factor for ST. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"       \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cumulative rates of ST at one year are comparable between BMS and most DES (with the possible exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      -eluting stents [EES], for which the rate is likely lower). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Late and one-year cumulative stent thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At two years, the cumulative rate of ST is approximately 1.5 to 2 percent, and similar for both BMS and DES. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Very late and cumulative long-term stent thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cumulative long-term risk of ST appears comparable among all DES, except for EES for which the risk appears lower. Given potential differences between DES for the period beyond two years, longer-term follow-up is needed. (See",
"      <a class=\"local\" href=\"#H283851917\">",
"       'Very late stent and cumulative two-year thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Data are limited to make inferences regarding the risk of stent thrombosis for RESOLUTE-zotarolimus-eluting stents (R-ZES) and for comparisons between any ZES and EES.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28376628\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/1\">",
"      Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/2\">",
"      Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/3\">",
"      Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/4\">",
"      L&uuml;scher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/5\">",
"      Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012; 5:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/6\">",
"      Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/7\">",
"      Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/8\">",
"      Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/9\">",
"      Lagerqvist B, Carlsson J, Fr&ouml;bert O, et al. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv 2009; 2:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/10\">",
"      van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/11\">",
"      Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/12\">",
"      Sch&uuml;hlen H, Kastrati A, Pache J, et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 2001; 37:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/13\">",
"      Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/14\">",
"      Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/15\">",
"      Leon MB, Wong SC. Intracoronary stents. A breakthrough technology or just another small step? Circulation 1994; 89:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/16\">",
"      Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/17\">",
"      Sutton JM, Ellis SG, Roubin GS, et al. Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation 1994; 89:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/18\">",
"      Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997; 29:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/19\">",
"      Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003; 108:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/20\">",
"      Moreno R, Fern&aacute;ndez C, Hern&aacute;ndez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/21\">",
"      Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/22\">",
"      Scheller B, Hennen B, Pohl A, et al. Acute and subacute stent occlusion; risk-reduction by ionic contrast media. Eur Heart J 2001; 22:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/23\">",
"      Ellis SG, Colombo A, Grube E, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 2007; 49:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/24\">",
"      Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/25\">",
"      Awata M, Kotani J, Uematsu M, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007; 116:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/26\">",
"      Sarno G, Lagerqvist B, Fr&ouml;bert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/27\">",
"      Roiron C, Sanchez P, Bouzamondo A, et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006; 92:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/28\">",
"      Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/29\">",
"      Faxon DP. Very late stent thrombosis and late target lesion revascularization: no end in sight. Circulation 2012; 125:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/30\">",
"      Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/31\">",
"      Jensen LO, Tilsted HH, Thayssen P, et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010; 5:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/32\">",
"      Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012; 125:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/33\">",
"      Aoki J, Lansky AJ, Mehran R, et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2009; 119:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/34\">",
"      Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation 2009; 119:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/35\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/36\">",
"      De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012; 172:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/37\">",
"      Ferreira-Gonz&aacute;lez I, Marsal JR, Ribera A, et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 2010; 122:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/38\">",
"      Cayla G, Hulot JS, O'Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 2011; 306:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/39\">",
"      Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/40\">",
"      Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/41\">",
"      Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/42\">",
"      Nakamura S, Colombo A, Gaglione A, et al. Intracoronary ultrasound observations during stent implantation. Circulation 1994; 89:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/43\">",
"      Goldberg SL, Colombo A, Nakamura S, et al. Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents. J Am Coll Cardiol 1994; 24:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/44\">",
"      Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/45\">",
"      Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/46\">",
"      Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/47\">",
"      Bouman HJ, van Werkum JW, Breet NJ, et al. A case-control study on platelet reactivity in patients with coronary stent thrombosis. J Thromb Haemost 2011; 9:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/48\">",
"      Guagliumi G, Sirbu V, Musumeci G, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv 2012; 5:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/49\">",
"      Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/50\">",
"      Matsumoto D, Shite J, Shinke T, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 2007; 28:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/51\">",
"      van Beusekom HM, Saia F, Zindler JD, et al. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 2007; 28:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/52\">",
"      Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/53\">",
"      Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/54\">",
"      Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007; 297:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/55\">",
"      Rodriguez AE, Mieres J, Fernandez-Pereira C, et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol 2006; 47:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/56\">",
"      Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/57\">",
"      Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/58\">",
"      Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005; 46:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/59\">",
"      Williams DO, Abbott JD. Bifurcation intervention: is it crush time yet? J Am Coll Cardiol 2005; 46:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/60\">",
"      Collins SD, Torguson R, Gaglia MA Jr, et al. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 2010; 122:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/61\">",
"      Lemos PA. Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis? Catheter Cardiovasc Interv 2007; 69:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/62\">",
"      McKee SA, Applegate RJ, Hoyle JR, et al. Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J 2007; 154:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/63\">",
"      Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009; 120:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/64\">",
"      Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/65\">",
"      Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/66\">",
"      Lee CW, Kang SJ, Park DW, et al. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol 2010; 55:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/67\">",
"      Weisz G, Leon MB, Holmes DR Jr, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009; 53:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/68\">",
"      Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/69\">",
"      Ormiston JA, Webster MW. Stent thrombosis: has the firestorm been extinguished? Lancet 2012; 379:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/70\">",
"      Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/71\">",
"      Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/72\">",
"      Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 2005; 45:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/73\">",
"      Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/74\">",
"      Caixeta A, Leon MB, Lansky AJ, et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009; 54:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/75\">",
"      Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/76\">",
"      Farb A, Boam AB. Stent thrombosis redux--the FDA perspective. N Engl J Med 2007; 356:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/77\">",
"      Kaltoft A, Jensen LO, Maeng M, et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 2009; 53:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/78\">",
"      Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/79\">",
"      Sch&ouml;mig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/80\">",
"      Gall&oslash;e AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008; 299:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/81\">",
"      Stefanini GG, Windecker S. Stent thrombosis: no longer an issue with newer-generation drug-eluting stents? Circ Cardiovasc Interv 2012; 5:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/82\">",
"      R&auml;ber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/83\">",
"      Park DW, Kim YH, Song HG, et al. Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study. Circ Cardiovasc Interv 2012; 5:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/84\">",
"      Silber S, Windecker S, Vranckx P, et al. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011; 377:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/85\">",
"      Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/59/9146/abstract/86\">",
"      Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012; 380:1396.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1582 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9146=[""].join("\n");
var outline_f8_59_9146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TIMING AND INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bare metal stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Drug-eluting stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165352083\">",
"      Impact of ACS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Early and late stent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Very late stent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other issues related to risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - On-label versus off-label use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Nonanatomic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Incomplete stent apposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COMPARISON OF DES AND BMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Late and one-year cumulative stent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Very late and cumulative long-term stent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COMPARISON OF DIFFERING DES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H616228991\">",
"      Late and cumulative one-year stent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H283851917\">",
"      Very late stent and cumulative two-year thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28376628\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1582|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/39/11901\" title=\"table 1\">",
"      Coronary artery stents approved in the United States",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_59_9147="ASCO DXA in breast ca";
var content_f8_59_9147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ASCO Guidelines for monitoring with DXA scans in women in breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Monitoring indicated for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women over age 65 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women ages 60 to 64 years with the one or more of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Family history of osteoporosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low body weight less than 70 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prior non-traumatic fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other risk factors such as sedentary, smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postmenopausal women on AI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premenopausal women who develop treatment-related premature menopause",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ASCO: American Society of Clinical Oncology; AI: aromatase inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pant, S, Shapiro, CL. Aromatase inhibitor-associated bone loss. Drugs 2008; 68:2591. Copyright &copy;2008 Adis Data Information BV.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9147=[""].join("\n");
var outline_f8_59_9147=null;
var title_f8_59_9148="Eosinophilic pneumonia causes";
var content_f8_59_9148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Known causes of acute eosinophilic pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Drug or toxin reactions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nitrofurantoin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenytoin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       L-tryptophan",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ampicillin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Minocycline",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acetaminophen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inhaled pentamidine isethionate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ranitidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       GM-CSF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oxaliplatin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trazodone (overdose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inhalation of heroin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inhalation of crack cocaine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inhalation of Scotchguard",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inhalational injury following building collapse",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Human immunodeficiency virus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parasitic infections (Toxocara, filaria, Strongyloides, Ascaris, and Paragonimus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fungal infections (Coccidioides immitis, Trichosporon terrestre, Trichosporon cutaneum, Trichoderma viride)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aspergillus sp*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coxsackie A2 virus*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stenotrophomonas maltophilia*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other associations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic myelogenous leukemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Guillain-Barr&eacute; syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersensitivity to \"red spider\" allergens",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postoperative respiratory failure of unknown etiology",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Following lung transplantation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9148=[""].join("\n");
var outline_f8_59_9148=null;
var title_f8_59_9149="Pediatric pneumonia history";
var content_f8_59_9149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the history in a child with pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Historical feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible significance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age of the child",
"       </td>",
"       <td>",
"        <p>",
"         Viral etiologies are most common in infants and preschool children",
"        </p>",
"        Atypical bacterial pathogens are more common in school-age children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent viral upper respiratory tract infection",
"       </td>",
"       <td>",
"        May predispose to bacterial superinfection with",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        or",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated symptoms",
"       </td>",
"       <td>",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"        is often associated with extrapulmonary manifestations (eg, headache, photophobia, rash)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of cough, chest pain, shortness of breath, difficulty breathing",
"       </td>",
"       <td>",
"        \"Classic\" features of pneumonia, but non-specific",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased work of breathing in the absence of stridor or wheezing",
"       </td>",
"       <td>",
"        Suggestive of severe pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choking episode",
"       </td>",
"       <td>",
"        May indicate foreign body aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of symptoms",
"       </td>",
"       <td>",
"        Chronic cough (&gt;4 weeks) suggests etiology other than acute pneumonia (refer to&nbsp;UpToDate topic on causes of chronic cough in children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous episodes",
"       </td>",
"       <td>",
"        Recurrent episodes may indicate aspiration, congenital or acquired anatomic abnormality, cystic fibrosis, immunodeficiency, asthma, missed foreign body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunization status",
"       </td>",
"       <td>",
"        Completion of the primary series of immunizations for",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        type b,",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        ,",
"        <em>",
"         Bordetella pertussis",
"        </em>",
"        , and seasonal influenza decreases, but does not eliminate, the risk of infection with these organisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous antibiotic therapy",
"       </td>",
"       <td>",
"        Increases the likelihood of antibiotic-resistant bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal history of chlamydia during pregnancy (for infants &lt;4 months of age)",
"       </td>",
"       <td>",
"        May indicate",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to tuberculosis",
"       </td>",
"       <td>",
"        May indicate",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ill contacts",
"       </td>",
"       <td>",
"        More common with viral etiologies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Travel to or residence in certain areas that suggest endemic pathogens",
"       </td>",
"       <td>",
"        <p>",
"         Measles: Developing world",
"        </p>",
"        <p>",
"         Coccidioidomycosis: Southwestern US, northern Mexico, Central and South America",
"        </p>",
"        <p>",
"         Blastomycosis: Southeastern and central US; states bordering the Great Lakes",
"        </p>",
"        <p>",
"         Histoplasmosis: Ohio, Missouri, and Mississippi River valleys in the United States; Canada; Central America; eastern and southern Europe; parts of Africa; eastern Asia; and Australia",
"        </p>",
"        Hantavirus: West of the Mississippi River; four corners region of United States (where borders of Colorado, New Mexico, Arizona, and Utah meet)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animal exposure",
"       </td>",
"       <td>",
"        May indicate histoplasmosis, psittacosis, Q fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Day care center attendance",
"       </td>",
"       <td>",
"        Exposure to viruses and antibiotic-resistant bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluid and nutrition intake",
"       </td>",
"       <td>",
"        Difficulty or inability to feed suggests severe illness",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9149=[""].join("\n");
var outline_f8_59_9149=null;
var title_f8_59_9150="BMD bone markers and hip fx";
var content_f8_59_9150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    BMD and bone turnover markers are independent predictors of hip fracture risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low BMD was defined according to the WHO guidelines, ie, by a value 2.5 SD or more below the young-adult mean (T-score &le;2.5). High bone resorption was defined by CTX or free D-Pyr values higher than the upper limit (mean +2 SD) of the premenopausal range. Women with both low hip BMD and high bone resorption were at a higher risk of hip fracture than women with either low hip BMD or high bone resorption.",
"    <div class=\"footnotes\">",
"     CTX: C-telopeptide; D-Pyr: free deoxypyridinoline.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Garnero, P, Hausherr, E, Chapuy, MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531. Copyright &copy;1996 American Society for Bone and Mineral Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9150=[""].join("\n");
var outline_f8_59_9150=null;
var title_f8_59_9151="Endogenous Candida endophthalmitis with vitritis";
var content_f8_59_9151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Endogenous Candida endophthalmitis with marked vitritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endogenous Candida endophthalmitis with marked vitritis; initially mistaken for uveitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marlene Durand, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_59_9151=[""].join("\n");
var outline_f8_59_9151=null;
